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Abstract 
Guanine-rich nucleic acids can fold into non-canonical DNA secondary structures called G-
quadruplexes. Bio-informatic studies have established that there are ca. 370,000 guanine-rich 
sequences in the human genome that can potentially form quadruplex DNA. Interestingly these 
sequences are not randomly distributed; they are present in the telomeres as well as the promoter 
region of certain oncogenes (such as c-Myc). Due to their biological relevance, G-quadruplex 
sequences have emerged as potential targets for the development of novel anticancer drugs. Recent 
interest in obtaining direct, physical evidence for the presence of G-quadruplex structures has 
fuelled research in the development of synthetic molecules and biomolecules for sensing quadruplex 
structures within a cellular environment.  
In this thesis a series of bi-metallic complexes (with platinum, copper and zinc) have been prepared 
and evaluated as G-quadruplex DNA (Htelo and c-Myc DNA) binders.  The metal complexes were 
designed to possess a metal(II)-terpyridine core capable of π-π stacking with the G-quartet of 
quadruplex DNA and a metal(II)-cyclen based side arm to provide additional interactions with the 
loops, grooves and phosphate backbone of DNA.  Both homo- and hetero-metallic complexes were 
prepared.  By chelating different metals to the terpyridine and cyclen modalities, different parts of 
the quadruplex scaffold could be favourably targeted.  
Once prepared, the ability of the complexes to π-π stack in solid and solution state was probed using 
X-ray crystallography and 1H NMR spectroscopy. This gave an insight into their propensity to π-π 
stack with quadruplex DNA. Complex-DNA (quadruplex and duplex) interactions were then studied 
using a number of biophysical techniques. Fluorescence intercalator displacement (FID) assays, 
circular dichroism (CD), fluorescence resonance energy transfer (FRET) and UV-vis spectroscopic 
studies were used. Overall, the studies showed that the bi-metallic complexes displayed high affinity 
and selectivity towards quadruplex DNA. 
The performance of the metal complexes in cells was also investigated. The MTS assay was used to 
determine the toxicity of the complexes towards two cancer (U2OS and SHSY5Y) and one normal 
(GM0575) cell line. The IC50 values showed the potential of the metal complexes as anti-cancer 
drugs. Furthermore, immunoblotting was used to probe the ability of these metal complexes to 
regulate c-Myc oncogene expression.  
Finally, resin bound G-quadruplex binders (based on platinum-terpyridine and nickel-, vanadium-, 
zinc-, and copper-salphen complexes) were designed and synthesised.  The ability of the resins to 
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bind and isolate (pull-down) fluorescently labelled quadruplex nucleic acid sequences from solution 
(in the absence and presence of competing biomolecules) was investigated. The affinity tag based on 
the cyclic amine functionalised nickel(II)-salphen complex gave the most promising results. This 
affinity tag was able to bind and isolate quadruplex forming DNA and RNA sequence in the presence 
of excessive amounts of competing biomolecules (including duplex DNA, tRNA, and BSA protein). 
Furthermore the affinity tag was able to release the bound DNA and RNA sequences upon 
incubation with denaturing reagents. Therefore the affinity tags presented in this thesis could be 
employed, after further optimisation, to identify novel quadruplex forming DNA and RNA sequences.  
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region of Pt complex, 3b
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at 100uM and 50uM in DMSO. 
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1
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Table 3-1: DC50 values obtained for L
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and complex series 1-6. The values are an average of three independent 
measurements. All error values are within 5%. 
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Figure 3-5. Example of FRET melting plot of Htelo DNA in the presence of increasing concentration of 4.  
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Table 3-2: ΔTm (°C) determined by the FRET melting assay for the three DNA sequences with complexes at 0.4 
μM (values are average of three independent measurements). 
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Figure 3-10: FRET competition experiments of selected complexes (3b, 4 and 5) at 0.4 μM concentration. The 
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Table 3-3: Binding constants obtained for the terpyridine-cyclen complex series. The values are an average of 
three independent measurements. 
 
Figure 3-12: Signature CD spectra of anti-parallel Htelo DNA (black line - obtained by adding compound 3b to 
Htelo DNA in the presence of potassium ions) and parallel c-Myc DNA (red line). 
 
Figure 3-13: The CD spectra of Htelo DNA (10 μM) in the presence of potassium ions, upon addition of 
increasing amounts of 4. The signal at 290 nm increases and the one at 260 nm reduces, producing a new 
signal with negative ellipicity.  
Figure 3-14: (a) The CD spectra of Htelo DNA (10 μM) in the presence of potassium ions, upon addition of 
increasing amounts of 1. The signal at 260 nm reduces, producing a new signal with negative ellipticity. (b) The 
CD spectra of Htelo DNA (10 μM) in the presence of potassium ions, upon addition of increasing amounts of 6.  
No significant spectral changes were observed upon addition of the complex.  
Figure 3-15: The CD spectra of Htelo DNA (10 μM) in the absence of potassium ions, upon addition of 2.5 
equivalents of 1, 2 and 6 at (a) 10 mins and (b) 2 hours incubation. The signal at 290 nm increases and a 
negative peak appears at 260 nm. 
Figure 3-16: The CD spectra of Htelo DNA (10 μM) in the absence of potassium ions, upon addition of 2.5 
equivalents of 3b, 4 and 5 at (a) 10 mins and (b) 2 hours incubation.  
Figure 3-17: The CD spectra of c-Myc DNA (5 μM) in the absense of potassium ions, upon addition of 2.5 
equivalents of 1-6. No changes in the CD spectra were observed.  
Figure 3-18: (a) Pictorial representation of c-Myc DNA unfolding during the CD melting experiment. B) The CD 
melting spectra of c-Myc DNA (5 μM) in Tris-HCl buffer. 
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Figure 3-19: CD melting curves for c-Myc DNA (5 μM) with and without the presence of the complexes (2eq., 
10 μM).  
 
Table 3-4: Change in melting temperatures (∆Tm) for c-Myc quadruplex DNA (5 μM) in the presence of 2 
equivalents of complex. The values are an average of three independent measurements.  
 
Table 3-5: IC50 values obtained for complexes 1- 6 and cisplatin against U2OS (cancerous), SHSY5Y (cancerous) 
and GMO5757 (normal) cell lines. The values are an average of three independent measurements.
 a
 IC50 values 
for cisplatin taken from reference
198
.  
Figure 3-20: IC50 values obtained for complexes 1- 6 and cisplatin against U2OS (cancerous), SHSY5Y 
(cancerous) and GMO5757 (normal) cell lines. The values are an average of three independent measurements. 
The associated error for each value is represented in form of capped error bars. 
Figure 3-21. Analysis of protein expression in U2OS cells following treatment with complexes 1 to 6 and 
TMPyP4 (10µM) after 24 h incubation. Whole cell lysates were resolved by SDS-PAGE and analysed by 
immunoblotting against c-Myc and α-tubulin (loading control). Results are representative of three 
independent experiments. MW: Protein Molecular Weight Marker. 
Figure 3-22. Graphical representation of c-Myc expression in U20S cells after treatment with a selection of 
metal complexes (10 µM). The expression values are normalised relative to the control gene, α-tubulin. The 
values are an average of three independent measurements and the associated error for each value is 
represented in form of capped error bars. 
Table 3-6: Table of IC50 values obtained for complexes 1- 6 with U2OS and percentage c-Myc protein down 
regulation levels.
a
 IC50 value corresponds to 48 h incubation, taken from reference
201
. 
Figure 3-23: Graph of IC50 values obtained for complexes 1- 6 with U2OS plotted against percentage c-myc 
protein down regulation levels.  
Figure 3-24: (a) Solution structure of Htelo DNA sequence (TAGGGTTAGGGTTAGGGTTAGGG) in K
+
 solution. (b) 
Solution structure of c-Myc DNA sequence (TGAGGGTGGGTAGGGTGGGTAA) in K
+
 solution. Figures taken from 
references
45,67
. 
Chapter 4: Affinity Tags for G-Quadruplex Nucleic Acids 
Figure 4-1: Affinity tag approach to isolate quadruplex nucleic acids from solution. 
Figure 4-2: Chemical architecture of the tentacle polymer, where n is ca. 60. Figure modified from reference. 
Figure 4-3: Depiction of the TentaGel® S SH resin with terminal thiol functional groups. 
Scheme 4-1: Reaction scheme for the preparation affinity tag, T
1
 using 3a and Tentagel® S SH.  
Figure 4-4: The UV-vis spectra recorded of the control sample (black line) and supernatant (red line). The 
spectra allowed the determination of the concentration of 3a in each sample.  
Figure 4-5: (a) Isolation experiments with T
1 
and labelled oligonucleotides; FAM Htelo, FAM c-Myc and FAM 
ds26. Mass of T
1
 (mg) was plotted against percentage decrease in FAM emission for each sequence. (b) 
Isolation experiments with the unmodified Tentagel® S H
 
(as a control) and labelled oligonucleotides; FAM 
Htelo, FAM c-Myc and FAM ds26. The plots are an average of three repeats.  
Figure 4-6: (a) General structure of the metal salphen affinity tag series, T
2-6
. The metal and side arms can be 
readily modified. (b) X-ray co-crystal structure of a nickel(II) salphen complex and Htelo DNA, demonstrating 
the binding mode. Figure taken from reference
117
. 
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Scheme 4-2: Reaction scheme for the synthesis of 8, nickel(II) salphen complex with carboxylic acid functional 
group for attachment to resin support.   
Figure 4-7: Depiction of the TentaGel® S NH2 resin with terminal amine functional groups. 
Scheme 4-3: Reaction scheme for the attempted attachment of 8 to the Tentagel S NH2 resin.   
Scheme 4-4: Reaction scheme for the attempted test reaction between 8 and 2-methoxyethylamine.   
Scheme 4-5: Synthesis of affinity tag, T
2
 via a step-wise, 6 step approach.   
Figure 4-8: The UV-vis spectra recorded of the control sample (black line) and supernatant (red line). The 
spectra allowed the determination of the concentration of 8 in each sample.  
Figure 4-9: Library of metal salphen affinity tags, T
2-6
 prepared using the step-wise approach. 
Table 4-1: Overall loading in µmol/mg (and as a % of original resin loading capacity) of complexes on affinity 
tags, T
2-6
. The loading values determined by UV-vis spectroscopy and ICP-MS spectrometry correlate well.   
Figure 4-10: Fluorescence spectrum displaying the “pull down” of FAM DNA from solution.  (a) Pull down of 
Htelo DNA by T
2
 and (b) Pull down of ds26 DNA by T
2
. 
Figure 4-11: DNA “pull down” graphs. Affinity tag mass versus percentage decrease in FAM emission 
corresponding to each FAM-labelled oligonucleotide (FAM-Htelo, FAM-c-Myc and FAM-ds26). Graphs (a) – (e) 
correspond to studies with T
2-6
 respectively. Graph (f) corresponds to the control resins with Htelo DNA. The 
plots are an average of three repeats and the error bars correlate to the standard deviation.   
Table 4-2: TC50 values obtained for the affinity tags, T
2-6
 and the affinity tag controls from the DNA pull down 
assay. The TC50 values are an average of three independent repeats. TC50 values are given in terms of mg of 
affinity tag but can be converted to “concentration” of complex using the loading values presented in Table 4-
1. 
Figure 4-12: Representation of the DNA isolation experiments. (a) The bar chart provides TC50 values (in terms 
of mass) for the affinity tags. (b) The bar chart portrays the percentage of labelled DNA picked up by 1 mg of 
affinity tag.  
Figure 4-13: (a) Competition assays with FAM labelled Htelo:unlabelled ds26 DNA (1:2, 1:5, 1:10, 1:20, 1:50 
and 1:100 equivalents). (b) TC50values determined from FAM Htelo:ds26 DNA competition assays.
 
Figure 4-14: (a) Isolation assays: FAM Htelo and FAM ds26 DNA “pull down” graphs. (b) Competition assays: 
FAM Htelo DNA “pull down” in competition with ds26 DNA (100 equivalents) and FAM ds26 DNA “pull down” 
in competition with Htelo DNA (100 equivalents). The plots are an average of three repeats. 
Figure 4-15: Competition assays (a) FAM HTelo DNA:ct-DNA (1:1, 1:10, 1:100, 1:1000, 1:5000) (b)  TC50values 
determined from FAM Htelo:ct-DNA competition assays. 
Figure 4-16: Competition assays (a) FAM HTelo DNA:BSA protein (1:1, 1:20, 1:100, 1:1000) (b)  TC50values 
determined from FAM Htelo:BSA protein competition assays.
 
Figure 4-17: Isolation assays (a) FAM TRF2 RNA and FAM hairpin RNA “pull down” by T
1 
(b FAM TRF2 RNA and 
FAM hairpin RNA “pull down” by T
2
 (c) TC50values determined from RNA isolation assays.
 
Figure 4-18: Competition assays (a) FAM TRF2 RNA:tRNA (1:1, 1:10, 1:100, 1:500, 1:1000) (b)  TC50values 
determined from FAM TRF2 RNA:tRNA competition assays. (c) FAM TRF2 RNA:ds26 DNA, FAM TRF2 RNA:Htelo 
DNA and FAM TRF2 RNA:hairpin RNA (1:100) (d)  TC50values determined from FAM TRF2:DNA and FAM 
TRF2:RNA competition assays.
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Table 4-3: The table illustrates the conditions investigated and the amount of FAM Htelo DNA recovered from 
T
2
 (as a percentage).  The corresponding resin was incubated for 30 minutes at 37
o
C.  
 
Figure 4-19: (a) Pull down of FAM Htelo with T
2 
(b) Recovery of FAM Htelo from T
2 
following treatment with 
Guanidine HCl 1M. 
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List of Abbreviations 
bp: Base pairs  
BSA: Bovine Serum Albumin  
ChIP: Chromatin Immunopreciptiation  
COSY NMR: Correlation Spectroscopy Nuclear Magnetic Resonance  
ct-DNA: Calf Thymus DNA  
DC50: Displacement Concentration  
DFT: Density functional theory  
DPA: Dipicolylamine  
DOTA: tetraazacyclododecane-tetraacetic acid 
EC50: Half maximal Effective Concentration  
ESI-MS: Electron Spray Ionisation Mass Spectrometry  
FAM: Fluorescein  
FID: Fluorescent Intercalator Displacement assay  
FRET: Fluorescence Resonance Energy Transfer assay  
hTERT: Human Telomerase Reverse Transcriptase  
hTR: Human Telomerase RNA  
IC50: Half maximal Inhibitory Concentration  
ICP-MS: Inductively Coupled Plasma Mass Spectrometry  
LMCT: Ligand to Metal Charge Transfer 
MLCT: Metal to Ligand Charge Transfer  
mRNA: Messenger Ribonucleic Acid  
MTS: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium  
NHE III1: Nuclear Hypersensitivity Element III1  
PMS: Phenazinemethosulfate 
POT1: Protection of Telomeres 1  
PQS: Putative G-quadruplex forming sequences  
Rap1: Ras-related Protein 1  
RNP:  ribonucleoprotein  
RT-qPCR: Quantitative Real Time Polymerase Chain Reaction  
TAMRA: Tetramethylrhodamine (TAMRA) 
TMPyP4: 5,10,15,20‐tetra(N‐methyl‐4‐ pyridyl) porphyrin  
TO: Thiazole Orange  
19 
 
TPP1: Tripeptidyl-Peptidase 1  
TQMP: 5,10,15,20‐tetra[4-hydroxy-3-(trimethylammonium)methyl-phenyl] porphyrin  
TRAP-LIG: Telomere Repeat Amplification Protocol – Ligand assay  
TRF1: Telomeric Repeat Binding Factor 1  
TRF2: Telomeric Repeat Binding Factor 2  
TRIS: 2-Amino-2-hydroxymethyl-propane-1,3-diol  
UTR: Untranslated regions 
VTCD: Variable Temperature Circular Dichroism  
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Oligo sequences: 
Htelo DNA: 5’-AGGGTTAGGGTTAGGGTTAGGG-3’ 
c-Myc DNA: 5’-GGGAGGGTGGGGAGGGTGGG-3’ 
ds26 DNA: 5’-CAATCGGATCGAATTCGATCCGATTG-3’ 
TRF2 RNA: 5’-CGGGAGGGCGGGGAGGGC-3’  
Hairpin RNA: 5’-CAATCGGATCG AATTCGATCCGATTG-3’ 
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1.1 Nucleic Acids 
DNA is made up of four bases: adenine (A), guanine (G), cytosine (C), and thymine (T), wherein each 
base is attached to a pentose sugar and a phosphate.  In 1953, Watson and Crick famously proposed 
an anti-parallel double helical structure for DNA in which the two strands are held together through 
canonical A/T and G/C base pairing.1 Hydrogen bonds, formed between complementary bases on the 
two strands, stabilise the double helix. Adenine was found to bond to thymine via two hydrogen 
bonding interactions and cytosine to guanine via three. Additionally supra-molecular π-π stacking 
interactions between bases contribute to the stability of duplex DNA.    There are three different 
conformations of duplex DNA; B-DNA, A-DNA and Z-DNA. Under physiological conditions, B-DNA is 
the most common, this conformation can be described as a right-handed spiral with the sugars 
adopting C2’-endo geometries.2 Furthermore, DNA can fold into the more diverse structures; hairpin, 
triple helix, i-motif and G-quadruplex (see Figure 1-1). 
 
Figure 1-1: Some examples of the diverse structures formed by DNA including; the predominant duplex 
(double helix), triplex and quadruplex structures. Structures taken from the Protein Data Bank (PDB). PDB 
ID: 1BNA (Duplex DNA), 1D3R (Triplex DNA) and 1KF1 (Quadruplex DNA). 
 
DNA targeting compounds make up some of the most effective anticancer drugs in clinical use.  
These drugs, often used in combination with other synergetic drugs, significantly reduce tumour 
mass.3  However, they can be extremely toxic to healthy cells and selectivity is an on-going 
challenge.  Secondary DNA structures, such as G-quadruplex DNA, offer a new class of molecular 
targets for DNA-interactive compounds. 
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1.2 G-Quadruplex DNA 
1.2.1 Structure and Polymorphism 
The ability of guanine residues to self-assemble into G-tetrads (G-quartets) was first reported by 
Gellert et. al. in 1962.4 These aggregates are formed by the pseudo-planar arrangement of four 
guanine residues which interact mutually, through hydrogen bonds between the Watson-Crick edge 
of each guanine base and the Hoogsteen edge of its neighbour (see Figure 1-2(a)).  In guanine rich 
sequences of DNA, the G-tetrads are able to π-π stack atop each other forming tetra-stranded 
helices known as G-quadruplexes (see Figure 1-2(b)).  These DNA quadruplexes are further stabilised 
by the presence of alkali-metal cations (such as K+ or Na+) within the central cavity of the tetrad.  
These metal ions partake in electrostatic interactions with the electronegative carbonyl group of the 
guanine, which is directed towards the centre of the cavity.5 
 
Figure 1-2: (a) A G-quartet highlighting the hydrogen bonding interactions between the Watson-Crick and 
Hoogsteen faces of the guanine bases, with an alkali metal ion located at the centre of the quartet.  (b) 
Schematic representation of an intramolecular quadruplex DNA structure.   
 
G-quadruplexes exhibit rich structural polymorphism, which depends on the number of strands 
involved in the structure, strand orientation and variations in loop size and sequence.  Quadruplexes 
can form intermolecularly, by bringing together two (bimolecular) or four (tetramolecular) strands of 
DNA or intramolecularly, from a single nucleic acid sequence (see Figure 1-3).6-8 This latter species is 
the more biologically relevant as DNA strands in the genome containing a continuous stretch of a G-
quadruplex sequence with four or more G-tracts will preferably fold into an intramolecular 
quadruplex.9-10  
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Figure 1-3: Possible G-quadruplex topologies (l to r): tetra-, bi- and intramolecular.  
The adjacent strands of a G-quadruplex may run in a parallel or an anti-parallel fashion, which is 
related to the conformational state of the glycosidic bond between the guanine base and sugar 
which can be either syn or anti. The tetramolecular structures are usually composed of parallel 
strands.11 Bimolecular quadruplexes give rise to more complex structures due to the formation of 
loops connecting the two strands together. Loops are intervening nucleotide sequences that are not 
involved in the make-up of the tetrads. Lastly, the most complex topology is obtained by the self-
assembly of a single strand, which can assume a plethora of topologies with diagonal (linking 
diagonally opposite anti-parallel strands), lateral (linking adjacent anti-parallel strands), double-
strand reversal (also called external or propeller, linking adjacent parallel strands around the sides of 
the structure) or V-shaped (connecting two corners of a tetrad core) loops, depending on the 
sequence (see Figure 1-4).12 
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Figure 1-4: Schematic of the different classes of loops that exist in G-quadruplex DNA. Figure taken from 
reference 
12
. 
The loops are major elements that define structural variability in G-quadruplexes (analogous to side 
chains in amino acids). One short loop length (<3 nucleotides) generally results in a quadruplex 
topology with at least two of the four backbones in a parallel orientation, and often with all four 
parallel. This appears to be the dominant fold in most gene promotor G-quadruplexes examined to 
date.13  The variable loop sequences result in four grooves or cavities, bounded by phosphodiester 
backbones, on the exterior of G-quadruplexes.  These grooves, which are sometimes flexible, are 
unique to the sequence from which they formed.  
 
1.2.2 Biological Relevance 
The identification of a G-quadruplex forming region in the telomere (single-stranded DNA overhang 
at chromosome termini) as well as the recognition that the enzyme telomerase (responsible for 
telomere maintenance) was selectively over expressed in the majority of human cancers sparked 
interest in inducing quadruplex formation to inhibit telomerase’s activity as an anticancer strategy.14-
15 Interest in G-quadruplexes as a more general therapeutic target has subsequently expanded 
during the last decade. Particular emphasis has concentrated on G-quadruplexes in oncogene 
promoter regions. A pivotal example of this was the observation that the c-Myc oncogene (over-
expressed in 80% of solid tumours) could be transcriptionally repressed by stabilisation of a G- 
quadruplex in the promoter region.16  Of equal importance, G-quadruplex sequences have been 
proposed to play significant roles in non-cancerous genes, for instance, cardiac function-related 
genes e.g human TInc.17 
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Bio-informatic studies have identified ca. 370000 G-rich DNA sequences with the potential to form 
quadruplexes within the human genome.18-19  These G-quadruplex-forming sequences are enriched 
in regions that are proximal to the transcriptional start site of protein-coding genes in the human 
genome.20-21  Further, in one genome-wide survey the prediction of G-quadruplex forming motifs 
correlated well with the function of human genes, demonstrating an over-representation in proto-
oncogenes and an apparent depletion in tumour suppressor genes.22  This observation suggests the 
therapeutic relevance of G-quadruplexes as a class of drug targets.  Very recently evidence has 
emerged supporting the existence of G-quadruplex structures in vivo.23 
 
The following sections will look in more detail at the G-quadruplex sequences that were targeted in 
this project; particularly in terms of their biological relevance and unique structures.  
 
 
1.3 Human Telomeric (Htelo) DNA 
1.3.1 Human Telomeric DNA as a Biological Target 
Telomeric DNA is a guanine-rich repetitive region of non-coding DNA at the ends of eukaryotic 
chromosomes.24  Telomeric DNA associates within nucleoprotein complexes to form the telomere, 
the primary function of which is to protect chromosomes from degradation, recombination, and 
end-to-end fusion. Telomeric DNA is a combination of double-stranded and single-stranded DNA. 
The double-stranded component is guanine- and cytosine- rich (TTAGGG-AATCCC repeats) and 
extends over 9 –15 kb. The 3’ single-stranded overhang which is typically 50 – 300 nucleotides in 
length consists entirely of TTAGGG repeats. This guanine rich overhang has the propensity to form 
quadruplex structures. Telomeric DNA is bound by shelterin, a complex made up of six protein sub-
units (TRF1, TRF2, Rap1, TIN2, TPP1 and POT1).25  Shelterin folds the telomeric DNA into a closed, t-
loop structure. In fact the shelterin complex binds in such a way that the overhang folds back on 
itself, forming an additional triplex D-loop structure with the telomeric double-stranded region.26 
This closed system masks chromosome ends and blocks the activation of the DNA damage response 
at telomeres (see Figure 1-5).27-28 The TRF2 protein plays an essential role in the shelterin function 
and has been shown to promote and stabilize loop formation.29 
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Figure 1-5: Schematic showing the location of the telomere within a normal cell and a simplified model of its 
structure. The t-loop and D-loop structures formed upon binding of the shelterin complex to the telomeric 
overhang are also depicted. Figure modified from reference 
30
. 
 
In proliferating eukaryotic cells, DNA polymerase is unable to fully replicate the lagging 3’ end of the 
telomeric DNA strand, as a result of the “end-replication problem” which arises due to the absence 
of a template strand for attachment of RNA primers. Consequently, after each replicative cell 
division, there is a truncation of the parental guanine-rich 3’ end (shortening of telomeric DNA) in 
the absence of any compensating mechanism. Telomeric DNA continues to shorten (by ca. 50 – 100 
bases) with every round of cell division until the “Hayflick limit” is reached.31  This limit is the critical 
point at which the strand is no longer able to form the t-loop or recruit the protective shelterin 
complex, after this point no further replication can take place resulting in cellular senescence or 
apoptosis.32   
Conversely in stem and germ line cells, the non-coding telomeric DNA at chromosome ends must be 
maintained in order to prevent cell death or any loss of genetic information upon replication.  The 
telomeric DNA is preserved in such cells by the activation of telomerase, a reverse transcriptase that 
serves to elongate telomeric DNA.  Additionally, the telomeric DNA of tumour cells (which display 
uncontrolled proliferation) does not shorten during replication and instead remains stable. In most 
cases, this stabilisation is also accomplished by telomerase, which is expressed in over 80–85% of 
proliferating tumour cells.33-34  
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Figure 1-6: Schematic representation of telomere elongation by telomerase. The enzyme is able to 
synthesise telomeric DNA by catalysing the addition of telomeric DNA repeats to the 3’ end of the single-
stranded telomere using its own associated RNA template.  Figure taken from reference 
35
. 
 
Telomerase is a eukaryotic ribonucleoprotein (RNP) complex made up of a reverse transcription 
protein (hTERT) and a RNA subunit (hTR). hTR is 445 nucleotides long, with a 11 nucleotide putative 
template sequence complementary to the telomeric overhang. The hTERT protein catalyses the 
addition of nucleotides (TTAGGG) to the telomere ends using the RNA template (hTR) which results 
in elongation of the telomeric overhang (see Figure 1-6). Telomerase activity in cancerous cells 
allows telomere length to be maintained and cellular senescence to be eluded. Therefore, the 
inhibition of telomerase is a potential anti-cancer strategy.36  
A variety of approaches have been investigated to achieve telomerase inhibition including; (i) direct 
inhibition of the enzyme by targeting the hTERT or hTR subunits,37-40 (ii) promotion of the formation 
of the shelterin protein complex, thus protecting the telomeric overhang through the formation of T-
loop structures,41 (iii) targeting the c-Myc gene which encodes the transcriptional regulation protein, 
c-Myc, which has a number of roles including the activation of hTERT,42 and (iv) inducing or 
stabilising quadruplex structures in the telomeric region, to prevent the telomerase enzyme from 
binding to/bypassing the folded form of the DNA.43 The last approach, depicted in Figure 1-7, will be 
investigated with respect to this project.   
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Figure 1-7: Schematic representation of telomere elongation by telomerase and its inhibition. Elongation of 
the telomere leads to cancer cell immortalisation (top). Telomerase inhibition by stabilising G-quadruplex 
formation, leads to cancer cell death (bottom). Figure modified from reference 
44
. 
 
1.3.2 Structure of Human Telomeric DNA  
Human telomeric DNA terminates in a singly stranded G-rich overhang, composed of TTAGGG 
repeats. These G-rich sequences have the ability to fold into G-quadruplexes. A number of diﬀerent 
topologies have been observed in the human telomere using both X-ray crystallography and NMR 
spectroscopy.  As discussed previously, diﬀerent G-quadruplex topologies are associated with; (i) the 
syn/anti conformation of guanine residues, (ii) the relative orientation of the G-quadruplex strands, 
(iii) the types of linking loops, the sequences and lengths of telomere DNA, and (iv) the nature of the 
accompanying metal cations. 
The telomeric sequence d[AGGG(TTAGGG)3] was initially resolved by NMR spectroscopy and shown 
to form an antiparallel quadruplex in Na+ solution (Figure 1-8(a)).45 Analysis revealed the formation 
of an intramolecular basket-type structure in which the opposing GGG columns were antiparallel, 
with one diagonal and two lateral TTA loops and the syn/anti mixed guanines. Interestingly, the 
same 22-mer sequence was revealed to adopt a completely diﬀerent, propeller-type structure in a 
crystal grown in the presence of K+ ions (Figure 1-8(b)).46 In this structure, the four core GGGs are 
parallel, with the three linking external loops positioned on the G-quartet core exterior.   
Subsequent NMR studies indicated that the same sequence forms multiple G-quadruplexes in K+ 
solution. In one such study the telomeric sequence (22-mer) was found to give a 3+1 strand folded 
topology where one guanine in each quartet was positioned opposite to the other three (Figure 1-
8(c)).47 In another study it appears to form a mixture of multiple G-quadruplex conformations in the 
presence of K+ ions, indicated by 1D NMR spectroscopy.  Another Htelo sequence (26-mer), resolved 
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by NMR spectroscopy in K+ solution, was found to adopt a mixture of parallel and anti-parallel 
topologies (a hybrid) with propeller and lateral loops.48 There is clear structural diversity displayed 
by the telomeric sequence in potassium solution and a universal agreement on its absolute 
orientation is yet to be reached. The hybrid-type G-quadruplex structure appears to be the 
physiologically relevant conformation of the human telomeric (22-mer) sequence in the presence of 
potassium ions. 
 
Figure 1-8: Structures of telomeric DNA G-quadruplexes. (a) Structure resolved by NMR spectroscopy in Na
+
 
solution. (b) Crystal structure in presence of K
+
. (c) Structure resolved by NMR spectroscopy in K
+
 solution. 
Figures taken from reference 
47
.  
 
In reality, the crowded intracellular environment can affect the structure, stability and activity of 
quadruplex DNA. The above telomeric structures were resolved in physiological buffer and so 
molecular crowding is unaccounted for.  The first high resolution structure of Htelo DNA in 
“crowded” solution was resolved using NMR spectroscopy in 2011.49  Htelo DNA was found to adopt 
a parallel structure with propeller-type loops when in solution containing K+ and 40% (v/v) PEG 200 
(which was used as the crowding agent). The structure most resembles that resolved using X-ray 
crystallography and was proposed to result as a consequence of water depletion. Comparison of the 
two structures found the loops to differ slightly, with the X-ray crystal structure featuring a flatter 
loop orientation in comparison to the “crowded” structure resolved by NMR spectroscopy. 
 
 
1.4 Promotor region: c-Myc DNA 
1.4.1 c-Myc DNA as a Biological Target 
The c-Myc gene is an important regulator of a wide array of cellular processes necessary for normal 
cell growth and differentiation.50 The gene can acquire mutations or dysregulated expression to 
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become an oncogene (proto-oncogene).  Aberrant c-Myc protein expression is a common hallmark 
in many cancers (including breast, colon, cervix, small-cell lung cancers osteosarcomas, and 
glioblastomas).51-53  It has been estimated that c-Myc is overexpressed in up to 80% of solid tumours. 
The nuclease hypersensitive element NHE III1 region of the c-Myc promoter has been shown to be 
particularly important in regulating c-Myc expression, controlling more than 75% of c-Myc 
transcriptional level. Interestingly, one strand of the NHE III1 region is a G-rich strand of DNA 
containing a 27-base-pair sequence (Pu27), located -142 to -115 upstream of the P1 promoter of c-
Myc gene. This region was shown to contain a G-quadruplex forming sequence (see Figure 1-9).  
Further, the formation of a G-quadruplex structure in this region was shown to promote repression 
of c-Myc transcription.42, 54  It should be noted that the control of c-Myc expression is extremely 
complex and other pathways may be used as alternatives to those involving the NHE III1.  
 
Figure 1-9: Different promoters of the c-Myc gene and location and sequence of the NHE III1 region. Arrows 
indicate the location of the different nuclease hypersensitive elements within the c-Myc promoter. Figure 
taken from reference 
55
. 
 
Unlike telomeric G-quadruplexes, which can be formed from the single-stranded DNA template at 
the end of telomeres, the G-quadruplexes in the c-Myc promoter region are constrained by the 
duplex nature of genomic DNA.   There are a number of factors that allow this secondary structure 
to form; (i) the negative superhelicity in the c-Myc promoter region that results from the movement 
of duplex DNA through the transcriptional protein complex of RNA polymerase, leads to exposure of 
the single strands.56 The G- and complementary C-rich regions can then fold into quadruplex and i-
motif structures, (ii) molecular crowding conditions in the nucleus may stabilize these structures 
once formed, and (iii) the G-quadruplexes can be trapped out by proteins that specifically bind to 
and stabilise them.13 
One such protein that has been shown to bind to G-quadruplex in the NHE III1 region of the c-Myc 
promoter is nucleolin.  The protein was not only seen to stabilise the structure but also facilitated its 
formation from a single strand.  Nucleolin has been shown to repress c-Myc transcription.55  
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Conversely, the NM23H2 protein has been shown to bind to the NHE III1 region of the c-Myc 
promoter to stimulate promoter activity.57-58 Studies have identified that the NM23H2 protein can 
unfold quadruplex structures, allowing the re-binding of transcription factors (Sp1, CNBP, HNRNP K, 
RNA POL II) and continuation of transcription.59 Remarkably, the formation of a quadruplex 
structure, by a small molecule, prevents the transcription factor NM23H2 from binding to the single 
strand template (see Figure 1-10).56 
 
Figure 1-10: Schematic showing the proposed role of quadruplex structures in controlling the transcription 
of c-Myc DNA. It also shows the role played by NM23H2, nucleolin and quadruplex binders in stabilising and 
de-stabilising these quadruplex structures. Figure taken from reference 
13
.  
 
The c-Myc protein, expressed by the c-Myc gene, controls a number of other genes involved in the 
proliferation aptitude of cells.60 Interestingly, c-Myc activates the telomerase protein, hTERT and 
binds to proteins that protect the telomere (such as TRF1).61  Activation of hTERT and binding to 
TRF1 by c-Myc leads to telomere elongation in vivo, resulting in cell senescence or cell 
proliferation.62  The induction of quadruplex formation in the promoter region of the c-Myc 
oncogene supresses the expression of the c-Myc protein and also indirectly prevents the elongation 
of the telomere.63 
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Figure 1-11: Schematic describing the cellular relationship between Htelo and c-Myc DNA.    
The capacity of c-Myc to regulate hTERT expression suggests one mechanism by which c-Myc may 
execute its immortalizing potential. However, the oncogenic actions of c-Myc are more complex and 
extend beyond its ability to upregulate the limiting component of the telomerase enzyme. 
 
1.4.2 Quadruplex structure in the c-Myc promoter region  
The 33-nucleotide sequence in the NHE III1 contains 6 G-tracts of unequal length, which form a 
complex mixture of G-quadruplex structures in solution.64  Simonsson and colleagues proposed the 
ﬁrst intramolecular G-quadruplex structure within the c-Myc NHE III1 region (27mer).  A model of the 
structure was proposed using detailed gel electrophoresis. The structure was antiparallel and 
involved three G-tetrads formed from four G-tracts linked by two lateral loops and a central diagonal 
loop.54  In a separate study Hurley et al. described two G-quadruplex DNA conformations from the 
same c-Myc sequence. The proposed structures, based on chemical footprinting experiments, were   
“basket” and “chair” forms.16 The “basket” structure was similar to that proposed by Simonsson, 
whereas the “chair” conformation consisted of three lateral loops (Figure 1.12(a) and 1.12(b)).  Upon 
further examination, by chemical footprinting in addition to circular dichroism (CD), they showed the 
G-rich sequence to fold into a parallel quadruplex structure and to exist as a dynamic mixture of four 
different loop isomers, with the isomers differing by the number of nucleotides making up the 
loops.65 
In contrast to telomeric DNA, there are limited reports of NMR structures of the c-Myc sequence in 
the literature and no reported crystal structure. Phan et al. revealed by NMR spectroscopy that a 
truncated c-Myc sequence (21mer, containing the central four G-stretches) formed an 
intramolecular propeller-type parallel-stranded G-quadruplex in K+ solution. The structure involved a 
core of three stacked G-tetrads formed by four parallel G-stretches with all anti guanines and three 
double-chain-reversal loops bridging three G-tetrad layers.66 Yang et al. reported the solution 
36 
 
structure for the predominant G-quadruplex conformer in potassium. The group proposed the G-
quadruplex structure adopts a stable intramolecular parallel-stranded conformation with three 
guanine tetrads and three side loops; including two single-nucleotide side loops and one double-
nucleotide side loop that connect the four guanine strands. The stability of the structure was 
attributed to the shortness of the loops. The 3'-flanking sequence forms a stable fold-back stacking 
conformation capping the top end of the G-quadruplex structure. The 5'-flanking A and G bases cap 
the bottom end of the G-quadruplex, with the adenine stacking very well with the bottom tetrad.67  
A modified five-guanine sequence (24mer) was also reported to exhibit the parallel structure 
regardless of the cation used (K+, Na+, Ca2+ or Mg2+) suggesting that the parallel conformation of c-
Myc is stable at physiological condition.68 
 
Figure 1-12: (a) NMR resolved quadruplex structure for the predominant stable intramolecular parallel-
stranded G-quadruplex conformer in potassium solution. Figure taken from reference 
69
.  (b) Simplified 
diagram representing the NMR resolved quadruplex structure for intramolecular c-Myc DNA formed in 
potassium solution. Figure taken from reference
67
.  
 
 
1.5 G-Quadruplex RNA 
There has been a recent emergence of interest in RNA G-quadruplexes, particularly in messenger 
RNA (mRNA).  mRNA is involved in the process of gene expression whereby the information in DNA 
is transferred to a mRNA molecule via transcription. The resulting mRNA is a single-stranded copy of 
the gene, which is then translated into a protein molecule. Computational studies for potential 
quadruplex forming regions in human mRNA have identiﬁed an over-representation of these regions 
in the 5’ and 3’ ends of the untranslated regions (UTRs) of mRNA.70  UTRs are located directly either 
side of the coding region and are critical for post-transcriptional regulation of mRNA and 
consequently gene expression. A considerable number of thermodynamically stable RNA G-
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quadruplexes have been discovered in the UTRs of genes of clinical interest.  Examples include 
mRNA sequences related to TRF2 (a telomere specific protein), NRAS (an onco-protein) and BCL-2 
(an apoptosis regulator).71-73  The considerable thermodynamic stability displayed by RNA G-
quadruplexes in vivo, over their DNA counterparts is likely to be due to a combination of factors; (i) 
the lack of a complementary strand in RNA molecules (ii) the participation of the ribose C2’ hydroxyl 
groups in an extended network of hydrogen bonds including interactions with the phosphate 
backbone and G-quartet and (iii) the preference for RNA G-quadruplexes to form stable 
intramolecular parallel quadruplexes. 
 
1.5.1 Biological Relevance of TRF2 RNA  
As discussed in Section 1.3.1, the protein TRF2 has been shown to promote and stabilize t-loop 
formation of telomeric DNA.29  In conjunction with its partner Rap1, TRF2 also triggers the inhibition 
of non-homologous end joining, relying on the DNA-dependent protein kinase at telomeres.74  TRF2 
is overexpressed in several human tumours, such as hepatocarcinomas, breast carcinomas and lung 
carcinomas, suggesting that TRF2 may play a role in tumorigenesis.75-77  Sequences with the ability to 
form quadruplex structures have been found within TFR2 mRNA.  A G-rich sequence located in the 
50 -UTR region of the TRF2 mRNA adopts a stable intramolecular G4 RNA structure in vitro, which is 
able to repress the expression of a reporter gene in vitro and in cells (see Figure 1-13). Mutation of 
this sequence impairing quadruplex stabilization leads to an increased expression.  Furthermore, the 
G-quadruplex RNA motif has been stabilised by selective G-quadruplex ligands, in vivo, and this 
stabilization of quadruplex RNA has a signiﬁcant effect on the expression of a reporter gene, 
suggesting that quadruplex formation in the 50 -UTR from TRF2 represents a novel mechanism to 
control TRF2 expression.  Additionally the TRF2 quadruplex was reported to have remarkable 
thermodynamic stability and was able to form under physiological conditions. According to CD 
spectroscopy the oligonucleotide is most likely fold into a parallel structure.71  
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Figure 1-13: Schematic showing the role of a quadruplex structure in the 5’ UTR of TRF2 mRNA. 
 
  
1.6 G-Quadruplex Nucleic Acid Binders  
Since the report of the first G-quadruplex ligand in 1997, 78 there has been a spectacular emergence 
of molecules designed to interact efficiently and selectively with quadruplex DNA.79-80  Many of these 
molecules have been shown to selectively inhibit the growth of cancer cells (by targeting telomeric 
or oncogene quadruplexes). The majority of G-quadruplex ligands reported to date have been 
organic compounds with predominantly planar, aromatic surfaces enabling the compounds to π-π 
stack atop the G quartet. Additionally compounds able to groove-bind have also been reported as 
successful stabilisers.  More recently, metal complexes have been shown to interact with high 
affinity and selectivity to their target quadruplexes.81  There are a number of structural features of 
the G-quadruplex that can be targeted when designing effective binders. These include; the G 
quartet, the sugar-phosphate backbone of the DNA, the bases in the loops linking the tetrads and 
the central channel of the G-quadruplex structure (see Figure 1-14).  
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Figure 1-14: Structural features of quadruplex DNA that can be targeted for binding. Figure taken from 
reference 
81
. 
 
1.6.1 Organic Molecules 
The majority of organic compounds developed to target G-quadruplex DNA comprise a planar, 
aromatic system prone to π-stacking with the G-tetrad.  Side chains are usually included to provide 
additional interactions with the loops and grooves. Side chains are also exploited to promote water 
solubility, a clinically desirable property. A plethora of organic molecules have been reported to 
interact with quadruplex DNA. These compounds have been surveyed in detail, in reviews and book 
chapters,80, 82 herein the most prominent examples are discussed. 
The bisamido-anthraquinone family was one of the first series of molecules to show effective 
quadruplex stabilisation and telomerase inhibition.78 These molecules possess a planar, aromatic 
core with two protonable side arms (Figure 1-15). However, the quadruplex (over duplex) selectivity 
displayed by the series was poor.83 The molecule template was revised in order to improve the 
selectivity and the core was progressively modified from anthraquinone to fluorenone, acridone and 
finally acridine.84-86  The 3,6-disubstituted acridine, BSU6039 was co-crystallised with quadruplex 
DNA.  The compound was seen to bind, as expected, by π-stacking interactions between the 
aromatic acridine core and the G-tetrad in addition to electrostatic interactions between the 
protonated side-arms and the quadruplex grooves.  An optimised ligand, BRACO-19 was designed 
featuring three side-arms able to interact with three of the quadruplex grooves.87  The compound 
displayed a 31-fold selectivity for quadruplex DNA and a strong potency for telomerase inhibition.82, 
88-89 The optimisation of this compound highlights the importance of the correct substitution pattern 
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in successful quadruplex recognition. The 2,7-dipropylaminoacridine is a very poor quadruplex ligand 
and serves to reinforce this point. 
 
Figure 1-15: (a) Chemical structures of early organic molecules known to bind to quadruplex DNA; Bis-
amindoantraquinone and BRACO-19, a tri-substituted acridine compound (b) The X-ray crystal structure of 
BRACO-19 bound to bi-molecular Htelo DNA, d(TAGGGTTAGGGT)2.  Figure taken from reference 
90
. 
 
The N- methylated pentacyclic acridinium derivate, RHPS4 was one of the first small molecules 
reported to be a strong quadruplex binder (Figure 1-16).  The compound was reported to induce 
quadruplex formation in the 3’ single-stranded telomeric overhang and significantly inhibit 
telomerase activity (IC50-TRAP = 330 nM).91 The compound was reported as an efficient telomere 
uncapping agent as well as a telomere binding proteins modulator (displacing the telomerase 
catalytic subunit (hTERT), leading to DNA-damage signalling and chromosome fusion).74 RHPS4 was 
the first quadruplex binder to enter clinical trials.92 
 
Figure 1-16: Chemical structure of the pentacyclic acridine compound, RHPS4. RHPS4 was the first 
quadruplex binder to enter clinical trials. 
 
A number of polycyclic aromatic systems with N-methyl groups have been used for quadruplex 
binding.  Methylation is understood to improve the water solubility and π-stacking ability of these 
systems.80  An example of such a compound is TMPyP4, a tetracationic porphyrin derivative (see 
Figure 1-17(a)).  TMPyP4 exhibits high affinity for quadruplex DNA and has also been shown to 
inhibit telomerase activity as well as down-regulating c-Myc expression.93-94  However, the 
compound displays very poor quadruplex (over duplex) selectivity.95  The compound has been shown 
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by X-ray crystallography and NMR spectroscopy to have a range of binding modes to quadruplex 
DNA; the expected stacking onto the external G-quartets as well as intercalation between adjacent 
G-tetrads have been reported. The poor selectivity may be a result of the ability of the ligand to 
intercalate between nucleotide bases in duplex DNA. The porphyrin, TQMP and porphyrazine, 3,4-
TMPyPz are examples of further tetracationic macrocycles shown to display impressive binding to 
quadruplex DNA (Figure 1-17(b) and (c)). TQMP displayed improved selectivity, likely by virtue of 
four flexible cationic side chains.96 These side arms were shown to disrupt intercalation into duplex 
DNA and enable electrostatic interaction with the loops and grooves of quadruplex DNA.  Further 
the four hydroxyl groups were thought to allow effective hydrogen bonding to the DNA scaffolds. 
The porphyrazine derivative, TMPyPz displayed a 100-fold increase in affinity compared to TMPyP4 
(measured by surface plasmon resonance) as well as improved selectivity.97 
Diselenosapphyrin, Se2SAP, a porphyrin molecule possessing an expanded core, was shown to bind 
both strongly and selectively (50-fold) to quadruplex DNA (Figure 1-17(d)). More significantly, this 
ligand was one of the first to be able to discriminate amongst various forms of quadruplex DNA.65  
The disadvantage of the ligand being its very low-yielding preparation. The natural product, 
telomestatin, a polyaromatic macrocycle was shown to stabilise quadruplex DNA. Telomestatin is a 
naturally occurring molecule isolated from Streptomyces anulatus (Figure 1-17(e)).98  The compound 
is one of the best known telomerase inhibitors (IC50 = 5nM) and displays a 70-fold selectivity over 
duplex DNA. The selectivity is likely to be due to its inherent neutral and cyclic nature. Again the 
total synthesis of the ligand is very low-yielding and is not conducive to large scale preparation.99-100 
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Figure 1-17: Selected G-quadruplex ligands. 
 
There are significant conformational differences in the grooves of quadruplex versus duplex DNA.  
Therefore ligands that target these loops are expected to provide improved quadruplex selectivity. 
Distamycin A is one such compound for which groove binding has been proven. The interaction of 
the ligand with d[TGGGGT]4 was investigated and it was found that the ligand binds in a 4:1 ratio to 
the quadruplex as a dimer in an anti-parallel fashion, by adopting a cresent shape, lying side-by-side 
in a groove and by establishing four hydrogen bonds with guanine (Figure 1-18).101 
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Figure 1-18: (a) Chemical structure of Distamycin A.  (b) The three-dimensional structure of the 4:1 
distamycin A, [d(TGGGGT)]4 complex determined by NMR spectroscopy and dynamics calculations. Figure 
taken from reference
101
. 
 
The bisquinolinium series containing a pyridodicarboximide (PDC) core has shown impressive 
properties as quadruplex ligands. Two notable members, 370A and 360A exhibit a high degree of 
stabilisation, remarkable selectivity (> 150 -fold) and have been shown to induce the inhibition of 
telomerase (Figure 1-19(a)).  These compounds have been shown to induce delayed growth arrest 
and apoptosis in immortalized cell lines. The synthesis of the compounds is via a simple two-step 
synthesis, making them even more attractive.102-103 A structurally similar ligand featuring three ethyl 
amine appendages, pyridostatin (PDS) also displayed attractive features (Figure 1-19(b)). The 
compound exhibits impressive stabilisation of and selectivity for quadruplex DNA in vitro. 
Pyridostatin was shown to alter the integrity of shelterin, through POT1 uncapping, thereby 
triggering a DNA-damage response at telomeres.104  Recently, the compound was used in 
conjunction with a chromatin Immunopreciptiation (ChIP) assay to allow mapping of the genomic 
targets of the G-quadruplex–binding small molecule (see Section 1.7.1).105  A series of 
phenanthroline analogues, Phen-DC3, with a cross-sectional area similar to the external Htelo G-
quartet displayed impressive selectivity for quadruplex DNA (Figure 1-19(c)). This finding highlights 
the huge potential of bisquinolinium ligands as quadruplex DNA stabilisers.106 
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Figure 1-19: Selected G-quadruplex ligands (a) pyridodicarboximide (PDC) (b) pyridostatin and (c) 
phenanthroline analogue, Phen-DC3. 
 
1.6.2 Metal Complexes 
More recently, the use of metal complexes as quadruplex DNA stabilisers has seen considerable 
activity.  Metal complexes offer a number of structural and electronic advantages over their organic 
counter-parts, which can be exploited when designing quadruplex ligands; (i) the metal centre can 
play a vital role in organising ligands in specific geometries that are optimal for quadruplex binding. 
These geometries can be difficult if not impossible to achieve in purely organic systems, (ii) libraries 
of metal complexes can be generated with relative ease by the introduction of alternative metal 
centres or ligands.  This allows the complexes to be fine-tuned to achieve optimal binding,  (iii) the 
metal centre can theoretically be positioned over the cation channel of the quadruplex, both 
increasing electrostatic stabilisation and optimising the stacking interactions of the chelating ligands 
with the accessible G-quartet, further (iv) the electronic withdrawal properties of the metal centre 
can reduce the electron density on co-ordinated aromatic ligands, thus promoting more effective π-
π interactions, and additionally (v) metal complexes often display interesting optical, magnetic or 
catalytic properties that could be exploited for the development of quadruplex probes or cleaving 
agents.81 
The majority of metal complexes are designed to π-stack atop the G-quartet with the metal serving 
to orientate the ligands in a planar manner and interact electrostatically with the cation channel.  
More recently metal complexes have been designed to interact with nucleic acids through 
alternative and/or additional modes, such as direct coordination to bases or the phosphate 
backbone (quadruplex DNA grooves). Extensive reviews on quadruplex DNA binding metal 
complexes have been reported, here, the most significant examples are discussed.81, 107 
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The earliest reported metal complexes investigated as quadruplex DNA binders were 
metalloporphyrins.108  The mode of binding for porphyrin-based metal complexes was proposed to 
be analogous to that of the free porphyrin ligands i.e. via π-stacking of the metalloporphyrin system 
on top of the G-tetrads at the termini of the quadruplex (end stacking).  This proposed mode of 
binding was supported by computational modelling and experimental data.109  The two main 
parameters that were determined to be critical for interaction of the metalloporphyrin with 
quadruplex DNA were; (i) the choice of meso substituent and (ii) the choice of metal ion. 
Metalloporphyrins with cationic meso substituents have been shown to display improved binding 
properties. The cationic substituents are envisaged to lead to electrostatic interactions with the 
negative DNA backbone in the loops or grooves of the quadruplex. Methylpyridinium or 
methylquinolinium meso-substituents have been shown to be effective in stabilizing the Htelo 
quadruplex and inhibiting telomerase in vitro.108  The metal centre of the metalloporphyrin system is 
proposed to engage in additional electrostatic interactions and more importantly is critical in 
dictating the geometry of the metal complex.  A plethora of metals (including main-group, 
transtition metals and lanthanides) have been investigated by insertion of the metal into the meso-
methylpyridinium-substituted porphyrin (TMPyP4) (Figure 1-20(a)).109 The results indicated that 
planar or square-pyramidal complexes bound strongly to preorganised quadruplexes (e.g of CuII and 
ZnII respectively).110-112  This was expected due to the availability of a planar face in the complex 
being accessible for π-stacking.  The complexes were found to bind to quadruplex DNA in a 2:1 (or 
1:1) stoichiometry. A MnII-containing porphyrin with extended methylpyridinium cationic arms 
exhibited strong binding affinity for Htelo DNA (ca. 108 M-1) and selectivity (4 orders of magnitude 
over duplex DNA) (Figure 1-20(b)).113 
 
Figure 1-20: First reported metal complex G-quadruplex stabilisers: (a) Metal-TMPyP4 and (b) a modified 
Mn
II 
containing porphyrin complex found to be selective for Htelo quadruplex DNA. 
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Recently a novel Zn(II)-Pt(II) hetero-bi-metallic porphyrazine was reported and shown to interact 
with Htelo DNA (Figure 1-21).  Interestingly, the interaction of the complex with the quadruplex is 
influenced by the nature of the cations present in solution.  In the presence of K+ the complex 
influences the quadruplex conformational equilibrium favouring the parallel form.  In contrast, in 
Na+ the starting antiparallel conformation of the quadruplex is retained upon addition of the 
complex.114 
 
Figure 1-21: Structure of the bi-metallic macrocyclic complex shown to interact with G-quadruplex DNA. 
Metal complexes of non-cyclic polypyridyl planar ligands have been reported as impressive 
quadruplex stabilizers.  In these complexes the metal ion plays a critical structural role by inducing a 
planar ligand conformation not intrinsic to the free ligand.  Again these complexes benefit from side 
arms which allow favourable interactions with the phosphate backbone and within the loops and of 
the quadruplex DNA. 
Work conducted in our group (in collaboration with Neidle) has shown nickel(II) -salphen complexes 
to be excellent quadruplex binders (Figure 1-22(a)).115-116  The nickel(II) salphen complexes, 
functionalised with cyclic amine side chains, displayed some of the highest degrees of stabilization of 
Htelo quadruplex DNA recorded by the FRET assay (at best ΔTm= 33 oC at 1 μM) (see Chapter 3, 
section 3.3).  The complexes also displayed considerable selectively over duplex DNA (1000-fold). 
Additionally, a number of the complexes were found to be potent telomerase inhibitors (telEC50 
values in low micromolar range as reported by TRAP-LIG assay).  The significance of complex 
geometry for improved binding to Htelo DNA was demonstrated in a comparative study of nickel(II), 
copper(II), zinc(II), and vanadyl(IV) complexes with the same salphen ligand.115  Square-planar 
complexes typically appeared superior to square-pyramidal ones.  Further modifications involved 
exploring the effect of electron withdrawing fluoride groups on the ligands.  This modification 
reduced the electron density of the aromatic group and was subsequently seen to promote more 
effective π-π stacking.  The first crystal structure of a metal complex interacting with quadruplex was 
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recently reported by our group (in collaboration with Neidle).117 The nickel(II) and copper(II) salphen 
complexes were found to π-π stack atop quadruplex DNA, verifying the hypothesised binding mode 
(see Figure 1-22(b)).  
 
Figure 1-22: (a) Chemical structure of members of the metal salphen complex series shown to be potent 
quadruplex stabilisers (b) The X-ray structure of the nickel(II) complex with Htelo DNA, it shows the 
complexes to π-π stack on both external G-tetrads. Figure taken from reference 
117
. 
 
Supramolecular architectures have been rationally designed to afford strong interactions with 
quadruplexes.  A PtII-based molecular square has been shown to successfully target telomeric 
quadruplex DNA (Figure 1-23(a)).118  The complex, which was prepared by a single-step self-assembly 
process from 4,4’-bipyridyl and [Pt(en)(NO3)2], is the correct size and shape to sit atop the terminal 
G-quartet.  Modelling studies have indicated that the four corner metal ions give rise to close-range 
electrostatic interactions.   Additionally the diamine ligands allow for hydrogen bonding with the 
DNA sugar-phosphate backbone.  Recently, other self-assembled platinum(II) molecular squares 
have been reported to bind extremely tightly to quadruplex DNA (with up to 109 M-1).119-120  These 
supramolecules comprise of platinum(II)-amine corners linked by 4,4’-dipyridyl, pyrizine and 
quinoxaline bridges.  The quinoxaline-bridged complexes were most effective in terms of telomerase 
inhibition and anticancer efficacy.  Interestingly, these complexes bound to quadruplex DNA with an 
unprecedented binding ratio of 6:1 (platinum(II):quadruplex) (Figure 1-23(b)).  
A series of chiral bimetallic triple-helical cylinders (NiII and FeII) based on a diimine ditopic ligand 
were reported by Qu and co-workers to selectively recognize Htelo DNA (Figure 1-23(c)).121  
Interestingly, only the P-enantiomer is able to interact with the Htelo quadruplex, and convert it 
from the antiparallel conformtaion (in the presence of Na+) to the hybrid form.  More recent studies 
found the P-enantiomer can induce Htelo quadruplex formation in salt deficient conditions.122 
Formation was reported to be fast, efficient and loop sequence dependent.  Some sort of end-
binding mode has been indicated as a result of the S1 nuclease cleavage assays, which shows the 
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Htelo sequence is protected from cleavage at the two ends.  The authors propose that the cylinders 
stack atop the quadruplex through their extensive hydrophobic exterior and that the metal centres 
concurrently engage in ionic interactions with the loops and grooves.  Furthermore the complex was 
found to not only be selective for Htelo DNA over duplex DNA but over other quadruplex forming 
sequences as well (namely c-Myc and c-kit DNA).122  Remarkably, the M-enantiomer of the di-nuclear 
nickel(II)-cylinder was shown to preferably bind to higher-order G-quadruplexes over a single G-
quadruplex (with up to 200-fold selectivity).  Interestingly the P-enantiomer did not display such 
selectivity.  This was the first example of small molecule mediated higher-order quadruplex DNA 
recognition.123 
Supramolecular cubic structures developed by Therrien et al. (in collaboration with our group) have 
been investigated as possible quadruplex DNA binders (Figure 1-23(d)).124 The rationale of this 
design was to eliminate the possibility of intercalation of the binder and hence increase the 
selectivity of the complex for quadruplex versus duplex DNA.  A series of structures that brought 
together two ZnII-tetrapryridinoporphyrins, bridged by dihydroxybenzoquinonato ligands, into 
octacationic cubes were shown to bind strongly to both Htelo and c-Myc sequences.  
 
Figure 1-23: (a) The chemical structure of the platinum(II) supramolecular “square” complex. (b) Self-
assembled platinum(II) squares with quinoxaline bridges. (c) The bi-metallic triple-helical cylinders, the 
nitrogen atoms participate in covalent bonds to the divalent metal ions, nickel(II) and iron(II). (d) Chemical 
structure of an octa-ruthenium cube.  
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Recently, Monchaud et. al., reported the first prototype of a nature-inspired G-quadruplex ligand 
(Figure 1-24).125 The ligand design was founded on its possible supra-intramolecular G-quartet 
formation, enabling it to interact with G-quadruplex DNA via a nature-mimicking binding mode, 
based on the association between two G-quartets, one being native (quadruplex) and the other 
artificial (ligand). The formation of the synthetic G-quartet was templated by a DOTA-like 
macrocycle.  A terbium centre was introduced into the DOTA cavity to induce planarity.  The 
complex displayed both affinity and very high selectivity indicating the responsibility of the metal-
mediated conformational switch for the quadruplex recognition. 
 
 
Figure 1-24: Schematic representation of the structural rearrangements related to the coordination of 
terbium by a DOTASQ: guanines (G) are represented as grey squares, nitrogen and oxygen atoms as blue and 
red circles, and N4, O4 and G4 planes as blue, red and grey squares respectively. Figure taken from 
reference
125
. 
 
Although platinum(II)-terpyridine complexes were known to intercalate into double stranded 
DNA,126-128 they were first recognised as effective quadruplex binders by Teulade-Fichou et al.129  
Terpyridine complexes of copper(II), platinum(II), zinc(II) and ruthenium(III) were prepared and 
studied (Figure 1-25(a)). The affinity and selectivity of the complexes for quadruplex DNA was shown 
to be dependent on the metal geometry.  The square planar and square pyramidal (of platinum(II) 
and copper(II) respectively) complexes were the most effective quadruplex stabilisers, with the 
copper(II) complex displaying the best selectivity.  While the trigonal bipyramidal and octahedral (of 
zinc(II) and ruthenium(III) respectively) complexes provided less stabilisation.  The study clearly 
demonstrated the need for quadruplex stabilisers to have at least one accessible planar surface to 
engage in effective π-π stacking interactions with the external tetrad.   
Detailed studies with longer incubation times (24 h), conducted by the same group on a series of 
platinum(II) terpyridine complexes (Figure 1-25(b)) suggested they interact with Htelo-like 
quadruplex structures through site-selective platination of certain adenine or guanine bases (present 
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in either the lateral or diagonal loops).130  The pattern of platination is dependent on the secondary 
structure of the quadruplex, accessibilities of the bases, and individual characteristic of the 
complex.131-132  Therefore platinum(II) terpyridine complexes are proposed to interact with 
quadruplex DNA, initially via non-covalent means (π-π or electrostatic interactions) and then, after 
longer exposure (24 h), by formation of covalent bonds. 
 
Figure 1-25:  (a) Terpyridine complexes used to investigate the relationship between the geometry around 
the metal centre and quadruplex DNA binding affinity. (b) Example of a platinum(II)-terpyridine complex 
found to covalently bind to adenine bases present on the quadruplex DNA loops. 
 
Our group developed the metal terpyridine complexes by modification of the ligand to include apical 
substituents.  It was demonstrated that the addition of side chains with cyclic amine head groups on 
the ligand can moderately enhance the binding affinity and selectivity (Figure 26(a)).133  Further 
modifications to the metal terpyridine series led to the design of novel dimetallic systems.134  These 
complexes are based on square planar or square-based pyramidal (of PtII and CuII respectively) 
terpyridine units linked via a suitable spacer to di-picolylamine group (Figure 26(b)).  The proposed 
mode of interaction of these complexes is via π-π end-stacking of the metal terpyridine unit and 
electrostatic/ coordination interactions to the phosphate backbone by a second metal (coordinated 
to the di-picolylamine group).  The dimetallic complexes have been shown to display higher affinity 
and selectivity for quadruplex DNA (Htelo and c-Myc) in comparison to their monometallic 
analogues.  
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Figure 1-26:  Functionalised metal-terpyridine complexes, with (a) organic or (b) metal-containing 
appendages, were found to bind with higher affinity than their unfunctionalised counterparts. Further, 
complexes with metal-containing appendages generally displayed higher affinity than their organic 
counterparts.  
Bi-modal targeting (like the terpyridine-DPA bimetallic systems) can be exploited in the development 
of metal complexes. The metal terpyridine study highlights the potential of dimetallic systems, 
where each metal has a distinct target, in the quest for stabilisers with high binding affinity and 
selectivity for quadruplex DNA. 
 
 
1.7 Identifying Cellular G-Quadruplex Structures and Functions 
 A large amount of biophysical and biochemical data has been collected on quadruplex DNA.  
However, evidence for the existence and biological relevance of G-quadruplex structures in a cellular 
context is still scarce.  The design of molecular tools to probe and monitor G-quadruplex formation 
throughout the genome is an on-going challenge.  There are a number of recent approaches that 
have been developed to address this challenge. 
1.7.1 Bioinformatics and Molecular Biology Approaches  
1.7.1.1 Computational Analysis 
As described previously, computational studies have been carried out to predict where putative G-
quadruplex forming sequences (PQS) occur in genomes.19   Algorithms have been developed based 
on a number of criteria to identify sequences with the propensity to fold into G-quadruplexes.22, 135-
137 It has been demonstrated that these guanine rich sequences can display multiple folding 
possibilities, further complicating the analysis of data.138 More recently, a novel prediction 
framework was established to determine the thermodynamic stability of G-quadruplexes based on 
sequence information alone.139  Overall, these computational studies have proved very valuable and 
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have served to stimulate wider interest in the potential biological roles of G-quadruplexes.  
However, there are limitations to these analyses, for example there is no algorithm that takes into 
account how the local chromatin structure or superhelicity of the DNA may affect G-quadruplex 
formation.56 
1.7.1.2 Chromatin Immunopreciptiation (ChIP): protein-DNA complexes (indirect) 
The identification of selective G-quadruplex binding proteins provides the prospect to locate these 
structures in cellular DNA.140  Chromatin Immunopreciptiation (ChIP) approaches can be employed to 
achieve this. ChIP enables the isolation of protein-DNA complexes with the aim of identifying the 
exact binding loci of a protein of interest.  The cells are first lysed and the proteins and nucleic acids 
are cross-linked with formaldeyde, the chromatin is isolated and the DNA is then fragmented.  DNA-
protein complexes are then selectively precipitated using antibodies against the protein of interest. 
The DNA sequences recovered can then be released (by breaking the protein-DNA cross-link) and 
analysed by high-throughput screening (ChIP-Seq).  Recent literature has successfully applied this 
technique to quadruplexes. In one instance, a quadruplex resolvase, Pif1 helicase, was shown to bind 
several guanine-rich sites, most of which were predicted by computational analysis.141-142   In another 
assay, the quadruplex DNA binding ATR-X syndrome protein was found to bind to tandem repeats 
with high guanine density.143  Other assays investigated the FMRP protein (involved in Fragile-X 
retardation syndrome) found FMRP-DNA complexes where the DNA component was largely tandem 
G-rich repeats.144-145  Interestingly, this approach was employed to provide an analysis of the 
genomic targets of the G-quadruplex–binding small molecule pyridostatin (PDS).105  Cells treated 
with PDS were shown to produce transcription- and replication-dependent DNA damage 
(phosphorylation of histone protein H2A, to γH2AX).  Consequently ChIP-seq was carried out using 
γH2AX antibodies and showed that PDS targets gene bodies containing clusters of sequences that 
are able to adopt a G-quadruplex conformation (see Figure 1-27).  Additionally, cellular labelling of a 
PDS analogue was used to enable (i) visualization of the localization of the small molecule and (ii) 
indirect imaging of quadruplex DNA in cells. 
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Figure 1-27: ChIP assay carried out using γH2AX antibodies.  The assay showed that PDS targets gene bodies 
containing clusters of sequences that are able to adopt a G-quadruplex conformation. Figure taken from 
reference 
146
.  
 
 
1.7.1.3 Antibodies (direct) 
In cellulo sensing of G-quadruplex DNA can be achieved using modified antibodies or G-quadruplex 
based aptamers.147-148 
A recent publication by Balasubramanian describes the application of an engineered, structure-
specific antibody probe that binds with high selectivity and low nanomolar affinity to DNA G-
quadruplex structures.23  This antibody was employed to visualize DNA G-quadruplex structures in 
the genomic DNA of human cells (Figure 1-28).  The study showed explicitly that G-quadruplex 
formation in DNA is modulated during cell-cycle progression. The finding provided substantive 
evidence for the formation of G-quadruplex structures in the genome of mammalian cells. 
 
Figure 1-28: (a) Visualisation of G-quadruplex structures in human cells (by the BG4 antibody). (b) 
Immunofluorescence for BG4 on metaphase chromosomes isolated from Hela cervical cancer cells. Discrete 
BG4 foci (red) can be observed at the telomeres. Figure taken from reference 
23
. 
 
The same group has recently published a different engineered antibody to probe G-quadruplex 
structures present in human breast adenocarcinoma cells. The isolation of genomic DNA fragments 
bearing single, as well as multiple G-quadruplex structures was achieved using a high sensitivity 
structure based pull-down strategy. Deep sequencing was then used to detect and map G-
quadruplexes at high resolution.  Stable G-quadruplex structures were found in sub-telomeres, gene 
bodies and gene regulatory regions.149  
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1.7.2 Small Molecules: Affinity tags 
Small molecules (affinity tags) have recently been reported as powerful tools to enable the sensing 
and isolation of G-quadruplex structures present in the genome.146 The types of ligands and 
strategies employed can be divided into three main categories. 
(i) The first approach relies on the use of a molecule containing an affinity tag capable of strong 
binding to G-quadruplex DNA via specific, non-covalent interactions. The approach is analogous to 
that of ChIP assays whereby stable DNA-ligand complexes can be pulled down from cellular 
solutions.  The DNA-ligand complexes can then be disrupted upon thermal denaturation or exposure 
to chaotropic reagents.  This is crucial to recover the pulled-down sequences for further analysis and 
sequencing. The first G-quadruplex affinity column, reported by Smith et al., describes the method 
for the attachment of a G-quadruplex binding ligand, N-methyl mesoporphyrin (NMM) to a 
sepharose resin.150  The ability of the resin to bind to radio-labelled DNA oligonucleotides with the 
capacity to form quadruplex structures was investigated.  There was a correlation between 
sequences with quadruplex forming potential and the binding of those sequences to the NMM-resin.  
An affinity tag matrix based on the potent and selective pyridostatin scaffold (see Section 1.6.1 and 
1.7.1.2), containing an additional biotin tag for affinity isolation was developed.151  The small 
molecule was envisaged to act as engineered mimics of naturally occurring proteins or antibodies.  In 
vitro experiments demonstrated the ability of the affinity tag to isolate G-quadruplex DNA from 
mixtures of competing nucleotides (1:1) including single stranded DNA, double stranded or hairpin 
RNA. The mixtures were incubated with the affinity reagent, followed by the addition of 
streptavidin-coated magnetic beads to allow solid phase separation.  The strategy was successful in 
pulling-down telomeric DNA from genomic DNA derived from cellular extracts. However, some 
technical issues were encountered using biotin as affinity tags in cellular experiments, limiting the 
approach to cell extracts.  
Alternatively, cross-linking strategies have been employed within the affinity tag approach.  
(ii) Formaldehyde cross-linking can be used to form a link between the probes and DNA motifs. 
Paraformaldehyde or gluteraldehyde can be used to form a stable covalent methylene bridge 
between a primary amine on the ligand and one of the free amino guanine functions on the G-
quadruplex motif and serves to strengthen the stability of the ligand-DNA adduct.  The covalent link 
can be reversed in relatively mild conditions to recover the oligonucleotide. The main disadvantage 
of this technique is the non-specific nature of the cross-linking agent which might introduce 
unwanted modifications within the cell resulting in artefacts.152  
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(iii) The probes can be embedded with alkylating agents, offering the advantage of creating selective 
cross-links proximal to the genomic area of interest, brought about by the DNA-ligand interaction at 
specific loci.  The first example of this was described by Bertrand et al.  Unfortunately, the strength 
of the newly formed covalent bond was such that it was not possible to recover the DNA.153  For this 
technique it is important that (i) the alkylation process is reversible to allow recovery of the alkylated 
sequence after pull-down and (ii) the possibility of non-specific nucleophilic attack is minimised. Di 
Antonio et al. employed a napthalene diimide (NDI) derivative (with a quinone methide precursor) 
as a G-quadruplex recognition moiety.154 Quinone methides can be chemically tuned, allowing 
reversible alkylation. Selective cross-linking for human telomeric G-quadruplex over duplex DNA was 
observed. Unfortunately, the alkylation efficiency was relatively poor. Recently, a novel Schiff-base 
catechol derivative combined with a biotin group was designed as G-quadruplex crosslinking 
candidates.155  The probe was found to isolate G-quadruplex DNA in vivo through cross-linking. 
 
In all cases it is crucial that the chemical handle (for affinity tag attachment, cross-linking purposes 
or labelling) must not affect binding to the quadruplex DNA.  
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1.8 Aims and Objectives 
 
The first major aim of this study is to design and synthesise a family of molecules with good affinity 
and selectivity for quadruplex DNA (over duplex DNA), and selectivity for specific quadruplex 
topologies over others (namely c-Myc or Htelo DNA).  The second aim is to develop small molecule 
containing affinity tags capable of selectively isolating quadruplex DNA from solutions containing 
other competing biomolecules (e.g. other topologies of DNA, RNA and proteins). 
Three main areas were targeted in order to achieve this overall aim:  
1.  Design and synthesis of a series of di-metal complexes (with a combination of covalent and non-
covalent binding modes) with the ability to target quadruplex DNA.  The complexes were designed 
to possess a metal-terpyridine core capable of π-π stacking with quadruplex DNA and a metal-cyclen 
based side arm to provide additional interactions with the loops, grooves and phosphate backbone 
of DNA.  Different metals were used to synthesise the di-metal systems with distinct roles for each 
metal. The complexes were characterised via spectroscopic, analytical and structural techniques. 
2.  The abilities of the complexes to π-π stack in solid and solution states using X-ray crystallography, 
1H NMR and UV-Vis spectroscopy were investigated.  This would give an indication of their 
propensity to interact with quadruplex DNA via π-π interactions.  The ability of the complexes to 
bind non-covalently to quadruplex (Htelo and c-Myc) and duplex DNA was assessed using 
fluorescence intercalator displacement (FID) assays, fluorescence resonance energy transfer (FRET) 
assays, UV-vis titrations and circular dichroism (CD) spectroscopic studies.  The cytoxicity (IC50 value) 
of the complexes towards cancer and normal cell lines was determined using the MTS assay.  Finally, 
the ability of the complexes to regulate c-Myc oncogene expression was determined using 
immunoblot analysis.  
3.  A family of metal terpyridine and metal salphen complexes were attached to solid supports and 
used to isolate labelled G-quadruplex DNA from solution in the absence and presence of competing 
agents (e.g. duplex DNA and proteins).  The final objective will be to apply this methodology to 
examine the genomic distributions of quadruplex DNA and possibly identify new quadruplex folding 
sequences. 
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Chapter 2 
Synthesis and Characterisation 
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2.1 Overview 
A series of di-metallic complexes were synthesised and characterised. These complexes will be 
presented in two main categories; homo-nuclear and hetero-nuclear complexes. This chapter will 
encompass a brief description of the complexes’ design and a detailed account of the synthetic 
approach used to prepare them.  The complexes were fully characterised using 1H, 13C, 19F and 31P 
NMR spectroscopy, as well as by ESI-mass spectrometry and elemental analysis.  X-ray crystal 
structures of some of the complexes were determined providing confirmation of their structure and 
enabling their binding potential to quadruplex DNA to be assessed.  Additionally, the X-ray 
crystallographic data was used to investigate the ability of the complexes to π-π stack in solid state 
whilst variable temperature 1H NMR spectroscopy was used to probe the ability of the complexes to 
display π-π interactions in solution.  Density functional theory (DFT) was used to optimise the 
structure of selected complexes in order to gain further structural insight.  DFT was used to enable 
docking of these optimised structures with a folded quadruplex sequence in order to decipher the 
most likely binding mode. 
 
 
 2.2 Complex Design 
The archetypal quadruplex stabiliser, as discussed in Chapter 1, largely consists of: (1) a polycyclic 
planar aromatic moiety capable of stacking on the face of the planar guanine quartet; (2) at least 
one substituent terminating in cationic group, where the substituents are typically short acyclic 
chains terminating in a cationic or readily protonatable groups.  These groups are expected to 
interact electrostatically with the grooves and phosphate backbone of quadruplex DNA.  
Furthermore these substituents are an important feature for enhancing water solubility, allowing for 
biophysical and cellular studies to be carried out; and (3) a partial positive charge that is able to 
occupy the centre of the guanine quartet thus stabilising the structure by electrostatic interactions 
(in a similar way to sodium and potassium ions which reside at this site under physiological 
conditions).  
A key issue when designing quadruplex DNA binders is to achieve selectivity for quadruplex over 
duplex DNA.  This design challenge can be addressed in terms of the difference between the surface 
area of a G-quartet and of a base-pair, but also in terms of loop- and groove- recognition. 
Furthermore, the ultimate goal is also to achieve selectivity between different quadruplex structures 
– an even more challenging issue.  Quadruplex scaffolds differ largely due to the rich variation in 
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loop and groove topologies, therefore the concept of loop- and groove- recognition can be 
employed to allow discrimination between different quadruplex sequences. With these principles in 
mind, a series of dual targeting di-homometallic and di-heterometallic terpyridine cyclen complexes 
were designed and synthesised (see Figure 2-1(a)).   
 
 
Figure 2-1: (a) Dual-targeting di-metallic terpyridine-cyclen complexes. (bi) and (bii) Qualitative docking of 
complex where M1 = Pt, M2 = Zn and X = Cl atop Htelo DNA in potassium solution (PDB: 1KF1). The external 
guanine tetrad is represented as CPK. The image was created using Maestro Schrodinger. The water 
molecules and hydrogen atoms have been removed for clarity. 
 
The terpyridine core contains an aromatic system, which when in a planar conformation (organised 
by metal coordination), can effectively stack atop quadruplex DNA platform via π-π interactions.  The 
ligand was designed to feature a second binding moiety, namely a cyclen macrocycle.  The cyclen 
provides a second site for metal coordination – yet considerably different to the terpyridine – and 
thereby provides potential additional interactions with the loops, grooves and negatively charged 
phosphate backbone of quadruplex DNA. The length of the linker selected to tether together the 
terpyridine and cyclen units was selected based on preliminary qualitative docking experiments.  The 
three carbon linker displayed the necessary length to allow the aromatic terpyridine to sit atop the 
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G-tetrad and allow the cyclen to extend into the groove of the quadruplex and interact with the 
phosphate backbone (see Figure 2-1(b)).  Different metals were used to determine the relationship 
between complex geometry and quadruplex DNA affinity.  The platinum(II) and copper(II) 
terpyridine complexes (those with at least one planar face) were expected to bind strongly with 
quadruplex DNA.  On the other hand, the zinc(II) terpyridine complex was expected to bind weakly 
and hence was synthesised and studied for comparison.   
 
One of the advantages of the terpyridine-cyclen framework is that it allows two different metals to 
be incorporated into a single molecule. The appropriate metal can be selected for each moiety to 
provide the optimum geometry and electronic properties to allow that moiety to target specific 
structural features of quadruplex DNA (tetrad, loops or grooves).  As discussed above, metals that 
can engineer a planar surface are ideal for terpyridine co-ordination as they facilitate π-π stacking 
interactions with the external quartet.  Metal cyclens, particularly zinc(II) cyclen have been widely 
reported to bind very strongly to free phosphate ions, nucleobases and DNA strands.156  Zinc(II) 
complexes recognise specific DNA sequences through thymine coordination.157-158 There are a 
number of quadruplexes that have loops featuring thymine bases (e.g. ATT loops of Htelo) and so it 
is reasonable to propose that these loops might be targets for the zinc(II) cyclen.  Considering the 
similar electronic properties of zinc and copper (both are “hard” metals), copper(II) cyclens were 
also expected to chelate thymine bases. Therefore the addition of zinc and copper to cyclen was 
expected to enhance binding to the DNA grooves and hence improve quadruplex affinity.    
 
While there is vast evidence that platinum binds strongly to terpyridine there is no known proof that 
it binds to cyclen.  The mis-match in size of the platinum metal diameter (van der Waals diameter ca. 
350 pm) and the cyclen cavity (ca. 0.35 nm2) explains the non-existence of a platinum(II)-cyclen 
adduct.  Conversely, zinc and copper bind to terpyridine with reasonable affinity (1013 M-1) but are 
known to bind to cyclen to a much greater extent (with dissociation constants in the femto-molar 
range).159-160 With this in mind it was rationalised that the di-metallic complexes could be prepared 
by (i) initially reacting the ligand with platinum, to enable platinum coordination to terpyridine, then 
(ii) introducing the second metal (e.g. zinc or copper) to bind to cyclen. The second metal (zinc or 
copper) is not expected to displace platinum from the terpyridine binding site, instead it is expected 
to coordinate rapidly to cyclen (owing to its significantly higher Kd value for cyclen over terpyridine).   
 
The platinum(II) complex, 3a, was functionalised further to include two side arms. This was achieved 
by attaching one substituent to the terpyridine core (π-π stacking component) and one to the metal 
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centre, through direct coordination.  The extra side arm was envisaged to enhance selectivity by 
sterically hindering intercalation between base pairs in duplex DNA (see Figure 2-2).  
 
 
Figure 2-2:  Rationale of dual targeting di-metallic terpyridine-cyclen complex motif. 
 
 
2.3 Synthesis 
2.3.1 Synthesis of Terpyridine Cyclen Ligand 
 The terpyridine cyclen ligand, L5 was prepared using a 5-step route (depicted in Scheme 2-1).  The 
first step was carried out as described by Meyerhoff et al.161  It involves the tri-Boc protection of 
cyclen, achieved by reacting cyclen with three equivalents of di-t-butyl dicarbonate.  The reaction 
proceeds via a base-assisted nucleophilic substitution of the anhydride by nitrogen atoms on cyclen. 
t-Boc protecting groups were chosen to allow facile removal using standard acid hydrolysis 
conditions.  The reaction was conducted in chloroform, in the presence of triethylamine, as the basic 
component.  Three equivalents of both base and anhydride were used to ensure that the tri-
substituted species was the major product.  The reaction was left at room temperature overnight. 
The resultant residue was purified by column chromatography using alumina (chloroform/hexanes) 
to yield the desired product, L1, as a white solid.  The product was characterised by 1H and 13C NMR 
spectroscopy and mass spectrometry.  The integration of the alkyl protons of the Boc group relative 
to the cyclen protons indicated that the tri-protected cyclen had been prepared and isolated.    
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The second step involved the attachment of 1,3-dibromopropane to the remaining unprotected 
amine.  This step was carried out as reported by Xia et al.162  L1 in acetonitrile was added slowly to a 
solution of the dibromo alkane, in large excess, under basic conditions. The reaction mixture was 
stirred at 80 oC for 72 hours. The reaction occurs through an SN2 mechanism where the lone pair 
from the nucleophilic amine attacks the electron deficient carbon centre adjacent to the bromine, 
thereby expelling the halide and forming a new C-N bond. L1 was added slowly to prevent 
displacement of both terminal bromides. The crude product was purified by column 
chromatography (ethyl acetate: petroleum ether) to yield a colourless amorphous solid.  The 
product was characterised by 1H and 13C NMR spectroscopy and mass spectrometry. The propyl 
proton signals displayed changes consistent with the formation of L2.  The methylene protons closest 
to the site of substitution shifted slightly downfield, reflecting the displacement of bromine by a 
more electronegative nitrogen atom. Furthermore, the 1,3-dibromopropane protons of the 
peripheral carbons became inequivalent, owing to the unsymmetrical nature of L2.  The ESI mass 
spectrum displayed the expected molecular ion peak (with sodium) m/z = 617 [M+Na]+ providing 
further proof for the formation of L2.      
The third step involved the reaction of L2 with 2,6-bis(2-pyridyl) 4(1H) pyridone in the presence of 
K2CO3 as a base. The compound was prepared by modification of a reported procedure.
133  The 
reaction follows a SN2 mechanism where the lone pair from the nucleophilic oxygen of the pyridone 
(in the alcoholic tautomer) attacks the electron deficient carbon centre adjacent to bromine. The 
reaction mixture was heated under reflux for 48 h. The base was filtered and water was added to the 
filtrate to remove any unreacted pyridone. The product then was extracted into diethyl ether. The 
ethereal extracts were washed with water and 5% sodium hydroxide and dried.  The ligand, L3, was 
characterised by 1H and 13C NMR spectroscopy and mass spectrometry. The 1H spectrum displayed 
the expected peaks with the appropriate integrals and multiplicities. The alkyl protons closest to 
bromine were seen to shift downfield (2.72 ppm to 4.28 ppm) confirming the attachment of L2 to the 
terpyridine core. This shift was also observed for the terminal carbon in the 13C NMR spectrum. The 
ESI mass spectrum displayed the expected molecular ion peak m/z = 762.5 [M+H]+ providing further 
evidence for the formation of L3.      
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Scheme 2-1: Reaction scheme for the 5 step synthesis of the terpyridine cyclen ligand, including ligands L1-
L
6
.   
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The penultimate step involved the removal of the t-Boc groups from the cyclen ring.  L3 was 
dissolved in a mixture of dichloromethane: trifluoroacetic acid (in a 1:1 ratio) and stirred at room 
temperature for 24 h.  The solvents were removed under reduced pressure and the resultant crude 
solid was dried.  A relatively strong acid (trifluoroacetic acid) was required to protonate the ester 
oxygen of the carbonate and allow decomposition of the carbonate into CO2, butyl cation and the 
desired amine: acid salt. The salt, L4 was analysed by 1H NMR and 19F NMR spectroscopy.  The 1H 
NMR spectrum displayed no t-Boc signals, indicative of complete removal of the protecting groups. 
The presence of trifluoroacetic acid was confirmed by 19F NMR spectroscopy (singlet at -77.8 ppm).  
In order to isolate L5, the protonated form L4 was dissolved in water and aqueous NaOH 2M was 
added dropwise until the solution became alkaline (pH 12).  The product was then extracted into 
dichloromethane.  The solvent was removed under reduced pressure to yield L5 as a pale yellow 
sticky solid. The solid was characterised by 1H and 13C NMR spectroscopy and mass spectrometry. 
Both NMR spectra displayed the correct number of signals with expected chemical shifts and 
integrals (see Figure 2-3 for a detailed analysis).  
 
 
Figure 2-3: (a) Chemical structure of the terpyridine cyclen ligand, L
5
. (b) 
1
H NMR spectrum of L
5
 in DMSO-d6. 
The inset features a magnification of the aromatic region. 
 
The molecular ion peak was also observed by ESI mass spectrometry, m/z = 462.0 [M+H]+.  Due to 
the physical properties of L5, its purity could not be assessed by elemental analysis, therefore the 
65 
 
corresponding protonated chloride salt, L6 was prepared.  To do this L5 was dissolved in methanol 
containing 1% HCl(aq).  Diethyl ether was then added to precipitate the product as an off-white solid. 
The purity of L6 was established by elemental analysis and LCMS-MS, m/z = 462.0 [M-nHCl+H]+ (see 
Figure 2-4). 
                        
 
Figure 2-4: (a) LCMS of L
6 
showing one peak
 
(b) ESI-MS of main peak in LCMS trace of L
6
, m/z = 462.0 [M-
HCl+H]
+
.   
 
 
2.3.2 Synthesis of Homometallic Complexes 
The dihomometallic zinc(II) and copper(II) complexes 1 and 2, were synthesised as described below 
(also depicted in Scheme 2-2).   The terpyridine cyclen ligand was dissolved in methanol and added to 
a solution of 2 equivalents of the appropriate metal chloride salt (ZnCl2 and CuCl2·2H2O respectively) 
in methanol. These solutions were heated at 40 oC for 48 h.  These conditions allowed coordination 
of the metals to both the terpyridine and cyclen modalities of the ligand.  The products were seen to 
precipitate out of the reaction mixture after this period. After which time white and blue 
precipitates were obtained for the zinc and copper complexes respectively.  The complexes were 
washed with methanol and diethyl ether and dried.  Further purification was necessary and so 
recrystallisations were carried out.  Acetone was allowed to slowly diffuse into concentrated 
aqueous solutions of the complexes over 3-14 days yielding crystals of 1 and 2 suitable for X-ray 
crystallographic analysis (see below). 
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Scheme 2-2: Reaction scheme for the synthesis of di zinc(II)-terpyridine and di copper(II)-terpyridine 
complexes, 1 and 2. 
 
The di-nuclear zinc(II) and copper(II) complexes, 1 and 2, were characterised by 1H and 13C NMR 
spectroscopy (zinc(II) complex only due to the paramagnetic nature of the copper complex), mass 
spectrometry, elemental analysis and X-ray crystallography (which revealed the presence of 0.5 mole 
of an unusual ZnCl4 anion). The 
1H NMR spectrum of 1 displayed the expected chemical shifts and 
splitting patterns (see Figure 2-5 for a detailed analysis).  The signals in the aromatic region of the 
spectrum (assigned using 1H-1H COSY NMR) were seen to shift downfield relative to the free ligand 
(0.1 – 0.4 ppm), indicative of metal coordination to terpyridine. The cyclen signals (Hcyclen) appeared 
to broaden and slightly shift downfield, consistent with the chelation of zinc(II) to cyclen.  The 13C 
NMR spectrum of the complex displayed the presence of eight signals in the aromatic region, 
resulting from the terpyridine carbons.  The aliphatic region of the spectrum revealed seven signals 
due to the cyclen and linker carbon environments.  Both sets of signals displayed marked shifts when 
compared to the 13C NMR spectrum of the free ligand indicating the coordination of zinc to L5. 
The ESI(+) mass spectrum provided further evidence for the successful formation of the di-zinc(II) 
complex.  A peak, with the appropriate isotopic distribution, corresponding to the molecular ion 
peak minus the ZnCl4 counter-anion ([1-0.5ZnCl4]
+ = 698 a.m.u.) was detected (see Figure 2-6). The 
purity of 1 was established by elemental analysis. 
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Figure 2-5: (a) Chemical structure of di zinc complex, 1. (b) Chemical structure of the terpyridine cyclen 
ligand, L
5
. (c) 
1
H NMR spectrum of the aromatic region of 1 (blue) in DMSO-d6 overlayed with the aromatic 
region of ligand, L
5 
(red) in DMSO-d6. The aromatic signals are shifted downfield relative to the 
corresponding free ligand, indicative of metal coordination to the terpyridine.  
 
 
 
Figure 2-6: (a) The experimental ESI signal for the [1-0.5ZnCl4]
+
 molecular ion. (b) The molecular ion 
observed for 1. (c) The simulated signal for the [1-0.5ZnCl4]
+
 molecular ion, generated using 
http://fluorine.ch.man.ac.uk/research/mstool.php.  The isotopic pattern obtained was the same as that 
predicted. 
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Crystals of the di-zinc complex, 1, suitable for X-ray crystallography, were obtained by slow diffusion 
of acetone into a concentrated aqueous solution of the compound over 14 days.  The complex 
crystallised as colourless needles with 0.5 acetone and 2 water molecules and 0.5 [ZnCl4]
2-
 as the 
counter-anion in the triclinic, P-1 space group.  The X-ray crystal structure of 1 (solved by Dr. A. J. P. 
White at Imperial College London) revealed the presence of two crystallographically independent 
cations, di-zinc I and di-zinc II (see Figure 2-7).   
 
Figure 2-7: The X-ray crystal structure of 1 revealed the presence of two crystallographically independent 
cations, di-zinc I and di-zinc II. 
 
The solid state structure exhibits the expected molecular structure with the zinc adopting a distorted 
trigonal bi-pyramidal coordination geometry with the terpyridine motif (via triple chelation to the 
terpyridine and single bonds to two chlorides). The Zn-N bond distances displayed the normal 
variations, 2.077-2.205 Å with that to the central nitrogen being shortest.163 Its lack of planarity is 
illustrated by (a) the Zn atom not residing in the basal plane defined by the terpyridine ligand 
[Cl,N,N,N], the metal lies about 0.597 Å out of this plane and (b) the non-perpendicular nature of the 
Cl-Zn-Cl angle, 109.38/113.46o. In terms of DNA binding, the nonexistence of an accessible planar 
surface suggests complex 1 would not be optimal for interaction with quadruplex DNA (via π-π 
interactions) (see Figure 2-8). 
The coordination geometry around zinc in the cyclen motif is distorted square pyramidal in which 
the four nitrogen atoms of cyclen provide the basal coordination and a chloride molecule defines the 
axial coordination. The cavity size of the tetra-aza-crown ether cyclen is not large enough for 
complete encapsulation of Zn2+ due to the size of the cation.  Thus, in the crystal structure, the Zn2+ 
ion is located away from the basal {N4} plane of the macrocycle (0.799 Å).  The average Zn–N bond 
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length for the complex cation is found to be 2.163 Å for cyclen coordination whereas the apical Cl 
molecule is located at a distance of 2.231 Å from Zn. 
 
 
Figure 2-8: X-ray crystal structure of the di-zinc terpyridine complex, 1. It provides confirmation of the 
proposed formulation. The hydrogen atoms are omitted from the structure for clarity.  
 
The di-copper(II) complex, 2 was characterised by ESI(+) mass spectrometry. A peak corresponding 
to the molecular ion peak minus chloride ([2-Cl]+ = 694 a.m.u), and displaying the appropriate 
isotopic distribution, was detected (see Figure 2-9).  The purity of 2 was confirmed by elemental 
analysis.  
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Figure 2-9: (a) The experimental ESI signal for the [2-Cl]
+
 molecular ion. (b) The molecular ion observed for 2. 
(c) The simulated signal for the [2-Cl]
+
 molecular ion, generated using 
http://fluorine.ch.man.ac.uk/research/mstool.php.  The isotopic pattern obtained was the same as that 
predicted.    
 
 
Crystals of the di-copper complex 2 were obtained by slow diffusion of acetone into a concentrated 
aqueous solution of the compound over 3 days. The complex crystallised as blue platy needles with 
6.5 water molecule in the C2/c space group. The solid state structure exhibits the expected 
molecular structure with the copper adopting a square based pyramidal coordination geometry with 
the terpyridine motif (via triple chelation to the terpyridine and single bonds to two chlorides (see 
Figure 2-10)).  The geometry is demonstrated by (a) almost linear N(14)-Cu(1)-N(8) and N(1)-Cu(1)-
Cl(2) angles of 158.3(2) and 155.73(13)o respectively and (b) N(1)-Cu(1)-Cl(1), N(8)-Cu(1)-Cl(1) and 
N(14)-Cu(1)-Cl(1) angles close to 90o. As previously reported for Cu(terpyridine)Cl2, the geometry can 
be more accurately described an “apical elongated” square pyramid as the apical chloride is only 
weakly coordinated.164-166  This is clearly demonstrated for complex 2, the axial Cu-Cl bond distance 
is ca. 0.30 Å greater than the equatorial.  The complex has one open planar face accessible for π-π 
stacking.  
The coordination geometry around copper in the cyclen motif is square pyramidal in which the four 
nitrogen atoms of cyclen provide the basal coordination and a chloride molecule defines the axial 
coordination. The cavity size of the tetra-aza-crown ether cyclen is not large enough for complete 
encapsulation of Cu2+ due to the larger size of the cation. Thus, in the crystal structure, the Cu2+ ion is 
located away from the basal {N4} plane of the macrocycle.  The average Cu–N bond length for the 
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complex cation is found to be 2.019 Å for cyclen coordination whereas the apical Cl molecule is 
located at a distance of 2.390 Å from Cu.167 
 
 
Figure 2-10: X-ray crystal structure of 2. It provided confirmation of the proposed formulation. The complex 
displays an “apical elongated” square pyramidal geometry. The hydrogen atoms are omitted from the 
structure for clarity. 
 
2.3.3 Synthesis of Heterometallic Complexes 
The platinum terpyridine complex was synthesised using the procedure described below (also 
portrayed in Scheme 2-3).  The terpyridine cyclen ligand, L5, was dissolved in DMSO and added to a 
solution of 1.1 equivalents of the potassium tetrachloroplatinate in dimethyl sulphoxide.  The 
solution was heated at 45 oC for 24 hours to yield an orange solution. Addition of acetone gave an 
orange solid which was characterised as the desired compound, 3a. Due to the hydroscopic nature 
of 3a the purity could not be confirmed by elemental analysis. To obtain the PF6 salt, the solid was 
re-dissolved in the minimum amount of DMSO and excess NaPF6 (as aqueous solution) was added 
dropwise.  This induced the exchange of counterions on the complex yielding 3b as a yellow solid.   
The complex was isolated as a salt containing four PF6 anions, owing to the protonation state of the 
nitrogen atoms on cyclen. The pKa of the protonation of the secondary amine nitrogen atoms are 
7.5-10168 therefore under the anion exchange reaction condition (pH =5.5), it is credible that three 
nitrogen atoms on cyclen are protonated, giving rise to the observed PF6 stoichiometry. 
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Scheme 2-3: Reaction scheme for the synthesis of platinum(II)-terpyridine complexes as chloride and PF6 
salts 3a and 3b respectively.  
 
The platinum(II) terpyridine complex was fully characterised by 1H NMR spectroscopy, mass 
spectrometry and elemental analysis. The 1H NMR spectrum showed characteristic shifts for some of 
the aromatic signals upon coordination to platinum (shown in Figure 2-11). Interestingly the cyclen 
signals broadened and shifted downfield suggesting some interaction between the platinum-
terpyridine unit and the free cyclen motif. 
The mass spectrum obtained by ESI provided further evidence for the successful formation of the 
Pt(II) complex.  A peak, with the appropriate isotopic distribution, corresponding to the molecular 
ion peak minus two H and three PF6 ions ([M-2H-3PF6]
+ = 838 a.m.u) was detected (see Figure 2-12). 
The purity of 3b was established by elemental analysis. 
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Figure 2-11: (a) Chemical structure of the platinum(II) complex, 3b
 
. (b) Chemical structure of the terpyridine 
cyclen ligand, L
5
.  (c) 
1
H NMR spectrum of the aromatic region of 3b (blue) in DMSO-d6 overlayed with the 
aromatic region of ligand, L
5 
(red) in DMSO-d6. The aromatic signals are shifted downfield relative to the 
corresponding free ligand, indicative of metal coordination to the terpyridine. 
 
 
Figure 2-12: (a) The experimental ESI signal for the [3b-2H-3PF6]
+
 molecular ion. (b) The molecular ion 
observed for 3b. (c) The simulated signal for the [3b-2H-3PF6]
+
 molecular ion, generated using 
http://fluorine.ch.man.ac.uk/research/mstool.php.  The isotopic pattern obtained was the same as that 
predicted.  
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The heterometallic PtII-ZnII and PtII-CuII complexes, 4 and 5, were synthesised as shown in Scheme 2-
4. To a DMSO solution of 3a, 1.1 eq of the appropriate metal chloride salt (ZnCl2 and CuCl2.2H2O 
respectively) was added and the solution was stirred at 40 
oC for 24 hours.  An aqueous solution of 
NaPF6 was added directly to the reaction mixture dropwise.  This yielded yellow and green solids as 
the platinum(II)-zinc(II), 4, and platinum(II)-copper(II), 5, complexes respectively.  
 
Scheme 2-4: Reaction scheme for the synthesis of platinum(II)-zinc(II) and platinum(II)-copper(II) terpyridine 
complexes, 4 and 5 respectively.  
 
The heterometallic terpyridine complex, 4 was fully characterised by 1H and 13C NMR spectroscopy 
and elemental analysis.  The 1H NMR spectrum showed the expected number of signals. The signals 
in the aromatic region of the spectrum were seen to shift marginally downfield relative to the 
aromatic peaks of the platinum(II) complex, 3b (shown in Figure 2-13). Upon coordination to zinc(II) 
the cyclen signals were seen to broaden and shift downfield relative to L5, consistent with the 
chelation of zinc to cyclen. This was also observed for the di-zinc(II) complex, 1 (see above).  The 13C 
NMR spectrum provided further evidence for the successful formation of the hetero-dimetallic 
complex.  The spectrum showed eight peaks in the aromatic region (resulting from the terpyridine 
unit) and seven aliphatic signals with significant shifts compared to the ligand indicating metal 
coordination to both L5 binding sites. The purity of 4 was confirmed by elemental analysis. 
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Figure 2-13: (a) Chemical structure of the platinum(II) zinc(II) complex, 4. (b) Chemical structure of the 
platinum(II) complex, 3b.  (c) 
1
H NMR spectrum of the aromatic region of 4 (blue) in DMSO-d6 overlayed with 
the aromatic region of complex, 3b
 
(red) in DMSO-d6. The aromatic signals of 4 are shifted very slightly 
downfield relative to 3b. 
 
The platinum-copper complex, 5 was characterised by ESI(+) mass spectrometry.  A peak (with the 
appropriate isotopic distribution) corresponding to the expected molecular ion of 5 minus one PF6
- 
ion ([M-PF6]
+ = 1450.0 a.m.u) was detected (shown in Figure2-14). The purity of 5 was established by 
elemental analysis. 
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Figure 2-14: (a) The experimental ESI signal for the [5-PF6]
+
 molecular ion. (b) The molecular ion observed for 
5. (c) The simulated signal for the [5-PF6]
+
 molecular ion, generated using 
http://fluorine.ch.man.ac.uk/research/mstool.php.  The isotopic pattern obtained was the same as that 
predicted. 
 
 
2.3.4 Synthesis of Thiol-Substituted Platinum(II) Complex  
The thiol-substituted platinum(II) complex, 6, was prepared as depicted in Scheme 2-5.  To an 
aqueous solution of 3a, four equivalents of 2-(piperidin-1-yl)ethanethiol, L7 (which was prepared by 
modification of a reported procedure – see Experimental Section 6.2169) was added dropwise and the 
solution was stirred at room temperature for 3 days.  During this period the solution was observed 
to change colour from red to dark pink. Upon completion of the reaction excess thiol was removed 
by extraction with diethyl ether.  An aqueous solution of NaPF6 was added directly to the reaction 
mixture with the aim of exchanging the counterion of the complex to induce its precipitation. Upon 
this treatment, the desired complex was obtained as a dark pink solid, which was filtered, washed 
with diethyl ether and dried.  The complex was isolated as a salt containing four PF6 anions, owing to 
the protonation state of the nitrogen atoms on the piperdine and cyclen units. The pKa of the 
protonation of the nitrogen atoms on cyclen and piperdine are >7.5, therefore under the anion 
exchange reaction condition (pH = 5.5), it is conceivable that some of these nitrogen atoms are 
protonated, giving rise to the observed PF6 stoichiometry. 
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Scheme 2-5: Reaction scheme for the synthesis of platinum(II)-terpyridine thiol, 6 in water.  
The platinum(II)-terpyridine-thiol complex 6, was fully characterised by 1H and 13C NMR 
spectroscopy, mass spectrometry and elemental analysis.  The signals in the aromatic region of the 
1H NMR spectrum (assigned using 1H-1H COSY NMR) were observed to shift downfield (ranging from 
0.05-0.6ppm) relative to the corresponding platinum(II) complex, 3b,  clearly demonstrating 
coordination of the thiol arm to the platinum(II), via the displacement of the chloride atom on the 
fourth position. The largest shifts were observed for the Ha and Hc peaks, probably due to the 
electronic effects of thiol coordination.  In comparison to the methylene signals of ligand, L7, those in 
6 were shifted downfield, indicative of the co-ordination of L7 to the platinum(II) centre.  The UV-
visible spectrum of the compound displayed a band with λmax centred at 550 nm.  This is assigned to 
the LMCT band arising from the shift of charge density between the sulphur p orbital to the platinum 
d orbital.  The band seen at ca. 400 nm is assigned to the MLCT band.  These characteristic bands 
provide further evidence for the successful attachment of the thiol moiety (see Figure 2-15).170  The 
purity of 6 was verified by elemental analysis. 
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Figure 2-15: (a) Chemical structure of platinum(II) thiol complex, 6
 
. (b) Chemical structure of platinum(II) 
complex, 3b
 
. (c) 
1
H NMR spectrum of the aromatic region of 6 (blue) in DMSO-d6 overlayed with the 
aromatic region of Pt complex, 3b
 
(red) in DMSO-d6. The aromatic signals are shifted downfield relative to 
the corresponding Pt complex, indicative of thiol coordination to the terpyridine. (d) UV-vis spectrum for 
platinum(II) thiol complex, 6
 
at 100uM and 50uM in DMSO. 
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2.4 π-π Stacking Interactions in Solid State 
π-π stacking interactions in solid state results from different geometric configurations. The three 
possible conformations are: sandwich; T-shaped; and parallel displaced.  Due to the orientation of 
the π systems associated to the aromatic rings involved, the T-shaped and parallel displaced 
conformations have been proven experimentally and theoretically to be the most 
thermodynamically stable. The parallel displaced model fits the packing pattern of many metal 
terpyridine complexes reported in literature.133, 171  This conformation is characterised by a centroid-
to-centroid distance of 3.3-3.8 Å. The X-ray crystal structures of 1 and 2 show these complexes to π-
π stack with a parallel displaced conformation. 
Despite the non-planar nature of the di-zinc complex, 1, in solid state, the complex packs in a 
manner that displays two distinctive π-π stacking interactions. The packing pattern is such that ring A 
I in one complex overlays ring B II in another Ci related complex and vice versa (ring B I overlays ring 
A II). The centroid–to-centriod and mean interplanar separations (about 3.56 Å) fall within the range 
usually associated to π-π stacking interactions (see Figure 2-16).  Therefore the π-π interactions can 
be considered to occur through a parallel displaced conformation. 
 
Figure 2-16: (a) Molecular structure of 1. The three poly-pyridyl rings are labelled A, B and C. (b) The π-π 
stacking between two dimers of 1, along the crystallographic a axis direction. The centroid-to-centroid 
distances are 3.560 Å. 
 
The planarity of the di-copper complex, 2 allows adjacent centrosymmetically related complexes to 
form dimers along the a axis through a series of π-πinteractions. The packing pattern is such that 
ring C in one complex is placed on top of another ring B in another complex. The centroid-to-
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centroid distance (about 3.811Å) is comparable to those reported for other π-π stacked systems (see 
Figure 2-17).  
 
Figure 2-17: (a) Molecular structure of 2. The three poly-pyridyl rings are labelled A, B and C. (b) The π-π 
stacked dimer of 2, along the crystallographic a axis direction. The centroid-to-centroid distance is 3.811 Å. 
 
 
2.5 π-π Stacking Interactions in Solution State 
The metal-terpyridine component of the homo-and hetero- metallic complexes were expected to 
interact with the quadruplex through π-π interactions. In order to interact in this manner, at least 
one planar surface is necessary. This is a characteristic inherent to the platinum(II), copper(II) and, to 
a lesser extent, zinc(II) terpyridine complexes.  In order to semi-quantitatively establish the existence 
of intermolecular π-π stacking interactions in solution, variable temperature (VT) 1H NMR 
spectroscopic studies were undertaken with complexes 1, 3b and 4. Compounds that have the 
propensity to self π-π stack are more likely to stack with other planar aromatic components e.g. the 
surface of the terminal G-tetrad.  
 
The detection of π-π interactions by VT 1H NMR spectroscopy relies on the temperature dependence 
of the chemical shifts of particular aromatic protons.172  As the temperature decreases the tendency 
for the molecules to come into close contact (aggregate) increases. This facilitates π-π interactions, 
thus protons involved in the π-ring systems become shielded. This results in an upfield shift of the 
proton signals. 
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VT 1H NMR spectroscopic studies were carried out for the di-zinc(II), platinum(II) and platinum(II)-
zinc(II) terpyridine complexes, 1, 3b and 4 (in DMSO-d6).  In the case of 3b and 4, the aromatic 
proton signals Ha and He were seen to shift downfield upon increasing temperature (from 298 K to 
373 K) consistent with intermolecular π-π stacking interactions (see Figures 2-18 and 2-19).   
Interestingly, not all the aromatic protons followed the same trend since some aromatic protons 
were seen to shift in the opposite direction. This suggests that only some of the aromatic protons 
are involved in π-π stacking interactions (namely, Ha and He).  Protons Hb, Hc and Hd shifted upfield 
upon increasing temperature, suggesting that they are not involved in π-π stacking interactions but 
more likely in some form of hydrogen bonding (e.g. with the solvent) that upon increasing the 
temperature is broken and hence they become more shielded.  It is well established that when 
dissolved in polar solvents, protons tend to shift upfield with an increase in temperature because of 
reduced solvation interactions with the solvent. The 1H NMR spectra were recorded in the polar 
DMSO solvent and so it is a probable explanation for the observation.  Similar trends were observed 
by Suntharalingam et al. for a terpyridine di-picolylamine di-platinum(II) complex.134 
 
In the case of 1 the aromatic proton signals Ha to He were seen to shift upfield upon increasing 
temperature (from 298 K to 368 K) suggesting an absence of intermolecular π-π stacking interactions 
(see Figure 2-20).   In addition to shifting upfield with increasing temperature, all the proton signals 
were seen to broaden.  The shifts seen for 1 can be attributed to a number of reasons including (1) 
the exchange of Zn ions between the two binding sites at high temperatures; or (2) structural 
changes occurring as a result of solvent coordination to the Zn centre; or (3) the Zn dissociating from 
the ligand.  Nevertheless the 1H NMR signal shifts detected for 1, are not related to π-π interactions 
(as downfield shifts are not observed) and therefore shows its inability to form such interactions in 
solution state. This is expected considering the non-planar geometry of the terpyridine unit in 1 (see 
X-ray crystal structure of 1). 
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Figure 2-18: (a) Chemical structure of 3b. (b) Graphical presentation of the changes in aromatic proton 
chemical shifts upon increasing temperature. (c) The 
1
H NMR spectra of 3b upon increasing temperature, 
298-368 K (bottom to top). 
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Figure 2-19: (a) Chemical structure of 4. (b) Graphical presentation of the changes in aromatic proton 
chemical shifts upon increasing temperature. (c) The 
1
H NMR spectra of 4 upon increasing temperature, 298-
368 K (bottom to top). 
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Figure 2-20: (a) Chemical structure of 1. (b) Graphical presentation of the changes in aromatic proton 
chemical shifts upon increasing temperature. (c) The 
1
H NMR spectra of 1 upon increasing temperature, 298-
368 K (bottom to top). 
 
In conclusion it can be said that complexes 3b and 4 have the propensity to π-π stack in the solution 
state.  It is therefore reasonable to suggest that they could π-π stack with other aromatic planar 
moieties in solution such as the external surface of quadruplex DNA.  Conversely, complex 1 is 
unable to self π-π stack, this is consistent with its non-planar structure (see crystal structure and 
solid state packing pattern in sections 2.3.2 and 2.4). 
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2.6 DFT Calculations and Computational Docking Studies  
The computational docking studies were performed by Dr. Oscar Mendoza Pomar (Imperial College 
London) 
Computational docking studies were carried out to gain theoretical insight into the interaction 
between 1, 2 and 4 and quadruplex Htelo DNA.  
The structures of complexes 1, 2 and 4 were optimised by DFT calculations using the Gaussian 03 
program at the B3lyp level of theory. In the case of 4, the LANL2DZ basis set was used for the 
platinum atom; other atoms were described by a 6-31G** basis set. For 1 and 2 three and two 
chlorines were removed respectively in an attempt to simulate the state of the compounds in 
solution. Three chlorines were removed from 4. 
The optimised structures were then docked onto the Htelo quadruplex structure (PDB:1KF1) using 
Autodock (Version 4.2) docking software.173  A detailed description of the parameters and settings 
used are provided in the Experimental Details (Section 6.5.3). A representative image of the 
interaction between the metal complexes and Htelo DNA is given below (Figure 2-21). 
The di-metallic complex, 4 bound with a calculated binding energy of -10.71 kcal/mol.  The 
platinum(II)-terpyridine moiety interacts with the G-quartet via - interactions while the zinc(II)-
cyclen side arm is embedded in the DNA groove. The binding mode of [Pt(terpyridine)Cl]Cl was 
determined as a comparison. [Pt(terpyridine)Cl]Cl interacts with the G-tetrad via - interactions 
with a binding energy -4.26 kcal/mol, no further interactions were observed.  For 4 the interaction of 
the zinc(II)-cyclen side arm with the grooves leads to the tilting of the planar core (away from the 
tetrad), thus reducing - interactions.  This decrease in - interaction is more than offset by 
groove binding of the zinc(II)-cyclen construct, this is portrayed in the calculated binding energy (-
10.71 kcal/mol is more favourable than -4.26 kcal/mol).  
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Figure 2-21: Optimal docking mode of 4 with Htelo DNA (a) top view (b) side view. (c) Optimal docking mode 
of [Pt(terpyridine)Cl]Cl with Htelo DNA (side view).  
A similar interaction was observed for 2, with the copper(II)-terpyridine component interacting with 
the G-quartet through - interactions and the copper(II)-cyclen interacting with the grooves (Figure 
2-22(a) and (b)).  The binding energy was calculated to be -11.68 kcal/mol, which is consistent with 
that calculated for 4.  1 displayed a completely different binding mode (Figure 2-22(c) and (d)).  The 
di-zinc(II) complex bound in an external manner, perhaps due to it’s non-planar nature. Interestingly 
the binding energy was comparable to 2 and 4.  
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Figure 2-22: Optimal docking mode of 2 with Htelo DNA (a) top view (b) side view. Optimal docking mode of 
1 with Htelo DNA (c) top view (d) side view. 
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Chapter 3 
Biophysical DNA Binding 
Studies 
& 
Cellular Studies 
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3.1 Overview  
 
A number of biophysical studies were carried out in order to investigate the ability of the prepared 
complexes to interact with DNA (both quadruplex and duplex). The initial assay used to screen the 
compounds was the Fluorescent Intercalator Displacement (FID) assay. This was used to semi-
quantitatively determine the affinity of the complexes for quadruplex DNA (Htelo and c-Myc 
sequences) and duplex DNA as well as give an indication of selectivity.  Fluorescence Resonance 
Energy Transfer (FRET) melting and competition assays were used to study the ability of the 
complexes to interact with and stabilise quadruplex DNA. UV-Vis titration studies were then 
performed to determine quantitative binding constants for the complexes with quadruplex and 
duplex DNA as well as to provide some insight into the binding mode of the complexes.  Circular 
Dichroism (CD) titration experiments were carried out to assess the ability of the complexes to 
template the formation of quadruplex DNA from singly stranded DNA. Further CD titrations were 
employed to monitor quadruplex DNA conformational changes induced by the complexes.  Finally 
the ability of the compounds to stabilise c-Myc DNA (in its folded form) was investigated via Variable 
Temperature Circular Dichroism (VTCD) studies.   
 
A number of cellular studies were conducted to establish the cytotoxicity of the compounds as well 
as the effect they have on c-Myc protein levels. The toxicity of the complexes was analysed for two 
cancerous (U2OS and SH-SY5Y) and one normal fibroblast (GM07575) cell lines.  Determination of 
the IC50 values for the complexes was of high importance because it enabled complexes that were 
active and selective for specific cell lines to be identified; moreover it allowed the non-lethal 
concentration for each compound to be determined i.e. the concentration at which further cellular 
assays could be performed without inducing cell death.  Immunoblotting studies were carried out to 
explore the effect of the complexes on c-Myc expression. 
 
 
 
3.2 Fluorescent Intercalator Displacement (FID) Assay 
 
The complexes were initially screened using the FID assay.  This method allows the semi-quantitative 
analysis of ligand affinity for quadruplex DNA and selectivity over duplex DNA.95, 174-176  The principle 
of this assay relies on the ability of a given ligand to displace the fluorescent probe, thiazole orange 
(TO), from quadruplex- and duplex-DNA matrices.  TO is known to bind to DNA (both quadruplex and 
duplex) with high affinity (binding constant, Ka= ca. 3 x 10
6 M-1).177  TO is strongly luminescent when 
bound to DNA, however, when free in aqueous solution, TO luminescence is essentially quenched. 
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Therefore, when the assay is performed in the presence of a ligand with high affinity for the target 
DNA, it displaces TO, resulting in a quenching of its emission and subsequent loss in observed 
fluorescence (see Figure 3-1).  
 
 
 
Figure 3-1: Schematic representation of the FID assay. Quadruplex DNA has been shown as the targeted 
oligonucleotide in this example.   
 
The decrease in fluorescence enables an approximate measure of the affinity of a given compound 
for DNA to be determined. The TO displacement (loss in fluorescence) can be quantified in the form 
of a calculated DC50. This is defined as the concentration of compound required to displace 50% of 
TO bound to DNA i.e. decrease TO fluorescence by 50% (shown in Figure 3-2 below).  
 
(a)                                                                          (b) 
 
 
Figure 3-2: (a) Raw data obtained from the FID assay showing a decrease in TO fluorescence upon addition 
of increasing concentration of compound 4. (b) Example of a plot showing % TO displacement vs. 
concentration of ligand. Figure shows the FID results for complex 4 interacting with Htelo, c-Myc and ds26 
DNA. DC50 is determined by interpolating the curve at 50% TO displacement.  
 
The affinities of the complexes for three DNA sequences were investigated: two quadruplex forming 
sequences (Htelo 22-mer; 5’-AGGGTTAGGGTTAGGGTTAGGG-3’ and c-Myc 20-mer; 5’-
GGGAGGGTGGGGAGGGTGGG-3’) and one duplex DNA sequence (26-mer; 5’-
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CAATCGGATCGAATTCGATCCGATTG-3’). DC50 values were determined for the free ligand and the 
series of terpyridine-cyclen metal complexes. The results are summarised in Table 3-1 and Figure 3-
3.  The metal complex series 1-6, can be seen to display a range of affinities across the sequences 
investigated. Ligand, L5 shows poor affinity for all of the three sequences of DNA, with failure to 
reach the DC50 upon addition of up to 10 μM (40 equivalents). This indicates that the metal in the 
terpyridine unit plays an essential role in organising the aromatic system into a planar conformation 
and provides favourable electrostatic interactions for DNA binding. 
 
Table 3-1: DC50 values obtained for L
5 
and complex series 1-6 against the Htelo, c-Myc, and ds26 strands. The 
values are an average of three independent measurements. All error values are within 5%. 
 
                                                     TO Displacement                                                     Selectivity 
 
Compound 
 
HteloDC50(μM) 
 
c-MycDC50(μM) 
 
ds26DC50(μM) 
 
ds26DC50/
HteloDC50 
 
 
ds26DC50/
c-MycDC50 
 
L5 >10 >10 >10 n/a n/a 
1 2.75 0.86 3.34 1.2 3.9 
2 0.21 0.09 0.60 2.89 6.7 
3b 0.28 0.16 0.70 2.5 4.4 
4 0.35 0.08 1.5 4.3 18.8 
5 0.18 0.17 0.77 4.3 4.5 
6 2.90 2.25 9.40 3.24 4.2 
 
 
 
The di-zinc(II) complex 1, displays the highest DC50 values in the series (with the exception of 
complex 6 with a thiolate in its 4th coordination position). This is expected as the zinc(II) centre 
adopts a distorted trigonal bi-pyramidal geometry (about the terpyridine locus) which lacks any 
accessible planar surface to interact with quadruplex DNA via π-π interactions. Considering this 
disadvantageous conformation, the DC50 value obtained with c-Myc is surprisingly low. In fact 1 
displays the lowest DC50 value for c-Myc of any zinc-terpyridine complex investigated to date (cf. 
[(Zinc(II)terpyridine-O-pip)Cl2], DC50 > 40 μM and di-zinc(II)terpyridine-dipicolylamine, DC50 = 1.63).
134 
This is likely to be due to the presence of the zinc(II) cyclen moiety which may interact with the 
grooves or backbone of the DNA. The zinc(II) complex, 1, displays some selectivity for quadruplex- 
over duplex- DNA and marginal selectivity for c-Myc over Htelo DNA.  
Complexes 2-5, appear to have similar trends in affinity and selectivity for the three sequences. It 
should be noted that ligands with a DC50 value below 0.5 are considered to be very effective binders 
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of quadruplex DNA. Complexes 2-5, display DC50 values for quadruplex DNA well below the 0.5 
threshold indicating that they bind to quadruplex DNA with very high affinity.  These complexes 
display marked selectivity for quadruplex- over duplex- DNA.  A reason for this may be due to their 
dual binding mode.  The complexes all possess a planar terpyridine unit, organised by a selected 
metal.  Docking studies have shown that these units have the right size to stack atop the tetrad (see 
Section 2.2 and 2.6).  Additionally the complexes feature a metal containing side arm which can 
interact with the grooves of the quadruplex scaffold. These complexes bind with reasonable affinity 
to duplex DNA, this could be due to non-specific electrostatic interactions between the positively 
charged metal complexes and the negatively charged DNA backbone.  Overall the complexes bind 
with lower affinity to duplex DNA, this could be due the steric bulk imposed by the metal-cyclen side 
arm which in turn could block intercalation between base pairs. The greatest selectivity was 
observed for the di-metallic platinum(II)-zinc(II) complex, 4 which displays a c-Myc- versus duplex- 
selectivity of 18.8.  Previous studies have indicated that a selectivity of over 10 is considered to be 
very high for this type of study.  The general trend is that the complexes bind to c-Myc with a higher 
affinity than Htelo (shown by a lower DC50 for the former over the later).  This may be due to the 
different conformations of the two quadruplex sequences under the conditions of the experiment.  
The c-Myc sequence folds into an intramolecular parallel structure with three tetrads and three well 
defined side loops (Figure 1-12).66-67, 178  It may be that the conformation of c-Myc provides the ideal 
binding platform for these complexes with the loops having the optimally sequence and position to 
allow the terpyridine unit to sit atop the quartet and the cyclen to reside and interact with the 
backbone. As the c-Myc single nucleotide loops predominantly consist of thymine, the zinc(II) cyclen 
motif can be envisaged to bind favourably to those. 
The thiolate-substituted complex 6, displays a similar trend of selectivity for quadruplex DNA (as 
compared to the other platinum(II)-L5 complexes) however affinity is significantly lower.  This may be 
due to the presence of the thiol at the position opposite to the cyclen arm.  It was hoped that this 
would serve to improve selectivity over duplex DNA by hindering the ability of the molecule to 
intercalate between base pairs. It is possible that the addition of this side arm has disrupted the 
optimal binding position of the complex to the quadruplex DNA and hence has unfortunately 
reduced the affinity to the two quadruplex sequences.   
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Figure 3-3: DC50 values for each of the complexes and ligand, against the Htelo strand (blue), c-Myc strand 
(red), duplex strand (green). The dotted line represents the threshold previously reported for good DNA 
binders.  
 
 
As described, the FID assay monitors the displacement of TO from DNA. TO interacts with 
quadruplex DNA via stacking on the external face of the quartet and with duplex DNA by 
intercalation between base pairs. The fact that the complexes displace TO from DNA, indicates that 
they bind to quadruplex and duplex DNA via end-stacking and intercalation, respectively. Whilst the 
FID assay is a good preliminary indicator of quadruplex affinity and selectivity, it merely probes π-π 
interactions while other potential interactions or binding modes are overlooked. In contrast the 
FRET spectroscopic method probes all interactions and so this was the next biophysical method 
employed to investigate the complexes.  
 
 
3.3 Fluorescence Resonance Energy Transfer (FRET) Assay 
The ability of the complexes to stabilise quadruplex and duplex DNA was further studied by 
fluorescence resonance energy transfer (FRET).  FRET is a mechanism describing energy transfer 
between two fluorophores.  A donor fluorophore, initially in its electronically excited state (having 
been irradiated at an appropriate wavelength), may transfer the excitation energy (emitted as 
radiation) to an acceptor fluorophore through dipole–dipole coupling.  For FRET to occur the 
fluorescence emission spectrum of the donor must overlap the absorption/excitation spectrum of 
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the acceptor and the acceptor has to be within a certain proximity, typically 10-80 Å.179  The FRET 
efficiency can be determined by measuring the decrease in fluorescence of the donor or, conversely, 
the increase in the fluorescence of the acceptor.  Based on the above FRET phenomenon, the FRET 
melting assay has been developed and applied to the study of a range of DNA structures (including 
quadruplex DNA).89  In this assay, the quadruplex forming single-stranded oligonucleotide is labelled 
with fluorescent dyes, at the 5’ and 3’ ends, which act as the donor and the acceptor respectively. 
Fluorophores fluorescein (FAM)-tetramethylrhodamine (TAMRA) as a donor-acceptor pair have been 
used widely for the studies of G-quadruplex DNA.180-181  These dyes were utilised in the current 
studies.  
 
To carry out the FRET-melting assay, a pre-folded quadruplex forming sequence is slowly denatured 
by increasing the temperature (from 25 to 95 oC). The donor FAM is excited at 450-495 nm and its 
emitted fluorescence detected at 515-545 nm. At low temperatures the oligonucleotide is folded, in 
a quadruplex structure, and TAMRA and FAM are close enough for FRET to occur and hence the FAM 
emission fluorescence is quenched. Upon increasing the temperature, quadruplex DNA unfolds and 
consequently the distance between FAM and TAMRA increases, which leads to an increase of the 
donor fluorescence due to a lower FRET efficiency (see Figure 3-4). A plot of increase in donor 
fluorescence emission versus temperature over this process yields a sigmoidal melting curve, from 
which a melting point (Tm) of the structure is obtained. Tm value is defined as the temperature at the 
midpoint between the minimum and maximum fluorescence emission, i.e. at which 50% of the 
unfolded structures and 50% of the folded structures are present. Normally, the Tm value is 
represented by the T1/2 value as the temperature at which the normalisation emission is 0.5 when 
the obtained FAM emission is normalised between 0 and 1.88 
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Figure 3-4. Representation of normalised fluorescence against increase in temperature for a FRET melting 
experiment. The figure includes a schematic representation of the melting process of a tagged quadruplex: 
yellow arrow represents the excitation radiation of the donor and blue arrow the emitted energy by the 
donor, absorbed by the acceptor when the DNA is folded or detected as radiation when unfolded.  
 
 
3.3.1 FRET Melting Assay  
The stability imparted by a ligand to quadruplex DNA can be evaluated by the determination of 
melting temperature (Tm) using the FRET melting assay.  In the presence of a ligand, a higher 
temperature is needed to unfold the quadruplex-ligand complex structure (in comparison to the 
quadruplex DNA alone). Monitoring the melting process of quadruplex DNA in the presence of 
increasing concentration of ligand, allows the difference in the melting temperature (ΔTm) to be 
determined (as shown in Figure 3-5).  The higher the ΔTm value obtained, the greater the compound-
quadruplex stabilisation.  
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Figure 3-5. Example of FRET melting plot of Htelo DNA in the presence of increasing concentration of 4.  
 
 
ΔTm value at 0.4 μM ligand concentration was used to compare the abilities of the different ligands 
to stabilise the quadruplex DNA.  Preliminary quenching studies were carried out to find a “working” 
concentration where no fluorescence quenching between the complexes and labelled DNA was 
observed (see Appendix, Figure A.4.1). These studies found that at 0.4 μM (which corresponds to 2 
equivalents of the complex with respect to DNA) there was no significant quenching of labelled DNA 
by any of the complexes.  
 
The results correlate well with the previous biophysical studies undertaken.  The FRET melting data 
clearly shows the capacity of the complexes to interact with and stabilise quadruplex DNA.  This is 
evident from the high ΔTm values recorded with the quadruplex sequences.  The ΔTm values recorded 
with duplex DNA are markedly lower (ΔTm ≤ 5 
oC in all cases) indicating poorer interactions and 
stabilisation. Generally the complexes stabilise c-Myc DNA to a higher degree than Htelo DNA. These 
trends were also observed in the FID assay and UV-vis titrations.   
 
 
 
 
 
 
 
Normalised Change in Fluorsence 
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Table 3-2: ΔTm (°C) determined by the FRET melting assay for the three DNA sequences with complexes at 
0.4 μM (values are average of three independent measurements). This was carried out in lithium cacodylate 
(10 mM, pH 7.2) and KCl/LiCl (10 mM/90 mM) for Htelo and ds26, and lithium cacodylate (10 mM, pH 7.2) 
and KCl/LiCl (1 mM/99 mM) for c-Myc. 
 
 
Compound HteloΔTm (
o C) c-MycΔTm (
o C) ds26ΔTm (
o C) 
1 5.2 ± 0.3 5.6 ± 0.5 1.5 ± 0.6 
2 9.6 ± 0.6 10.2 ± 1.1 1.4 ± 0.7 
3b 12.9 ± 0.3 17.7 ± 0.8 2.5 ± 1.5 
4 15.0 ± 1.6 18.1 ± 1.3 3.0 ± 1.3 
5 14.4 ± 2.0 18.3 ± 0.7 3.0 ± 1.1 
6 7.8 ± 2.1 7.2 ± 1.8 1.2 ± 0.3 
 
 
 
Complex 1 displays the lowest ΔTm values for the three sequences.  This can be rationalised by the 
lack of a planar, aromatic surface of 1 resulting in loss of π-π stacking to the guanine quartet.  
Complex 2 shows reasonably high ΔTm values for the two quadruplex sequences. Complexes 3b, 4 
and 5 display high ΔTm values for the quadruplexes indicating a strong interaction with the target 
structures. They display very good selectivity for quadruplex DNA and some selectivity for c-Myc 
over Htelo DNA. Complex 6, as expected, proved to have lower ΔTm values compared to the other 
platinum(II) complexes.  This may be due to the additional substituent disrupting the optimal binding 
of terpyridne.  Interestingly, it displays a slightly higher ΔTm value for Htelo over c-Myc, however, 
considering the errors associated to the FRET measurments this difference is not significant.  
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Figure 3-6: Bar chart displaying ΔTm (°C) determined by the FRET melting assay for complexes at 0.4 μM with 
the three DNA sequences. 
 
 
 
3.3.2. FRET Melting Competition Assay 
 
In order to gain a better understanding of the selectivity displayed by the metal complexes, FRET 
competition assays were carried out.182  This method involves performing the FRET melting assay for 
a labelled quadruplex DNA sequence in the presence of various concentrations (excess) of non-
labelled duplex DNA. If the complex binds strongly to duplex DNA then it will be less available to bind 
to quadruplex DNA and therefore there will be a reduction in the ΔTm (compared to the single 
sequence melting experiment).183 If the ligand does not bind to duplex DNA, the quadruplex DNA 
stabilisation will remain unchanged.  The competition assay is depicted in Figure 3-7.  
 
 
 
 
0
2
4
6
8
10
12
14
16
18
20
1 2 3b 4 5 6
Δ
T m
 (
o
C
) Htelo
cMyc
ds26
99 
 
 
 
Figure 3-7: Schematic representation of the FRET competition assay applied to the study of a compound’s 
selectivity for quadruplex over duplex DNA in two different hypothetical cases. (a) The compound is 
selective for quadruplex DNA resulting in a high quadruplex DNA ΔTm. (b) The compound is unselective for 
quadruplex DNA resulting in a low quadruplex DNA ΔTm.  
 
Measurements for complexes 3b, 4 and 5 were performed in view of their very high quadruplex 
affinities.  Competitions were undertaken for c-Myc and Htelo sequences in competition with ct-DNA 
and ds26-mer respectively. The results confirm the high selectivity of these complexes for 
quadruplex DNA versus duplex DNA. In particular the data obtained for c-Myc and Htelo in 
competition with ct-DNA are indicative of high qudruplex selectivity (Figure 3-8(a) and 3-8(b) 
respectively). For example, as the ct-DNA concentration is increased, from 1 to 250 equivalents (base 
pairs) the c-Myc ΔTm value decreases < 20%.  For the analogous competition between Htelo and ct 
DNA the ΔTm values decrease by approximately 50% with 100 equivalents and approximately 75% 
with 250 equivalents.  This result is expected from the FRET melting data where the compounds 
were seen to have higher affinity for c-Myc over Htelo DNA.  Interestingly, the results obtained for 
the quadruplexes in competition with ds26-mer display a much greater reduction in quadruplex 
melting temperature (Figure 3-9(a) and 3-9(b) respectively). This can be explained by the shorter 
ds26-mer strand which offers the possibility for the complexes to bind non-specifically to the DNA 
tail thus preventing quadruplex binding. The presence of 250 equivalents of ds26-mer decreases the 
ΔTm values by ca. 40% in the case of c-Myc, the same excess with Htelo DNA is sufficient to remove 
all stabilisation of the Htelo imparted by the complexes.  
 
 
 
 
 
(a) 
(b) 
100 
 
 
 
                                                                                                             
Figure 3-8: FRET competition experiments of selected complexes (3b, 4 and 5) at 0.4 μM concentration. The 
bar charts show the reduction of (a) the c-Myc DNA ΔTm and (b) Htelo DNA ΔTm with increased concentration 
of ct- DNA. 
 
 
 
 
Figure 3-9: FRET competition experiments of selected complexes (3b, 4 and 5) at 0.4 μM concentration. The 
bar charts show the reduction of (a) the c-Myc DNA ΔTm and (b) Htelo DNA ΔTm with increased concentration 
of ds26 DNA. 
 
As the complexes displayed some selectivity for c-Myc over Htelo DNA, FRET competition assays 
were then carried out for c-Myc DNA in competition with Htelo and vice versa. The results can be 
seen in Figure 3-10.  The results clearly demonstrate the selectivity of the complexes for c-Myc over 
Htelo, in agreement with the results obtained using the other biophysical assays (see previous 
sections).  It can be seen that in the case of c-Myc in competition with Htelo, a 10 equivalent excess 
of Htelo only results in a decrease in the stabilisation temperature by 30 - 40%.  Whereas in the 
reverse experiment, 1 equivalent of c-Myc results in a decrease of Htelo stabilisation by over 50% 
and complete loss in stabilisation in the presence of 10 equivalents.   
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Figure 3-10: FRET competition experiments of selected complexes (3b, 4 and 5) at 0.4 μM concentration. The 
bar charts show the reduction of (a) the c-Myc DNA ΔTm with increased concentration of Htelo DNA and (b) 
Htelo DNA ΔTm with increased concentration of c-Myc DNA. 
 
 
 
3.4 UV-Vis Spectroscopic DNA Titration 
UV-vis spectroscopic titration experiments were carried out with complexes 1 – 5 and DNA (Htelo, c-
Myc and ct-DNA – the later as an example of duplex DNA) using a previously established protocol.184 
Quantitative binding constants for the complexes to the DNA sequences were determined by 
monitoring changes in intensity of the absorption spectra of the compounds upon binding to DNA. In 
order to perform these studies the test compounds were required to have an absorption maximum 
above 300 nm (higher than the λmax of DNA, 260 nm) and show optical changes when interacting 
with DNA.  The DNA was added in aliquots (in the mM range) to the corresponding metal complex 
solutions of known concentration.  The absorption bands of the complex were seen to decrease 
(hypochromism) upon addition of the DNA.  Using the absorption values, the concentrations of 
bound and unbound metal complex were calculated and extrapolated to determine the binding 
constants. This was done by fitting the data to a reciprocal plot of D/Δεap versus D using the 
following equation:                
 D/Δεap=D/Δε + 1/(Δε× K) 
where D is the concentration of DNA and is expressed in terms of base pairs (determined by 
measuring the absorption at 260 nm and applying the appropriate extinction coefficients), the 
apparent molar extinction coefficient εa = Aobserved / [Complex], Δεap = [εa - εf] and Δε = [εb -εf]. εb is 
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the extinction coefficient of the DNA bound complex, and εf is the extinction coefficient of the free 
complex.  
 
  
Figure 3-11: Example of UV-vis titration spectra of a known concentration of 3b upon addition of Htelo DNA. 
Addition of increasing amount of DNA leads to decrease in absorption intensity. From the plotted graph, the 
y-intercept is equal to 1/(Δε x K) whereas the slope is equal to 1/Δε. K is obtained by dividing the slope value 
by the y-intercept. 
 
The trends observed from the UV-vis titration experiments correlate well with those obtained from 
the FID assay.  All the complexes showed strong binding to quadruplex DNA (in the micro-molar 
range) and good selectivity over duplex DNA (see Table 3.3).  Furthermore the complexes displayed 
some selectivity for c-Myc over Htelo DNA.  Complex 1 was the weakest binder, displaying the 
lowest binding constants for both quadruplex and duplex DNA. As discussed in Section 3.2 with 
respect to the FID assay data, this result is expected due to the lack of a planar surface to interact 
with quadruplex or duplex DNA.  Nevertheless in the context of previously reported quadruplex 
binders, the binding constants displayed by complex 1 are relatively high. This may be attributed to 
the dual targeting ability of 1.  Complex 1 displays slight selectivity for quadruplex- over duplex- DNA 
(10-fold).  Complexes 2-5 interact very strongly with quadruplex DNA (both Htelo and c-Myc), with 
binding constants comparable to and surpassing those of other compounds reported to be excellent 
quadruplex DNA binders (in the range 107-108 M-1).  The complexes also have reasonable affinity for 
ct-DNA, this is likely to be a result of non-specific interactions between the positively charged metal 
centres and the negatively charged DNA backbone.  Despite this the complexes exhibited 2-3 orders 
of magnitude greater binding to quadruplex over duplex DNA (100-fold to 1000-fold selectivity).  As 
was observed with the FID assay, the complexes display an apparent selectivity for c-Myc over Htelo 
(one order of magnitude). This could be due to the differing architectures of c-Myc and Htelo DNA 
(see Conclusion for further discussions). UV-vis titration experiments were unable to be conducted 
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with complex 6 as there was no clear band above 300 nm.  The MLCT and LMCT bands appeared as 
very broad shoulders rather than well-defined peaks, making it difficult to derive any binding data.  
 
Table 3-3: Binding constants obtained for the terpyridine-cyclen complex series. The values are an average 
of three independent measurements. This was carried out in 50 mM Tris-HCl (pH 7.4)/100 mM KCl buffer. 
 
Compound HteloK (M–1) c-MycK (M–1) ct-DNAK (M–1) 
1 1.12 ± 0.45 x 106 7.45 ± 1.05 x 106 2.40 ± 1.56 x 105 
2 1.46 ± 0.19 x 107 5.57 ± 3.58 x 108 2.80 ± 0.41 x 105 
3b 1.47 ± 0.93 x 107 1.12 ± 0.55 x 108 1.92 ± 1.39 x 105 
4 1.90 ± 1.27 x 107 2.81 ± 0.31 x 108 4.00 ± 2.06 x 105 
5 2.35 ± 0.35 x 107 1.41 ± 0.94 x 108 9.43 ± 1.11 x 105 
 
 
The UV-Vis spectroscopic titrations were also used to probe the binding mode. Red shifts in 
absorption bands above 300 nm (those corresponding to MLCT or intra-ligand π-π* transitions) are 
characteristic of π-π interaction with DNA bases. This is generally suggestive of an end stacking or 
intercalative binding mode for quadruplex DNA and duplex DNA respectively.185-188 Significant 
hypochromicity was seen for the complexes upon addition of Htelo, c-Myc and ct DNA (9 - 25%).  
Interestingly no significant bathochromicity (red shift) was observed indicating that the binding 
mode of the complexes to the DNA is not exclusively a result of π-π stacking interactions but rather a 
combination of this binding mode and an electrostatic and covalent interaction e.g. groove binding. 
Indication of more than one binding mode can be rationalised by the dual targeting nature of the 
complexes.  It is hypothesised that the complexes bind via π-π stacking interactions, with the 
metal(II) terpyridine moiety being positioned atop the quadruplex quartet, as well as through 
electrostatic or covalent interactions, with the metal(II) cyclen moiety targeting the quadruplex 
grooves/DNA backbone. 
 
 
3.5 Circular Dichroism (CD) Spectroscopy 
Having ascertained binding of the complexes to quadruplex DNA (using FID assays, FRET melting 
assays and UV-vis titrations), it was of interest to explore whether binding of the complexes resulted 
in any structural changes to the quadruplex structure.  To investigate this, circular dichroism (CD) 
spectroscopy was used.  CD is a phenomenon originating from interactions of chiral molecules with 
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circularly polarized electromagnetic rays.  Spectral studies of DNA usually employ ultraviolet light 
within 180–300 nm, where bases of DNA absorb light. Absorption of right- and left-handed circularly 
polarized light by chiral molecules differs, and the difference is called CD. The quantity used to 
describe this phenomenon is called ellipticity and is expressed in degrees. A plot of ellipticity against 
the various wavelengths of light gives a CD spectrum.  The CD spectra of quadruplexes can indicate 
whether they fold into a parallel or an anti-parallel conformation, because quartet stacking and 
polarity of DNA strands are determining factors of CD intensity and shape. The rotation angle 
between the stacks also contributes to the CD signal observed.48, 189 Signature CD spectra have been 
reported for the different quadruplex structures.190  A positive ellipticity in the 290 nm region in 
addition to a negative ellipticity around 260 nm represents an anti-parallel quadruplex structure.  On 
the other hand a maximum at 260 nm and a minimum at 240 nm denote a parallel quadruplex 
structure (Figure 3-12).191-193  
 
Figure 3-12: Signature CD spectra of anti-parallel Htelo DNA (black line - obtained by adding compound 3b to 
Htelo DNA in the presence of potassium ions) and parallel c-Myc DNA (red line). This was performed in 50 
mM Tris-HCl (pH 7.4) and 50 mM Tris-HCl (pH 7.4)/150 mM KCl buffer respectively. 
  
 
3.5.1 Htelo DNA CD Titrations (in the presence of K+ ions)  
Htelo DNA in the presence of K+ ions forms a hybrid structure (mixture of anti-parallel and parallel 
structures). To see whether the complexes bind preferentially to one of the conformations, CD 
spectra were recorded for mixtures of the test complexes 1 - 6 and Htelo (0.5 - 3 ratios) in Tris-HCl 
(10 mM, pH 7.4)/KCl (150 mM) buffer (the spectra obtained for 4 are shown in Figure 3-13).  
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Figure 3-13: The CD spectra of Htelo DNA (10 μM) in the presence of potassium ions, upon addition of 
increasing amounts of 4. The signal at 290 nm increases and the one at 260 nm reduces, producing a new 
signal with negative ellipicity.  
 
The CD spectrum of Htelo DNA alone is indicative of an anti-parallel/ parallel mixture.  The spectrum 
(Figure 3-12; black line) clearly shows a maximum band ca. 290 nm with a shoulder in the 260 nm 
region.  With increasing equivalents of complex 4, an increase in ellipticity at 290 nm and a decrease 
at 260 nm were observed. The intensification of the 290 nm band characterizes the stabilisation of 
the anti-parallel conformation by 4.  At the same time, the attenuation of the 260 nm band shows 
the de-stabilisation of the parallel structure. Therefore, under these conditions, 4 binds preferably to 
the anti-parallel conformation. Similar CD spectral changes were observed upon addition of 
complexes 2, 3b, and 5 (see Appendix A-6). An increase in ellipticity at 290 nm and a decrease at 260 
nm were observed. Therefore the complexes (under these conditions) bind preferentially to the anti-
parallel conformation. It should be pointed out that the complexes may not simply distinguish and 
stabilise the anti-parallel conformation, but might directly support the formation of anti-parallel 
topology and shift the equilibrium towards it.194  Addition of complex 1 to the Htelo DNA does not 
lead to a significant increase in ellipticity at 290 nm.  Interestingly, however, a decrease at 260 nm 
was observed with addition of increasing equivalents of complex (see Figure 3-14(a)).  A distinctive 
signal in the 330 nm region was observed upon incremental addition of 1, indicative of groove 
binding interactions. Remarkably, in silico studies show that 1 does indeed interact with Htelo DNA 
via the groove (discussed further Section 2.6). 
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Addition of complex 6 to the Htelo DNA does not lead to any changes in the spectrum (see Figure 3-
14(b)) suggesting that, unlike the other complexes in the series, it is unable to bind with enough 
strength to induce a conformational change.   
 
Figure 3-14: (a) The CD spectra of Htelo DNA (10 μM) in the presence of potassium ions, upon addition of 
increasing amounts of 1. The signal at 260 nm reduces, producing a new signal with negative ellipticity. (b) 
The CD spectra of Htelo DNA (10 μM) in the presence of potassium ions, upon addition of increasing 
amounts of 6.  No significant spectral changes were observed upon addition of the complex.  
 
3.5.2 Htelo DNA CD Titrations (in the absence of K+ ions)  
The next test carried out was the addition of 2.5 equivalents of the test compound to a solution of 
Htelo DNA (10 μM) in Tris-HCl in the absence of potassium salts. It is known that in the absence of 
suitable cations, quadruplexes do not form. Hence, these experiments were carried out to see 
whether the metal complexes under study were able to fold the sequence into a quadruplex in the 
absence of salts.  The changes in the CD spectra were monitored and recorded after 10 min and 2 h 
incubation (see Figures 3-15(a) and 3-15(b) respectively). The CD spectrum of Htelo DNA at both 
time points, shows two maxima: one centred at ca. 250 nm (associated to the unfolded sequence) 
and a less intense one centred at ca. 290 nm (corresponds to some of the DNA being already folded 
into a quadruplex structure due to the presence of traces of cations intrinsic to the DNA sample).  
Upon addition of complexes 1, 2 or 6 some spectral changes were observed (similar for the three 
complexes). After 10 min, a small amplification of the 290 nm band and a small reduction in the 250 
nm band were seen.  There is also the appearance of a negative minimum in the region of 260 nm. 
This suggests that upon addition of 2.5 equivalents of these complexes and 10 min incubation, the 
singly stranded Htelo sequence starts to fold into an anti-parallel quadruplex structure (but not fully 
convert). After 2 h incubation the CD graphs resemble an anti-parallel structure (positive peak 
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around 290 nm and negative peak around 260 nm). This suggests that at longer incubations times of 
complexes 1, 2 and 6, quadruplex DNA can be templated. 
  
Figure 3-15: The CD spectra of Htelo DNA (10 μM) in the absence of potassium ions, upon addition of 2.5 
equivalents of 1, 2 and 6 at (a) 10 mins and (b) 2 hours incubation. The signal at 290 nm increases and a 
negative peak appears at 260 nm. 
 
Upon addition of complexes 3b, 4 and 5 spectral changes were observed after 10 min and 2 h 
incubation, however, the resultant signals do not appear to correspond to the (partial) formation of 
quadruplex structures (see Figures 3-16(a) and 3-16(b) respectively). An explanation for this 
observation could be the formation of Pt-DNA adducts.195-196 These lesions could in turn prevent the 
folding of Htelo DNA into a quadruplex scaffold. Pt-DNA adducts are thought to result via the 
displacement of the chloride ligand present in 3b, 4 and 5. 
 
  
Figure 3-16: The CD spectra of Htelo DNA (10 μM) in the absence of potassium ions, upon addition of 2.5 
equivalents of 3b, 4 and 5 at (a) 10 mins and (b) 2 hours incubation.  
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3.5.3 c-Myc DNA CD Titrations (in the absence of K+ ions) 
 
c-Myc DNA exists as a parallel structure giving a characteristic CD spectrum with a maximum at 260 
nm and a minimum at 240 nm (see Figure 3-17). CD titration experiments were carried out with the 
complexes and c-Myc DNA (as were described above with Htelo DNA).  Addition of 2.5 equivalents of 
complexes 1, 2, 3b, 4, 5 and 6 to c-Myc DNA (5 μM), resulted in no significant changes to the CD 
spectrum, indicating that the complexes were not able to bring about conformational changes.  This 
result is expected due to the intrinsic structural stability of the c-Myc sequence, as discussed in 
Chapter 1. It should be noted that the DNA solutions may contain trace amounts of salts leading to 
the folding of c-Myc into a quadruplex structure which could mask the ability of the complexes to 
induce conformational change. 
 
Figure 3-17: The CD spectra of c-Myc DNA (5 μM) in the absense of potassium ions, upon addition of 2.5 
equivalents of 1-6. No changes in the CD spectra were observed.  
 
3.5.4 Variable Temperature CD (VTCD) 
 
The ability of the complexes to stabilise folded c-Myc DNA structure was studied by variable 
temperature CD (VTCD) spectroscopy.  This involved measuring the melting temperature (Tm) of c-
Myc DNA in the absence/presence of a particular complex.134 The ∆Tm values give a good indication 
of the affinity of a particular compound for DNA. Tm values were determined by monitoring the loss 
in ellipticity at 260 nm upon increasing the temperature (see Figure 3-18).   
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Figure 3-18: (a) Pictorial representation of c-Myc DNA unfolding during the CD melting experiment. B) The 
CD melting spectra of c-Myc DNA (5 μM) in Tris-HCl buffer. 
 
The melting temperature (defined as the temperature at which half the original c-Myc ellipticity is 
lost) of the native quadruplex occurred at 49 oC.  Figure 3-19 shows the CD melting curves for c-Myc 
DNA (5 μM) with and without the presence of complex 5 (2 eq., 10 μM). Table 3.4 summarises the 
results from the CD melting experiments conducted in the presence of given compounds. 
 
 
 
Figure 3-19: CD melting curves for c-Myc DNA (5 μM) with and without the presence of the complexes (2eq., 
10 μM). The data was fitted to a sigmoidal curve, normalised ∆Tm (T) = 1/(1-e
-T
). 
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Table 3-4: Change in melting temperatures (∆Tm) for c-Myc quadruplex DNA (5 μM) in the presence of 2 
equivalents of complex. The values are an average of three independent measurements.  
 
 
Complex (2eq) ∆Tm 
1 5.0 ± 1.0 
2 9.5 ± 0.5 
3b 12.3 ± 1.2 
4 13.1 ± 2.0 
5 14.0 ± 1.9 
6 8.0 ± 2.1 
 
 
Complex 1 gave the lowest ΔTm, which was expected considering its non-planar geometry. Complex 2 
gave a reasonable ΔTm value indicating that the complex is a good stabiliser of c-Myc DNA. 
Complexes 3b, 4 and 5 produced high ΔTm values, comparable to or surpassing values reported for 
well-established quadruplex ligands in the literature (i.e. TMPyP4 where ΔTm = 11 oC).197 The results 
demonstrate the ability of the complexes to interact with and stabilise c-Myc DNA in its quadruplex 
structure. Complex 6 was seen to have a reasonable ΔTm value, but considerably lower than that of 
the other platinum(II) complexes in the series. This result is in agreement with the data obtained 
from other biophysical techniques.  
 
 
3.6 Cytotoxicity Studies: MTS Assay  
Having studied the ability of the complexes to interact with quadruplex and duplex DNA it was of 
interest to study them in a cellular environment. The cellular toxicity of the complexes towards 
cancer and normal cell lines was determined.  This was done to assess the ability of the complexes to 
kill cancer cells and additionally to determine a working concentration for further cellular 
experiments.   
The cellular toxicity was analysed using the MTS assay (CellTiter 96® AQueous Assay (from Promega).198  
This is a colorimetric assay for measuring the activity of cellular enzymes that reduce the tetrazolium 
dye (MTS) to formazan giving an orange colour. The dye is used in conjunction with an electron 
coupling reagent, phenazine methosulfate (PMS).  The dehydrogenase activity found in metabolically 
active cells is measured.  Production of formazan (monitored by absorption at 490 nm) is directly 
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proportional to the viability of the cells; therefore the intensity of absorption at 490 nm gives a good 
indication on the quantity of living cells.  
The cytotoxicity of the complexes was tested against two cancer cell lines (U2OS and SHSY5Y) and 
one normal cell line (GM05757). U2OS is a human osteosarcoma cell line which is known to express 
the c-Myc protein. SHSY5Y is a cancerous cell line derived from neuroblastoma cells which expresses 
high levels of c-Myc and over-expresses N-myc. Therefore U2OS and SHSY5Y were ideal cell lines to 
correlate c-Myc downregulation (through quadruplex DNA stabilisation) and cytotoxicity.199-201  The 
primary human fibroblast GM05757 cell line was used as a control.  As GM05757 is non-cancerous, 
c-Myc levels are expected to be present at standard levels. 
The cells were treated with the compounds 1 to 6 across a range of concentrations (0.2 – 500 μM) 
and incubated for 24 hours. The optical absorption of the cells was then measured and the IC50 (the 
concentration that leads to 50% cell death) values were determined using the Conventional Method 
(see Experimental Section for details). The IC50 value was also obtained for cisplatin, a clinically used 
anti-cancer drug, as a reference. 
The complexes displayed a range of toxicities across the three cell lines under the conditions used 
(see Table 3-5 and Figure 3-20).  The highest IC50 values were observed for complex 1 (IC50 values 
ranging from 339-460 μM).  Complex 2 displays some selective toxicity for SHSY5Y (IC50 value for 
SHSY5Y is 3-fold lower than that for U20S). Complexes 3b, 4 and 5 displayed similar trends in their 
toxicities towards the respective cell lines. The IC50 values for the two cancer cell lines were observed 
to be lower than that for the normal cell line (95-121 μM). Furthermore these values were 
comparable to those observed for cisplatin (IC50 = 48 μM for U2OS and 54 μM for SHSY5Y). 
Encouragingly, the IC50 values for the normal cell line were higher than that observed for cisplatin 
indicating better selectivity. Complex 6 displayed very poor toxicity towards all cell lines (IC50 > 150 
μM).  
Interestingly, complexes 1 and 6, determined by biophysical studies to be weakest quadruplex 
binders, displayed the least cytotoxic effects. Similarly complexes 3b, 4 and 5, shown to have strong 
affinity for quadruplex DNA, were the most cytotoxic to the three cell lines (particularly the cancer 
cells lines with intrinsically high levels of c-Myc).  Therefore, it is possible, that the toxicity may be 
mediated by the interaction of the complexes with quadruplex DNA.  
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Table 3-5: IC50 values obtained for complexes 1- 6 and cisplatin against U2OS (cancerous), SHSY5Y 
(cancerous) and GMO5757 (normal) cell lines. The values are an average of three independent 
measurements.
 a
 IC50 values for cisplatin taken from reference
202
.  
 
Complex U2OS IC50  
(μM) 
SHSY5Y IC50  
(μM) 
GM05757 IC50  
(μM) 
1 463 ± 9 406 ± 81 339  ± 6 
2 290  ± 64 89 ± 7 155 ± 10 
3b 57  ±  12 77 ± 5 121 ± 13 
4 64  ± 11 48 ± 8 132 ± 3 
5 49  ± 8 50 ± 1 95 ± 7 
6 257  ± 33 366 ± 95 150 ± 1 
cisplatina  48  ± 6 54 ± 4 74 ± 6 
 
The general trend indicates higher potency for compounds containing Pt-chloride bonds and redox 
active copper centres. Platinum(II)-terpyridine chloride complexes have been widely reported to 
platinate DNA (including quadruplex DNA) via displacement of the chloride ligand in a two-step 
process, first aquation and then nucleobase conjugation. The formation of Pt-terpyridine-DNA 
adduct disrupts the secondary structure of DNA and consequently leads to a number of downstream 
pathways culminating in apoptotic cell death.130, 195-196   At the same time, these platinum agents 
could bind to sulphur containing proteins and compromise their activity. This could possibly 
contribute to the toxicity observed. As complexes 3b, 4 and 5 contain Pt-Cl bonds, cells treated with 
these compounds could undergo cell death in the manner described above. The ineffectiveness of 
complex 6 might be due to the inertness of the Pt-S bond. Generally Pt-S bonds are resistant to 
aquation and displacement by nitrogen based nucleophiles like nucleobases (e.g. guanine and 
adenine).203 Therefore 6 is unlikely to covalently interact with DNA and induce DNA damage related 
cell death.   
Copper(II)-terpyridine complexes and other copper(II)-coordinating scaffolds are reduced 
intracellularly, yielding reactive oxygen species (ROS) which can cleave DNA and cause general 
cellular stress.204 Therefore toxicity observed for 2 and 5 could, in part, be due to the biological 
reduction of copper(II) to copper(I) and the concurrent formation of lethal ROS.   
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Figure 3-20: IC50 values obtained for complexes 1- 6 and cisplatin against U2OS (cancerous), SHSY5Y 
(cancerous) and GMO5757 (normal) cell lines. The values are an average of three independent 
measurements. The associated error (standard deviation) for each value is represented in form of capped 
error bars. 
 
 
3.7 c-Myc Expression: Immunoblot Analysis  
Having both i) studied the binding and stabilization properties of the complexes with c-Myc DNA 
(FID, UV-vis, FRET and CD) and ii) established a “working” concentration of the complexes in vivo, the 
effect of the complexes on c-Myc protein expression was explored. This was done by 
immunoblotting analysis.  This technique is used to detect specific proteins in a given sample of 
tissue homogenate or extract. It uses gel electrophoresis to separate denatured proteins by the 
length of the polypeptide. The proteins are then transferred to a membrane 
(typically nitrocellulose or PVDF), where they are detected with antibodies specific to the target 
protein.  
U2OS cells (1 × 106) were treated with complexes 1 to 6 (10 µM) for 24 h at 37 oC, analysis was also 
carried out for TMPyP4 as a positive control.  The cells were collected, lysed and resolved by gel 
electrophoresis.  The proteins were then electro-transferred onto a nitrocellulose membrane in 
order to make them accessible to antibody detection.  The membranes were blocked (to prevent 
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non-specific binding) and incubated with the relevant primary antibodies: c-Myc (the target protein) 
and α-tubulin (a structural protein used as an internal control). The membranes were then incubated 
with horseradish peroxidase-conjugated secondary antibodies and a chemiluminescent substrate. 
The enzyme cleaves the chemiluminescent agent, converting the soluble dye into an insoluble form 
of a different colour that precipitates next to the enzyme and thereby stains the membrane.  The 
luminescence produced is in proportion to the amount of protein present, allowing immune 
complexes to be detected and analysed. The amount of target protein was normalized to α-tubulin 
(control). This practice ensures correction for the amount of total protein on the membrane in case 
of errors or incomplete transfer. 
 
 
Figure 3-21. Analysis of protein expression in U2OS cells following treatment with complexes 1 to 6 and 
TMPyP4 (10µM) after 24 h incubation. Whole cell lysates were resolved by SDS-PAGE and analysed by 
immunoblotting against c-Myc and α-tubulin (loading control). Results are representative of three 
independent experiments. MW: Protein Molecular Weight Marker. 
 
Treatment with complexes 1 to 6 generally resulted in a decrease in c-Myc protein levels (see Figure 
3-21 and 3-22).  Complex 1 was observed to produce the smallest reduction (10% decrease relative 
to the untreated control).  This was expected based on the biophysical data. Treatment with 2, 3b, 4 
and 5 resulted in loss in c-Myc protein levels (ranging from 37 to 54 % decrease) comparable to and 
surpassing the reduction observed with TMPyP4 (39%).  This result can be rationalised by 
considering the inherent affinity of the complexes to c-Myc DNA (shown by biophysical studies). 
Complex 6 was observed to produce moderate downregulation (21% decrease).  Again this 
correlates well with the behaviour displayed by this complex for c-Myc DNA. 
In general, the complexes were seen to downregulate c-Myc protein expression. The trends 
observed correlate well with the binding affinities observed for the complexes via various 
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biophysical studies. Complexes 2, 3b, 4 and 5 downregulate protein expression significantly and 
compare well to TMPyP4. 
 
Figure 3-22. Graphical representation of c-Myc expression in U20S cells after treatment with a selection of 
metal complexes (10 µM). The expression values are normalised relative to the control gene, α-tubulin. The 
values are an average of three independent measurements and the associated error for each value is 
represented in form of capped error bars. 
 
It was of interest to see whether there was any correlation between the cytotoxicity of the 
compounds for U2OS cells and the downregulation of c-Myc protein.  Therefore a graph was plotted 
of IC50 against percentage decrease in c-Myc protein (see Table 3-6 and Figure 3-23).  The graph 
displays a reasonable correlation between c-Myc downregulation and cell toxicity. This suggests that 
the downregulation of c-Myc may be a part of the mode of cyctotoxic action of the complexes, 1-6.  
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Table 3-6: Table of IC50 values obtained for complexes 1- 6 with U2OS and percentage c-Myc protein down 
regulation levels. 
a
 IC50 value corresponds to 48 h incubation, taken from reference
205
. 
  
Complexes U2OS IC50  
µM 
% Decrease in c-Myc 
protein expression 
1 463 10 
2 290 37 
3b 57 51 
4 64 54 
5 49 51 
6 257 21 
TMPyP4 > 50a 39 
 
 
 
Figure 3-23: Graph of IC50 values obtained for complexes 1- 6 with U2OS plotted against percentage c-Myc 
protein down regulation levels.  
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3.8 Conclusion 
Having carried out numerous biophysical and cellular studies with the metal complexes several 
conclusions can be made with regard to the affinity and selectivity of the complexes for the 
particular oligonucleotides. 
3.8.1 Conclusion: Biophysical studies 
The di-zinc(II) complex, 1 displayed relatively low affinity toward quadruplex DNA as indicated by the 
FID, UV, FRET and VTCD data. This is consistent with the hypothesis that quadruplex binders require 
at least one accessible planar aromatic surface to facilitate π-π interactions with the external tetrad. 
Despite lacking this property, complex 1 displays improved binding compared to other zinc(II) 
terpyridine complexes previously studied.134 This can be attributed to the zinc(II)-cyclen moiety 
which enables additional interactions with the DNA backbone. Furthermore 1 displayed favourable 
binding to the anti-parallel topology of Htelo DNA in the presence of potassium ions.  
The di-copper complex, 2 displayed strong affinity toward quadruplex DNA, as indicated by the FID, 
UV, VTCD and FRET data (DC50 = 0.09, K = 5.57 ± 3.58 x 10
8, FRET ∆Tm = 10.2 ± 1.1 and VTCD ∆Tm = 9.5 
± 0.5). Notably, 2 exhibited greater quadruplex DNA binding properties compared to complex 1, this 
can be attributed to the fact that complex 2 possesses a planar aromatic surface (see crystal 
structure, Figure 2-15 and 2-16) which allows interaction with the external tetrad through 
favourable π-π interactions.  Furthermore, 2 displayed good selectivity for quadruplex DNA, 
particularly c-Myc, over duplex DNA. Up to 1000-fold selectivity was observed for c-Myc DNA over 
duplex DNA from the UV spectroscopic titrations. Similar to 1, 2 also displayed preferential binding 
to the anti-parallel conformation of Htelo in the presence of potassium ions.  
The platinum complexes, 3b, 4 and 5 displayed the highest quadruplex DNA binding properties in the 
series. This can be attributed to the platinum centre, which organises the terpyridine ligand into the 
optimal geometry (square planar) to interact with quadruplex DNA. The positively charged metal-
cyclen (for 4 and 5) or protonated cyclen (for 3b) are also thought to promote quadruplex binding 
through electrostatic interactions with the DNA backbone, especially the grooves. Overall 3b, 4 and 
5 exhibit excellent quadruplex affinities comparable or surpassing well established quadruplex 
binders. Encouragingly, 3b, 4 and 5 displayed selectivity over duplex DNA. In the presence of 250-
fold ct-DNA and 25-fold ds26, the ∆Tm for c-Myc decreased as little as 16%. Interestingly, the 
complexes displayed strong intra-quadruplex selectivity for c-Myc DNA over Htelo DNA. This was 
clearly indicated in the FRET competition studies. The ∆Tm for c-Myc DNA decreased 30% in the 
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presence of excess Htelo DNA (10 eq.) however in the reverse experiment, the ∆Tm for Htelo DNA 
decreased sharply in the presence of excess c-Myc DNA.  
Preferred binding to c-Myc DNA (over Htelo DNA) under the conditions used could be due to a 
number of reasons. These include; (i) easier accessibility to the external tetrads, the tetrads of Htelo 
DNA (in potassium buffer) are partially blocked by the long propeller and lateral loops whereas the 
tetrads of c-Myc DNA are more exposed with single nucleotide side loops, and (ii) availability and 
position of thymine bases in the grooves for the metal-cyclen motif to bind. See Figure 3-24. 
                     
Figure 3-24: (a) Solution structure of Htelo DNA sequence (TAGGGTTAGGGTTAGGGTTAGGG) in K
+
 solution. 
(b) Solution structure of c-Myc DNA sequence (TGAGGGTGGGTAGGGTGGGTAA) in K
+
 solution. Figures taken 
from references 
45, 67
. 
The platinum complex 6 featuring a thiolate substituent on the fourth position of the platinum(II), 
displayed reasonable affinity toward quadruplex DNA, as indicated by the FID, VTCD and FRET data 
(DC50 = 2.25, FRET ∆Tm = 7.8 ± 2.1 and VTCD ∆Tm = 8.0 ± 2.1). The affinity was not as high as expected 
(DC50 values observed were high compared to the series average), this could be due to the steric 
clashes between the additional side arm and the DNA loops surrounding the external tetrad. It was 
envisaged that the design of the complex would improve selectivity for quadruplex DNA (over duplex 
DNA). The additional arm was expected to prevent intercalation between base pairs in duplex DNA. 
However this was not observed, selectivity was 4-fold according to the FID assay. Unlike the other 
complexes, no intra-quadruplex selectivity was observed.  
In general, the series displayed selectivity towards c-Myc DNA. A possible reason for this can be 
drawn from reported structures of the c-Myc sequence (determined NMR studies).45, 67  c-Myc DNA 
folds into a parallel topology, which contains only side loops and four grooves. It can be 
hypothesised that complexes 1 to 5 would interact with the parallel quadruplex via favourable 
stacking of the aromatic coordination core on the G-quartet, while the cyclen side arm could be well 
accommodated in any of the four side grooves to lock the stabilizer into quadruplex c-Myc. Since 
Htelo DNA adopts a hybrid/anti-parallel quadruplex with lateral and diagonal loops, these loops may 
(a) 
 
(b) 
 
119 
 
hinder the interaction of the cyclen anchor and only allow the complexes to partially stack on the 
terminal G-quartet.   
 
3.8.2 Conclusion: Cellular studies 
The MTS cytotoxicity assay enabled determination of a “working concentration” of the complexes 
for further cellular assays as well as providing evidence of the toxicity of the complex series against 
several cell lines (two cancerous and one non-cancerous). Complexes 3b, 4 and 5 diplayed some 
selectivity for cancerous cells (with IC50 values comparable to cisplatin) over normal cells. According 
to previous reports, one would expect these complexes to induce cell death by forming covalent 
adducts to DNA and/or proteins (via displacement of the chloride ligand). However, the 
immunoblotting data suggests that toxicity could also result from the downregulation of c-Myc, a 
pleiotropic nuclear protein involved in many proliferative processes.  
Immunoblot analysis was carried out to determine the effect of complexes had on the cellular 
expression of c-Myc protein.  Complexes 2, 3b, 4 and 5 were seen to downregulate protein 
expression significantly (comparable to or surpassing TMPyP4). Taking into account their high affinity 
for c-Myc DNA (elucidated by DNA binding studies), the inhibition of c-Myc protein expression can 
be proposed to result from the stabilisation of c-Myc quadruplex DNA. As a correlation between 
toxicity and c-Myc downregulation was identified (Figure 3-23), the toxicity of these complexes 
could, in part, be due the downregulation of c-Myc.  
Overall the cellular studies suggest that some of the complexes are able to regulate the expression 
of the c-Myc oncogene possibly through interaction with the quadruplex forming DNA sequence and 
therefore induce (in some case) cell death in human osteosarcoma cells (U2OS). The data clearly 
highlight the anti-cancer potential of the synthesised metal complexes. 
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Chapter 4 
Affinity Tags for G-Quadruplex 
Nucleic Acids 
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4.1 Overview  
 
The platinum terpyridine cyclen complex, 3a described in Chapter 2 and a series of metal salphen 
complexes (reported previously by Vilar et al. to be strong quadruplex binders) were used to design 
affinity tags for quadruplex nucleic acids.116-117 The metal complexes were attached covalently to 
solid supports. The resin bound complexes were i) prepared, fully characterised and subsequently 
attached to the resins via a functional “handle” or ii) built onto the resin in a step-wise manner using 
well characterised components.  Loading of the complexes onto the supports was monitored by UV-
vis spectroscopy and inductively coupled plasma mass spectrometry (ICP-MS).  The ability of the 
affinity tags to selectively stabilize and isolate quadruplex motifs in solution was explored. Solutions 
of FAM-labelled quadruplex DNA (Htelo or c-Myc), quadruplex RNA (TRF2), hairpin RNA or duplex 
DNA were incubated with different amounts of the affinity tags. The supernatants were collected 
and subjected to fluorescence measurements to calculate the amount of residual nucleic acid. Upon 
increasing the amount of affinity tags, a reduction in fluorescence at 520 nm (corresponding to the 
emission of the FAM fluorophore) was observed, indicative of oligonucleotide “pulled down” from 
solution. Interestingly, the ability of the affinity tags to bind to nucleic acid was sequence-dependent 
with quadruplexes being pulled-out of solution in preference to duplex DNA.  
 
 
 
4.2 Rationale  
 
As discussed in previous chapters, over the last two decades a large number of quadruplex 
interacting small molecules have been developed. This chapter aims to prepare quadruplex affinity 
tags based on some of these potent and selective small molecules. The rationale for this approach 
was that small molecules could act as quadruplex DNA binding mimics on the resin peripheries to 
selectively stabilise and isolate quadruplex forming sequences from diverse mixtures of 
oligonucleotides (eventually progressing to mixtures containing the whole genome). This is depicted 
in Figure 4-1.  The affinity tags could uncover new quadruplex forming sequences that have failed to 
be identified by current computational or bioinformatic methods. If the sequences are found to be 
of biological relevance then further work could be carried out to develop binders to target these 
sequences.  
 
There have been very few examples of affinity tags for quadruplex nucleic acids based on small solid-
supported nucleic acid-binders.150-151, 155 The methodology presented here has several novel aspects 
compared to previous examples. As the tags comprise of metal complexes with individual selectivity 
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profiles, specific sequences can be targeted by systematically changing the metal. Further, this 
approach improves efficiency. Here, quadruplex-DNA-targeting molecules are attached directly to 
the tags, allowing DNA to be directly extracted from mixtures in a single step. Previous methods 
involve two steps, pre-mixing small molecules with DNA and then extracting the small molecule-DNA 
adducts.150, 155   
 
Importantly, this strategy offers the possibility to disrupt the DNA-solid support interaction upon 
thermal denaturing and/or exposure to a set of chaotropic reagents. This step is crucial to recover 
the pulled down nucleic acids for further sequencing (PCR sequencing) and genome-wide mapping 
(in future work). 
 
 
Figure 4-1: Affinity tag approach to isolate quadruplex nucleic acids from solution. 
 
 
4.3 Solid Support 
The requirements of an efficient solid support for this application are considered to be: i) particles 
with appropriate size and shape to permit facile manipulation and filtration from liquids; ii) inert to 
all reagents and solvents used during the synthesis as well as stable to conditions used, such as 
temperature and pH; iii) ability to swell extensively in the solvents used for synthesis, allowing all 
reagents to penetrate readily throughout the polymer; and iv) readily modified via introduction of 
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functional groups, to allow attachment of the quadruplex binding molecule to the solid support 
through covalent bonds.    
With this in mind, TentaGel® was selected as the solid support to prepare the quadruplex affinity 
tags.206  Tentagel® resins are copolymers consisting of a low cross-linked polystyrene matrix on 
which polyethylene glycol (PEG) is grafted.207 As PEG is a "chameleon type" polymer with 
hydrophobic and hydrophilic properties, the graft copolymer shows modified physicochemical 
properties. Anionic graft copolymerization is used to build layers of PEG, in a step by step manner, 
directly onto the resin matrix. PEG chains of molecular masses up to 20 kilo Dalton (kDa) are 
immobilized on functionalized crosslinked polystyrenes resin matrix. Graft copolymers with PEG 
chains of about 2000-3000 Da proved to be optimal with respect to kinetic rates, mobility, swelling 
and resin capacity. The process results in a very narrow molecular weight distribution of the grafted 
PEG spacers. Figure 4-2 illustrates the chemical architecture of the tentacle polymer. The copolymer 
contains about 50 - 70 % PEG (w/w). Therefore, the properties of these polymers are highly 
dominated by the properties of PEG and no longer by the polystyrene matrix. 
 
 
 
Figure 4-2: Chemical architecture of the tentacle polymer, where n is ca. 60. Figure modified from 
reference
206
.
 
 
 
The reactive sites which are located at the end of the spacer arms are flexible, displaying fluidic 
properties. Additionally, the PEG-tentacles display flexibility and good solvation properties. Typical 
loading of TentaGel® beads are in the range of 0.2 - 0.3 mmol/g.  This information enables the 
number of binding sites available within a certain amount of resin to be calculated as well as the 
capacity of a single bead.   
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There are several types of TentaGel® resins available displaying tailored properties for various 
applications. TentaGel® S resin was chosen for the affinity tag application. The PEG spacer is 
attached to the polystyrene backbone via an alkyl linkage which is not sensitive towards acids or 
bases. This type of resin is a standard type of resin used for peptide synthesis, solid phase organic 
synthesis and combinatorial chemistry.208-212 The resin exists with a number of terminating functional 
groups (e.g. Br, COOH, NH2, OH, SH) making it an attractive choice for attaching modified ligands via 
a plethora of potential chemical reactions.  
 
 
4.4 Affinity Tags: Platinum(II) Terpyridine-Cyclen Series 
The metal terpyridine-cyclen series described in Chapters 2 and 3 was seen to exhibit strong binding 
affinities to quadruplex DNA as well as reasonable selectivity over duplex DNA, therefore it was 
hypothesised that the complexes of this series would be strong candidates for the affinity tag 
project.  
4.4.1 Synthesis of Affinity Tags 
In order to enable attachment of the complexes, described in Chapter 2, to the beads it would be 
necessary to introduce a functional handle into the ligand. However, the synthesis of the ligand, L5, 
and subsequent complexes was not trivial and there was no obvious position where a functional 
group could be introduced with ease.  Therefore it was decided to utilise the labile Pt-Cl bond 
present in three of the platinum(II) complexes (3b, 4 and 5) to attach the complex to the solid 
support via coordination to a thiol.  Following an analogous synthetic procedure to that used to 
prepare 6 (Section 2.3.4), complex 3a was reacted with a thiol-modified bead (namely Tenagel® S SH, 
see Figure 4-3) to prepare the first metal complex affinity tag, T1.  TentaGel® S SH resin is a 
polystyrene grafted solid support with polyethyleneglycol (PEG) functionalized with a thiol group on 
the terminal.213-215 
 
Figure 4-3: Depiction of the TentaGel® S SH resin with terminal thiol functional groups. 
Tentagel® S SH resin was swollen in water and an aqueous solution of complex 3a (1.25 equivalents 
relative to the SH group) was added to this suspension. The reaction mixture was left to stir for 3 
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days at room temperature (see Scheme 4-1). Over this period the resin changed colour from pale 
yellow to deep pink.  This was consistent with the formation of a Pt-S bond in the terpyridine 
complex. To calculate the amount of 3a loading a control reaction was also set up, whereby 3a was 
stirred in water in absence of resin. 
 
Scheme 4-1: Reaction scheme for the preparation affinity tag, T
1
 using 3a and Tentagel® S SH.  
After 3 days the reaction mixture was filtered to isolate the resin using a syringe fitted with a frit.  
The resin was repeatedly washed with water (of a known volume) and after each wash, the amount 
of unreacted platinum(II) complex present in the filtrate was measured by UV-vis spectroscopy.  The 
beads were washed until no more complex could be detected.  The UV-vis trace of the combined 
washings was used to determine the concentration of unbound complex (Figure 4-4). The 
concentration of total complex available was calculated by measuring the UV-vis spectrum of the 
solution in the control experiment (i.e. that with no resin present, Figure 4-4). It should be noted 
that this solution was diluted to the same volume as the combined washings. The difference in total 
complex available and unbound complex yielded the amount of complex on the beads. 
 
Figure 4-4: The UV-vis spectra recorded of the control sample (black line) and supernatant (red line). The 
spectra allowed the determination of the concentration of 3a in each sample.  
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The concentration of unbound complex was determined as 9.2 µM (A = 0.660 at λ = 282 nm), 
whereas the concentration of total complex initially available was 26.2 µM (A = 0.207 at λ = 282 nm). 
Therefore the amount of complex on the resin was estimated to be 17.0 µM. This corresponds to 
80% loading (taking into account that 1.25 equivalents of 3a for every SH site was used in the 
reaction) i.e. 80% of the terminal SH groups contain 3a. The loading of the Tentagel S SH resin is 0.2 - 
0.3 mmol/g (indicated by the manufacturer), since ca. 80% of the sites reacted, 1 mg of resin 
equates to ca. 0.16 – 0.24 µmol of 3a. The resultant affinity tag, T1 was then used in subsequent 
nucleic acid isolation studies.     
 
4.4.2 DNA Isolation Studies  
The ability of the affinity tag T1 to bind to and isolate nucleic acid sequences (two quadruplex-
forming and one duplex sequence) from solution was investigated using FAM-labelled (in the 5’ 
position) oligonucleotides, more specifically, the sequences were FAM-labelled Htelo 
([6FAM]AGGGTTAGGGTTAGGGTTAGGG), c-Myc ([6FAM]GGGGAGGGTGGGGAGGGTGGG), and ds26 
DNA ([6FAM]CAATCGGATCGAATTCGATCCGATTG).  The fluorescent label approach was chosen to 
allow an efficient, reliable method to quantify DNA in solution.  Other approaches previously 
reported have included monitoring DNA uptake by UV-vis spectroscopy or using radiolabelled 
sequences.150-151   
The oligonucleotide solutions were prepared to a concentration of 20 µM in buffer containing 10 
mM Tris-HCl (pH 7.4) and 60 mM potassium chloride and annealed, prior to use, by heating at 95 oC 
for 5 min followed by slow cooling to room temperature overnight. DNA solutions (quadruplex and 
duplex) were incubated at constant concentration (0.5 µM) with various masses of affinity tag, T1, 
(i.e. increasing complex concentration) ca. 0.5 mg – 10 mg/0.1 µM – 2 µM, to give DNA: affinity tag 
ratios ranging from 1:0.2 to 1:4. After 1 h incubation, with mixing, the solutions were filtered 
through fritted syringes.  The beads were washed once with 1 mL of buffer and this was combined 
with the supernatant.  The fluorescence of the supernatant was recorded between 500 nm and 600 
nm with excitation at 490 nm, to gauge the amount of unbound DNA. The fluorescence intensity 
decreased with increasing amount of T1, indicative of DNA “pull down” from solution i.e. DNA 
binding to the affinity tag. The amount of fluorescence decrease corresponds to the binding affinity 
of the affinity tag, T1, to a particular DNA sequence. To represent this visually, a graph was plotted of 
mass of T1 against percentage decrease in FAM emission corresponding to each labelled 
oligonucleotide (with respect to FAM emission with no beads); see Figure 4-5(a).  
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Figure 4-5: (a) Isolation experiments with T
1 
and labelled oligonucleotides; FAM Htelo, FAM c-Myc and FAM 
ds26. Mass of T1 (mg) was plotted against percentage decrease in FAM emission for each sequence. (b) 
Isolation experiments with the unmodified Tentagel® S H
 
(as a control) and labelled oligonucleotides; FAM 
Htelo, FAM c-Myc and FAM ds26. The plots are an average of three repeats.  
 
T1 displayed strong interactions with all three labelled DNA sequences.  To quantify the binding 
potential of the affinity tag to DNA, TC50 values (i.e. affinity tag mass required to isolate half of the 
DNA from solution) were calculated. It should be noted that the TC50 value was determined simply to 
gauge the efficiency of the affinity tags and it is not a universally used parameter. The affinity tag, T1, 
gave TC50 values of 0.25 mg, 0.19 mg, and 0.29 mg (corresponding to 3a concentration = 0.05 µM, 
0.04 µM, and 0.06 µM) for Htelo, c-Myc and ds26 DNA respectively. The inability of T1 to discriminate 
between DNA sequences could be related to structural modifications of the complex upon resin 
coordination. Having attached 3a to the resin via a thiol linkage, the complex appears to structurally 
resemble 6. Complex 6 was shown in Chapter 3 to be less selective for quadruplex- over duplex- DNA 
than the other members of the series.  It should be noted that the interpretation of binding affinity 
should be taken with some caution as the resolution of the assay (0.5 mg, 0.1 µM) was not sufficient 
to measure extremely strong binding, as observed for T1, accurately. 
To ensure that the observed interactions of T1 with the DNA sequences were due to 3a and not to 
non-specific binding of the resin, the DNA isolation experiments were carried out with the Tentagel® 
S SH resin alone (see Figure 4-5(b)).  The resin did not “pull down” any of the three DNA sequences, 
indicating that the DNA isolation was a result of interaction with the metal complex (3a) attached to 
the solid support. 
Having carried out DNA isolation studies with T1, it was of interest to prepare affinity tags containing 
4 and 5.  Based on the preliminary DNA isolation results obtained for T1 and the synthetic difficulties 
0 2 4 6 8 10
0
20
40
60
80
100
%
 d
e
c
re
a
s
e
 i
n
 F
A
M
 D
N
A
 e
m
is
s
io
n
Mass of T
1
 (mg)
 FAM Htelo
 FAM c-Myc
 FAM ds26
0 2 4 6 8 10
0
20
40
60
80
100
%
 d
e
c
re
a
s
e
 i
n
 F
A
M
 D
N
A
 e
m
is
s
io
n
Mass of T
1
 (mg)
 FAM Htelo
 FAM c-Myc
 FAM ds26
(a)                                                                               (b)                                                                               
128 
 
of attaching metal-terpyridine complexes to the resins, it was decided to investigate a second metal 
complex affinity tag series in parallel.   
 
 
4.5 Affinity Tags: Metal Salphen Series 
A second affinity tag series was prepared, based on metal salphen complexes. Extensive work in our 
group has shown that square-planar metal-salphen complexes are strong quadruplex DNA 
binders.115-116  The metal salphen complexes were chosen for a number of reasons: (i) facile synthesis 
and structural modifications (e.g. attachment of different side arms and introduction of different 
functional groups to the ligand); (ii) allows quadruplex DNA binding properties to be tuned by 
changing the metal centre; and (iii) well studied with respect to DNA binding. 
In order to attach the resin to the metal salphen complexes without perturbing their preferred 
binding mode (shown in the X-ray co-crystal structure of a nickel(II) salphen complex and Htelo DNA 
– see Figure 4.6), a long linker was required. Careful consideration was also taken to attach the linker 
to the metal salphen in a position such that binding was not hindered (π-π stacking or electrostatic 
interactions).117 
                                       
Figure 4-6: (a) General structure of the metal salphen affinity tag series, T
2-6
. The metal and side arms can be 
readily modified. (b) X-ray co-crystal structure of a nickel(II) salphen complex and Htelo DNA, demonstrating 
the binding mode. Figure taken from reference
117
. 
 
 
 
 
(a)                                                                               (b)                                                                               
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4.5.1  Synthesis of Affinity Tags 
Initially, a nickel(II) salphen complex with a carboxylic acid functional group, 8, was prepared (see 
Scheme 4-2).  This complex was synthesised by modification of a previously reported procedure.116 
Diaminobenzoic acid was reacted with hydroxybenzaldehyde and nickel(II) acetate to yield 7. 
Complex 7 was reacted with an excess of chloroethylpiperidine to yield 8. Complex 8 was purified by 
recrystallization in dichloromethane/toluene with slow addition of pentane.  The complex was fully 
characterised by 1H NMR and 13C NMR spectroscopy, mass spectrometry and elemental analysis. 
 
Scheme 4-2: Reaction scheme for the synthesis of 8, nickel(II) salphen complex with carboxylic acid 
functional group for attachment to resin support.   
 
Coupling of 8 to the resin was attempted through the formation of an amide bond by reacting 8 with 
TentaGel® S NH2 resin under peptide coupling conditions. TentaGel S NH2 is a resin coated with PEG 
linkers with terminal amines that allow facile coupling to carboxylic acid groups such as the exposed 
carboxylic acid group on 8 (see Figure 4-7).216-217 
 
Figure 4-7: Depiction of the TentaGel® S NH2 resin with terminal amine functional groups. 
To prepare T2, the resin was first swollen in dimethylformamide (DMF) (to allow reagents to 
penetrate the polymer).  The resin was treated with piperidine, as a precautionary measure, to 
ensure all the amine groups were deprotected. The resin was then reacted with 8 in the presence of 
peptide coupling reagents; hydroxybenzotriazole (HOBt), 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDCI) and triethylamine (NEt3) to yield T
2 (Scheme 4-3). The 
coupling reagents used were based on reported methods for analogous reactions.218-219 To calculate 
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the amount of 8 loading, a control reaction was also set up whereby the coupling reagents and 8 
were reacted in the absence of resin. After 24 hours, the resin was repeatedly washed with a known 
volume of DMF. After each wash, the amount of complex in the filtrate was measured by UV-vis 
spectroscopy.  The beads were washed until no more complex could be detected and the amount of 
8 loading was calculated using UV-vis spectroscopy traces as described for 3a loading (on T1). The 
intensity of the UV-vis band corresponding to total available complex and unbound complex 
remained the same, indicative of no reaction. This could be explained by taking the reactivity of the 
carboxylic acid functional group into account. In the presence of a metal, as is the case for 8, the 
carboxylic acid group may be subject to unfavourable electronic effects which could lead to its 
deactivation. This could ultimately prevent conjugation of 8 to the amine functionalised resin. 
 
 
Scheme 4-3: Reaction scheme for the attempted attachment of 8 to the Tentagel S NH2 resin.   
 
In order to further study the reaction between 8 and amines, and to rule out any unaccountable 
effects arising from the resin, a test reaction was carried out.  Complex, 8, was reacted with a short 
PEG linker terminating with an amine group (2-methoxyethylamine) (Scheme 4-4).  The reaction was 
carried out under the same conditions used for the resin and followed by 1H NMR spectroscopy. The 
isolated products were characterised and identified as unreacted starting materials, namely 8 and 2-
methoxyethylamine. Therefore the test reaction proved that even in the absence of a solid support, 
the carboxylic acid moiety on 8 was unable to react readily with an amine functionality. This meant 
another approach had to be considered in order for 8 to be coupled onto the resin. 
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Scheme 4-4: Reaction scheme for the attempted test reaction between 8 and 2-methoxyethylamine.   
 
An alternative approach was taken to prepare T2 which involved “building” metal complex 8 onto the 
resin in a step-wise manner.  This approach offers several advantages over the previously described 
method: (i) allows a library of complexes to be prepared using simple building blocks; (ii) allows 
facile diversity by incorporating different metal centres or by modifying the benzaldehyde 
component to incorporate alternative side arms at various positions; (iii) allows facile purification 
after each step, by washing of the resin to remove any unreacted starting material.  
Thus, the affinity tag, T2 was prepared following the 6 steps outlined below (see Scheme 4-5):   
Step 1: Boc-protected diaminobezoic acid, L8 was synthesised following a reported procedure.220 The 
3,4-diaminobenzoic acid, di-tert-butyl dicarbonate and guanidine hydrochloride were reacted in 
ethanol (35 oC) for 8h.  L8 was characterised by 1H NMR and 13C NMR spectroscopy and mass 
spectrometry. The integration of the alkyl protons of the Boc group relative to the aromatic protons 
indicated that the di-protected product had been prepared and isolated. The Boc-protected 
diaminobezoic acid was prepared to prevent polymerisation or self-conjugation of diaminobenzoic 
acid in the subsequent step.  
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Scheme 4-5: Synthesis of affinity tag, T
2
 via a step-wise, 6 step approach.   
 
Step 2:  Boc-protected 3,4-diaminobenzoic acid (L8) was attached to the resin via an amide bond to 
form T2a. The methodology employed was the same as that used in the attempted synthesis of T2 
(from 8): the resin was added to L8 in the presence of peptide coupling reagents, i.e. HOBt, EDCI and 
NEt3. The mixture was reacted by agitation overnight after which time the resin was washed 
thoroughly with DMF to remove any remaining starting material. The amount of L8 loading was 
calculated from the difference between the total concentration of L8 available and the concentration 
of unreacted L8. The concentrations were measured by UV-vis spectroscopy.  
The concentration of unbound L8 was determined as 0.85 µM (A = 0.34 at λ = 283 nm), whereas the 
concentration of total L8 initially available was 2.5 µM (A = 1.00 at λ = 283 nm), giving the estimated 
amount of L8 on the beads to be 1.65 µM. This corresponds to 80 % loading, taking into account that 
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1.25 equivalents of L8 for every NH2 site was used in the reaction. The maximum loading of the 
Tentagel S NH2 resin is 0.27 mmol/g (indicated by the manufacturer), since ca. 80 % of the sites 
reacted, 1 mg of resin equates to ca. 0.22 µmol of L8. Resin, T2a was then used in subsequent 
reaction steps. 
Step 3: The reaction of L8 with the resin is not quantitative, resulting in several unreacted amine 
groups. Therefore the third step involved capping these free amine groups with acetyl protecting 
groups. To do this T2a was swollen in DMF and then reacted with acetic anhydride (Ac2O) and 
diisopropylethylacteate (DIPEA) in DMF for 2 hours.  The capped precursor, T2b was then used in 
subsequent reaction steps. 
Step 4: Having attached L8 to the resin and capped unreacted amine groups on the resin, the Boc-
protecting groups on L8 were removed to give T2c. This was achieved by suspending T2b in 
trifluoroactic acid (TFA) overnight. The capped amines are expected to be stable under the 
conditions used for Boc deprotection (TFA treatment).221-222 The resin was washed thoroughly to 
remove residual acid, great care was taken as the next step involved the pH sensitive formation a 
Schiff base. The resultant affinity precursor, T2c was then used in subsequent reaction steps. 
Step 5: 2-hydroxy-4-(2-(piperidin-1-yl)ethoxy)benzaldehyde, L9, was synthesised following a reported 
procedure.223 The compound was characterised by 1H NMR and 13C NMR spectroscopy and MS 
spectrometry.  
Step 6: The salphen complex was formed by in situ metal chelation following the formation of a 
Schiff base.  Resin, T2c was reacted with L9 in the presence of nickel(II) acetate to yield the desired 
complex on the resin. Upon addition of Ni(OAc)2·4H2O there was an instantaneous change in colour 
of the resin from pale yellow to deep red, indicative of complex formation on the resin. This resin 
was assigned affinity tag T2. The amount of nickel complex loading was calculated using UV-vis 
spectroscopy traces as described for L8 loading (on T2a). The difference in intensity of the UV bands 
corresponding to total available L9 and unbound L9 gave the amount of complex loading (see Figure 
4-8). 
The concentration of unbound L9 was determined as 2.5 µM (A = 0.70 at λ = 279 nm), whereas the 
concentration of total L9 initially available was 5 µM (A = 1.35 at λ = 279 nm). Therefore the amount 
of nickel complex on the resin was estimated to be 2.5 µM. This corresponds to 75 % loading (taking 
into account 1.5 equivalents of L9 were used for every amine on T2c).  The maximum loading of T2c is 
0.22 mmol/g (calculated from Step 2), since ca. 75 % of the sites reacted, 1mg of resin equates to ca. 
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0.17 µmol of nickel(II) complex.  The overall loading of the nickel(II) salphen complex, 8, on the 
Tentagel S NH2 resin  was 63 %. 
 
Figure 4-8: The UV-vis spectra recorded for the control sample (black line) and supernatant (red line). The 
spectra allowed the determination of the concentration of 8 in each sample.  
 
A small library of metal salphen affinity tags was then prepared using the step-wise approach (see 
Figure 4-9).   
 
Figure 4-9: Library of metal salphen affinity tags, T
2-6
 prepared using the step-wise approach. 
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The resins were prepared in an analogous fashion to T2 from the precursor, T2c. To prepare T3 (which 
contains the unsubstituted nickel(II) salphen complex) commercially available 
dihydroxybenzaldehyde, was added to a suspension of T2c.  Nickel(II) acetate was added and the 
reaction stirred overnight.  Upon addition of nickel(II) acetate the resin became deep red. To prepare 
T4-6, L9, was added to a suspension of T2c.  The metal salt (VOSO4⋅H2O, Cu(OAc)2·H2O  or 
Zn(OAc)2·2H2O) was then added and the reaction stirred overnight.  Upon addition of the 
vanadium(IV), copper(II) and zinc(II) solutions the resin was observed to rapidly change colour from 
pale yellow to green, brown and dark yellow respectively. The change in colour was indicative of 
complex formation. The affinity tags, T3-6 were washed as described for T2 and the final loading was 
determined by UV-vis spectroscopic analysis. The loading values are presented in Table 4-1. 
Inductively coupled plasma mass spectrometry (ICP-MS) was used as a second method to determine 
the loading of metal complexes onto the resin. ICP-MS is a highly sensitive method that allows the 
detection of metals in the ppm/ ppb range. The resins were boiled in 65% concentrated nitric acid 
overnight and filtered. The supernatant was diluted with ddH2O and analysed by ICP-MS. The data 
were converted to mass of metal per mg of resin. Encouragingly, the results obtained in terms of 
percentage loading of the complexes generally correlated well with those obtained from UV-vis 
spectroscopy calculations (Table 4-1).  
 
Table 4-1: Overall loading in µmol/mg (and as a % of original resin loading capacity) of complexes on affinity 
tags, T
2-6
. The loading values determined by UV-vis spectroscopy and ICP-MS spectrometry correlate well.   
 
Affinity Tag Overall Loading (µmol/mg)  
(UV-vis spectroscopy) 
Overall Loading (µmol/mg)  
(ICP-MS spectrometry) 
T2 0.17 (63 %) 0.20 (74 %) 
T3 0.19 (70 %) 0.17 (63 %) 
T4 0.20 (74%) 0.22 (81 %) 
T5 0.18 (67 %) 0.17 (63%) 
T6 0.18 (67 %) 0.21 (78 %) 
 
 
Once the affinity tag series T2-6 had been prepared and their loading determined, they were used in 
subsequent nucleic acid isolation and competition studies. 
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4.5.2 DNA Isolation Studies  
The metal salphen affinity tag series, T2-6 were tested for their ability to bind and isolate nucleic acid 
sequences from solution using FAM-Htelo, FAM-c-Myc and FAM-ds26. The oligonucleotide solutions 
were prepared as described in section 4.4.2. The labelled oligonucleotides were incubated with 
increasing amounts (1 mg – 15 mg) of resin (T2-6) for 1 h. The reaction mixtures were filtered, the 
resin washed with buffer and the residual DNA measured by fluorescence spectroscopy of the 
corresponding solutions (including the washings).  A decrease in fluorescence intensity with 
increasing amount of T2-6 was indicative of DNA “pull down” from solution. The amount of 
fluorescence decrease (across a range of masses) corresponds to the binding affinity of the affinity 
tag, T2-6, to a particular DNA sequence.   
The ability of these affinity tags to bind to DNA was sequence dependent. Generally, quadruplex 
forming sequences were isolated favourably over duplex DNA sequences. A graphical representation 
of the “pull down” experiment is presented in Figure 4-10, in this example Htelo DNA is readily 
isolated compared to ds26 DNA by T2 (at equivalent masses).  
 
  
Figure 4-10: Fluorescence spectrum displaying the “pull down” of FAM DNA from solution.  (a) Pull down of 
Htelo DNA by T
2
 and (b) Pull down of ds26 DNA by T
2
. 
 
Graphs were plotted of affinity tag (T2-6) mass versus percentage decrease in FAM emission.  
Isolation studies for each FAM-labelled oligonucleotide (FAM-Htelo, FAM-c-Myc and FAM-ds26) 
were plotted, see Figure 4-11.  
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Figure 4-11: DNA “pull down” graphs. Affinity tag mass versus percentage decrease in FAM emission 
corresponding to each FAM-labelled oligonucleotide (FAM-Htelo, FAM-c-Myc and FAM-ds26). Graphs (a) – 
(e) correspond to studies with T
2-6
 respectively. Graph (f) corresponds to the control resins with Htelo DNA. 
The plots are an average of three repeats and the error bars correlate to the standard deviation.   
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Each member of the affinity tag family, T2-6, displays a unique binding profile.  The binding profiles 
correlate well with what was expected based on the biophysical data (FID assay, UV-vis titrations 
and FRET) obtained for the “free” complexes.115, 117  Table 4-2 displays the TC50 values obtained for 
the affinity tags from the DNA pull down assay. 
T2 displays strong affinity and good selectivity for quadruplex DNA.  T2 also exhibited some intra-
selectivity for Htelo DNA over c-Myc DNA.  T2 gave TC50 values of 0.8 mg, 1.8 mg, and 6.8 mg 
(corresponding to complex concentration = 0.14 µM, 0.31 µM, and 1.16 µM) for Htelo, c-Myc and 
ds26 DNA respectively. This is consistent with the trends reported by FID for the “free” nickel(II) 
complex which gave DC50 values of 0.20 µM (Helo), 0.11 µM (c-Myc) and 0.40 µM (ds26).
  T3, the 
nickel(II) salphen resin with no side arms, showed comparatively lower affinity to all sequences, with 
marginal selectivity for quadruplex DNA. T3, gave TC50 values of 11.9 mg, >20 mg, and >20 mg 
(corresponding to complex concentration = 2.29 µM, >3.80 µM, and >3.80 µM) for Htelo, c-Myc and 
ds26 DNA respectively. Again this is consistent with the trends reported for the corresponding free 
nickel(II) complex. This highlights the important role played by the side arms in binding to 
quadruplex DNA. 
The oxovanadyl(IV) salphen complex, T4, displayed strong affinity and good selectivity for quadruplex 
DNA. T4 gave TC50 values of 1.5 mg, 2.1 mg, and >20 mg (corresponding to complex concentration = 
0.30 µM, 0.42 µM, and >4 µM) for Htelo, c-Myc and ds26 DNA respectively. This is consistent with 
the trends reported for the “free” oxovanadyl(IV) complex; HteloDC50 = 1.2 µM and 
ds26DC50 > 10 µM.
  
The high quadruplex DNA selectivity over duplex- may be due to the square-pyramidal structure of 
the vanadium complex, the V=O bond extends from one face of the planar surface thus preventing 
intercalation into duplex DNA.  
The copper(II) and zinc(II) salphen affinity tags, T5 and T6, generally displayed poorer affinity and 
selectivity to the quadruplex sequences. T5 gave TC50 values of 9.3 mg, 2.3 mg, and >20 mg 
(corresponding to complex concentration = 1.67 µM, 0.41 µM, and >3.6 µM) for Htelo, c-Myc and 
ds26 DNA respectively. T6 gave TC50 values of 1.7 mg, 2.6 mg, and 3.1 mg (corresponding to complex 
concentration = 0.31 µM, 0.44 µM, and 0.53 µM) for Htelo, c-Myc and ds26 DNA respectively.  
Controls were also used to determine if DNA could be isolated with unmodified resins – i.e. in the 
absence of attached metal-salphen complexes. To gauge this, two control beads were prepared. The 
controls were T2c (preparation described above) and capped Tentagel S NH2 resin, T
capped.  This 
control bead, Tcapped, was prepared by swelling the resin in DMF and adding the acetic anhydride 
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capping solution described previously.  Encouragingly, the controls (T2c and Tcapped) displayed no 
significant binding to any of the three sequences (see Figure 4-11(f)). 
Table 4-2: TC50 values obtained for the affinity tags, T
2-6
 and the affinity tag controls from the DNA pull down 
assay. The TC50 values are an average of three independent repeats. TC50 values are given in terms of mg of 
affinity tag but can be converted to “concentration” of complex using the loading values presented in Table 
4-1. 
Affinity Tag                                  TC50 (mg) 
      Htelo                    c-Myc                  ds26 
T2 0.8 ± 0.2 1.8 ± 0.5 6.8 ± 0.9 
T3 11.9 ± 0.9 >20 >20 
T4 1.5 ± 0.3 2.1 ± 0.6 >20 
T5 9.3 ± 1.0 2.3 ± 0.6 >20 
T6 1.7 ± 0.3 1.6 ± 0.6 3.1 ± 0.6 
Tcapped >20 >20 >20 
T2c >20 >20 >20 
 
 
The DNA isolation studies provided a proof of concept for the affinity tag approach.  The affinity 
tags, prepared with different metal centres, displayed unique binding profiles for the three 
sequences of DNA used.  Further, these binding profiles generally correlated well with those 
observed for the analogous free complexes, indicating that the linker and resin did not interfere with 
the binding ability of the complex.  A bar chart of TC50 (in terms of mass) is depicted in Figure 4-12(a).  
The affinity tags T2 and T4 display the lowest TC50 values for quadruplex DNA and the best selectivity 
over duplex. Figure 4-12(b) portrays the percentage of labelled DNA picked up by 1 mg of affinity 
tag. Figures 4-12(a) and (b) both show T2 and T4 as the most efficient affinity tags.  T2 was selected 
over T4 for further studies because (i) using 1 mg of T2 allows isolation of more quadruplex DNA and 
moreover (ii) the nickel(II) free complex associated with T2 has been studied more widely compared 
to the oxovanadyl(IV) complex associated to T4. 
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Figure 4-12: Representation of the DNA isolation experiments. (a) The bar chart provides TC50 values (in 
terms of mass) for the affinity tags. (b) The bar chart portrays the percentage of labelled DNA picked up by 1 
mg of affinity tag.  
 
4.5.3 DNA Competition Studies  
The majority of genomic DNA is folded into a double helical structure, therefore for the affinity tags 
to be used for the extraction of quadruplex DNA from cell lysates; they must display selectivity over 
duplex DNA.  Thus, the ability of T2 to successfully isolate quadruplex DNA from solution in the 
presence of competing oligonucleotides (ds26 DNA and ct-DNA) or proteins (bovine serum albumin 
(BSA)) was investigated.  
 
4.5.3.1 FAM HTelo:unlabelled ds26 DNA   
Affinity tag competition experiments were carried out between labelled Htelo DNA and unlabelled 
ds26 DNA.  In experiments involving FAM Htelo DNA:ds26 DNA mixtures, 500 µL of a 1 µM ds26 DNA 
solution was added to 500  µL of a 1 µM FAM Htelo DNA solution, and the mixture was incubated 
with a defined quantity of affinity tag, T2,  (ca. 0.5 – 16 mg) for 1 hour, with shaking at room 
temperature.  The beads were filtered and washed once with 1 mL of buffer and this was combined 
with the supernatant.  The fluorescence of the supernatant was recorded to gauge the amount of 
unbound DNA.  
A graph was plotted of T2 mass against percentage decrease in FAM emission (with respect to FAM 
emission with no beads). Competition assays with FAM labelled Htelo and unlabelled ds26 DNA were 
subsequently carried out with 1:2, 1:5, 1:10, 1:20, 1:50 and 1:100 equivalents (FAM Htelo:ds26 
DNA).  The results, plotted on the same graph, are presented in Figure 4-13.  The TC50 remains fairly 
constant even in the presence of 100-fold excess of ds26 DNA.  The results indicate that T2 has a 
strong selectivity for quadruplex DNA and that T2 can be used to specifically isolate quadruplex DNA 
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even in the presence of a large excess of duplex DNA. Overall T2 displays comparable or superior in 
vitro quadruplex DNA selectivity than any other quadruplex affinity tags reported to date. The 
threshold for reported affinity tags is generally 1:10 (quadruplex:duplex DNA), however,  T2 is able 
to selectively isolate quadruplex DNA in the presence of 100 equivalents of duplex DNA. 
 
Figure 4-13: (a) Competition assays with FAM labelled Htelo:unlabelled ds26 DNA (1:2, 1:5, 1:10, 1:20, 1:50 
and 1:100 equivalents). (b) TC50values determined from FAM Htelo:ds26 DNA competition assays.
 
 
In a further investigation, the ability of T2 to pick up FAM labelled duplex DNA in competition with 
unlabelled quadruplex DNA was investigated (1:100 equivalents).  The results are presented in 
Figure 4-14.  In the presence of 100 equivalents of Htelo DNA, duplex DNA is out-competed and no 
FAM ds26 DNA is “pulled down”. This was expected considering the reverse competition assay 
described above. 
  
Figure 4-14: (a) Isolation assays: FAM Htelo and FAM ds26 DNA “pull down” graphs. (b) Competition assays: 
FAM Htelo DNA “pull down” in competition with ds26 DNA (100 equivalents) and FAM ds26 DNA “pull 
down” in competition with Htelo DNA (100 equivalents). The plots are an average of three repeats. 
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4.5.3.2 FAM HTelo:ct-DNA or HTelo:BSA   
Competition studies between labelled Htelo DNA and ct-DNA or BSA protein were also carried out. 
The use of ct-DNA allows competition with higher amounts (compared to ds26 DNA). ct-DNA also 
provided a more accurate representation of genomic DNA.  The results of the competition assay are 
shown in Figure 4-15. Upon increasing from 10-fold to 1000-fold excess of ct-DNA, a small, but 
significant, increase in the TC50
 is observed.  The TC50 increases further upon competition with 5000 
equivalents of ct-DNA.  The increase in TC50
 with higher amounts of ct-DNA concentration shows that 
ct-DNA is able to compete with quadruplex DNA – however only when a relatively large 
concentration of the former is used.  Therefore, these experiments confirmed the ability of T2 to 
isolate quadruplex DNA in a competitive environment. 
 
  
Figure 4-15: Competition assays (a) FAM HTelo DNA:ct-DNA (1:1, 1:10, 1:100, 1:1000, 1:5000) (b)  TC50values 
determined from FAM Htelo:ct-DNA competition assays. 
 
It was also of interest to investigate the affinity of T2 for proteins that might be present in biological 
samples. BSA was chosen as a representative protein as it is well characterised and readily available. 
In the presence of 1000 equivalents of BSA the TC50
 value remained constant (see Figure 4-16). This 
shows that T2 is not only able to “pull down” quadruplex DNA in the presence of other nucleic acid 
topologies but also in the presence of proteins. This is promising in terms of future applications such 
as the isolation of quadruplex DNA from cell extracts. 
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Figure 4-16: Competition assays (a) FAM HTelo DNA:BSA protein (1:1, 1:20, 1:100, 1:1000) (b)  TC50values 
determined from FAM Htelo:BSA protein competition assays.
 
 
 
4.6 Affinity Tags for Quadruplex RNA  
The ability of the affinity tags to stabilise and isolate quadruplex RNA was subsequently investigated. 
As discussed in the introduction section, bioinformatic studies have shown that there are over 2900 
5'-untranslated regions (UTR) of gene transcripts that have the potential to fold into quadruplex 
structures. Recently many thermodynamically stable RNA G-quadruplex structures have been 
discovered. Examples include mRNA sequences related to NRAS (an onco-protein) and BCL-2 (an 
apoptosis regulator).70, 224 
The RNA sequence selected for isolation and competition studies was the 5’-UTR region of the 
telomeric repeat binding factor 2 (TRF2). TRF2 is a component of the telomere nucleoprotein 
complex (shelterin complex). TRF2 (i) forms a complex with telomeres in metaphase of the cell cycle; 
(ii) acts as a second negative regulator of telomere length; (iii) plays a key role in the protective 
activity of telomeres. 
Control isolation experiments were also carried out with a hairpin RNA sequences (analogous to that 
used for the DNA isolation experiments). Specifically, the labelled RNA sequences used were FAM 
labelled TRF2 ([6FAM] CGGGAGGGCGGGGAGGGC), and hairpin RNA ([6FAM] CUACAG 
UACAGAUCUGUACUGUAG). 
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4.6.1 RNA Isolation Studies 
The RNA competition assays were carried out using the same procedure as for the DNA competition, 
however, RNase free water and buffer was used to prepare all solutions.  The binding profiles for the 
affinity tags, T1 and T2, with the two RNA sequences (quadruplex and hairpin) were obtained and the 
plots are presented in Figure 4-17.  Affinity tag, T2 is more selective for the quadruplex forming RNA 
(TC50 = 0.44 mg) compared to the duplex/hairpin sequence (TC50 = 3.5 mg).  Contrastingly, T
1 binds 
indiscriminately to both quadruplex and duplex/hairpin sequences (TC50 = 0.3 and 0.05 respectively). 
Controls, T2c and Tcapped were used to investigate whether RNA could be isolated in the absence of 
the metal complexes. Encouragingly, the controls (T2c and Tcapped) displayed no significant binding to 
the RNA sequences. This proved that the metal component is essential to isolating RNA 
quadruplexes. 
 
 
 
Figure 4-17: Isolation assays (a) FAM TRF2 RNA and FAM hairpin RNA “pull down” by T
1 
(b) FAM TRF2 RNA 
and FAM hairpin RNA “pull down” by T
2
 (c) TC50values determined from RNA isolation assays.
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4.6.2 RNA Competition Studies 
As with the DNA sequences, the next assay carried out was to see if the affinity tag, T2, could isolate 
quadruplex RNA in competition with hairpin RNA and DNA (both quadruplex and duplex). 
Additionally, transfer RNA was also used as a competing agent (present in cells and economically 
viable). Transfer RNA (tRNA) is an adaptor molecule composed of RNA, typically 73 to 
94 nucleotides in length, that serves as the physical link between the nucleotide sequence of nucleic 
acids (DNA and RNA) and the amino acid sequence of proteins. It does this by carrying amino acids 
to the ribosome directed by a three-nucleotide sequence (codon) on messenger RNA (mRNA). As 
such, tRNAs are a necessary component of protein translation and the biological synthesis of 
new proteins according to the genetic code. Therefore tRNA was used to represent another class of 
biomolecule present in the cell (i.e. not DNA, mRNA, hairpin RNA or protein). 
In competition with 10 equivalents of duplex RNA, duplex DNA and quadruplex DNA (Htelo) the TC50 
value of affinity tag, T2 for TRF2 RNA remained constant (see Figure 4-18(a) and (b)). Further, the 
TC50 value is unaffected in presence of large excess of tRNA. Even at one thousand fold excess, the 
TC50 value remains constant (see Figure 4-18(c) and (d)). Overall the data show that T
2 is able to 
isolate TRF2 RNA extremely efficiently and with high selectivity against other biomolecules.  
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Figure 4-18: Competition assays (a) FAM TRF2 RNA:tRNA (1:1, 1:10, 1:100, 1:500, 1:1000) (b)  TC50values 
determined from FAM TRF2 RNA:tRNA competition assays. (c) FAM TRF2 RNA:ds26 DNA, FAM TRF2 
RNA:Htelo DNA and FAM TRF2 RNA:hairpin RNA (1:10) (d)  TC50values determined from FAM TRF2:DNA and 
FAM TRF2:RNA competition assays.
 
 
 
4.7 Removal of Nucleic Acids from Affinity Tags 
The recovery of the nucleic acids from the affinity tags is a critical step that renders the methodology 
applicable for future sequencing. After isolation of specific nucleic acid sequences using affinity tags 
as described in this chapter, the nucleic acids can be recovered through thermal denaturing or 
exposure to chaotropic reagents, both of which are designed to disrupt DNA-ligand interactions. 
Chaotropic reagents are substances which disrupts the structure of macromolecules such as nucleic 
acids by interfering with intramolecular interactions (hydrogen bonds, van der Waals forces, 
and hydrophobic effects). 
The removal of the DNA and RNA sequences was, in fact, not as trivial as expected. The resins were 
initially heated in buffer to denature the quadruplex sequences thus allowing facile recovery.  
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Unfortunately no DNA was recovered under these conditions.  A number of chaotropic reagents and 
acid/base conditions, known to disrupt quadruplex DNA, were screened to identify a system 
whereby the majority of nucleic acid could be successfully removed from the resin.  The conditions 
investigated and the amount of FAM Htelo DNA recovered (as a percentage) from T2, are presented 
in Table 4-3.   
 
Table 4-3: The table illustrates the conditions investigated and the amount of FAM Htelo DNA recovered 
from T
2
 (as a percentage).  The corresponding resin was incubated for 30 minutes at 37
o
C.  
 
 
Conditions % of FAM DNA recovered 
Buffer 0 
Urea 8M 2 
LiCl 8M 11 
10% SDS 75 
PBST 1 
Guanidine HCl 1M 64 
HCl 1M 0 
NaOH 1M 131 
 
 
Treatment with HCl (1M) appears to result in no DNA removal whereas treatment with NaOH (1M) 
appears to result in the recovery of more DNA than was originally on the resin.  These results may be 
due to the respective protonation and deprotonation of the FAM molecule. Below pH 7, FAM 
becomes protonated, which results in decreased fluorescence. Conversely, in alkaline solutions, the 
emission of FAM increases.225  Therefore the changes in emission of the FAM substituent under HCl 
(1M)/ NaOH (1M) could mask the detection of DNA recovery thus producing false negatives and 
false positive. 
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Figure 4-19: (a) Pull down of FAM Htelo with T
2 
(b) Recovery of FAM Htelo from T
2 
following treatment with 
Guanidine HCl 1M. 
 
The “pull down” of Htelo with T2 (increasing mass) is shown in Figure 4-19(a).  The recovery of Htelo 
from T2 (increasing mass) by treatment with guanidine·HCl (1M) is shown in Figure 4-19(b). The 
amplitude of Htelo recovery was higher for samples with higher amounts of DNA-T2 complexes.  It 
should be noted that Htelo DNA recovered was not quantitative under any of the conditions used.  
 
Similar trends were seen for RNA removal; however, the percentage recovery was significantly 
lower.  This may be due to the fact that the RNA quadruplex is more stable and binds more tightly.   
 
In summary, high molar concentrations of the chaotropic agents were required to unfold and 
recover the DNA and RNA oligonucleotides from affinity tag, T2.  This finding supports the fact that 
the affinity tags bind very strongly to quadruplex nucleic acids.  
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4.8 Conclusion 
The first quadruplex affinity tags containing metal complexes were prepared and studied for their 
ability to pull down quadruplex DNA from solution. This was carried out in the absence and presence 
of competitors.  
An affinity tag based on the platinum terpyridne-cyclen complex, 3a was prepared via the formation 
of a Pt-S bond.  The affinity tag, T1 was used to isolate successfully quadruplex DNA from solution. 
Despite being very potent, T1 was unfortunately unselective and isolated both quadruplex and 
duplex DNA (and RNA) with the same binding profile.  
A metal-salphen affinity tag was then synthesised via a “build-up” approach. This involved 
synthesising the complex on the resin.  This facile approach allowed the preparation of a small 
library utilising different building blocks and metal centres.  The affinity tags, T2-6 were used in DNA 
pull down experiments.  T2-6 displayed unique binding profiles for the three oligo sequences under 
study.  Further, the affinities and selectivities observed correlated well with those obtained for the 
analogous “free” complexes.  Affinity tag, T2 was able to selectively isolate Htelo quadruplex DNA 
when in the presence of high equivalence of competing species (e.g ds26 DNA, ct-DNA and BSA 
protein).   T2 also successfully isolated quadruplex RNA from solution as well as in the presence of 
competing RNA and DNA oligonucleotides.  
Conditions were established to enable the isolated DNA/RNA to be recovered from the resin.  Molar 
concentrations of denaturing reagents were required, characteristic of a strong interaction of T2 with 
quadruplex DNA/RNA.  
The ability of the metal complex affinity tags to selectively isolate nucleic acids sequences in a 
structure dependent manner is promising and proposes a possible use in isolating novel quadruplex 
forming DNA and RNA sequences in cells.  
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This thesis has demonstrated that bi-metallic complexes can act as potent G-quadruplex binders.  Bi-
metallic terpyridine-cyclen complexes were designed to act in a bi-modal manner, with each metal 
moiety playing a distinct role; (i) the metal(II)-terpyridine providing a planar core to π-π stack atop 
the guanine tetrad and (ii) the metal(II) cyclen side arm facilitating electrostatic interactions with the 
unique loops, grooves and phosphate backbone of G-quadruplex DNA.  By interacting in the fashion 
described, the complexes displayed improved affinity, and in some cases selectivity, towards 
quadruplex DNA, compared to other metal complexes reported in literature. 
The platinum and copper complexes (with at least one planar surface) were shown to π-π stack in 
solid and solution states using X-ray crystallography and 1H NMR spectroscopy respectively. This 
demonstrated their propensity to interact with quadruplex DNA via π-π interactions. Further, 
computational docking studies provided valuable insight into the binding mode. The bi-metallic 
copper(II)-copper(II) and platinum(II)-zinc(II) complexes were found to π-π stack atop the guanine 
tetrads via the metal-terpyrdine core and bind to the DNA backbone through the metal-cyclen unit.  
Non-covalent interactions with quadruplex DNA (both Htelo and c-Myc) and duplex DNA were 
probed using a number of biophysical techniques (FID, FRET, CD and UV-Vis titration studies). In 
general, the platinum(II)-terpyridine complexes with differing cyclen arms, 3b, 4 and 5 (see scheme 
2-3 and 2-4), displayed the highest quadruplex affinities and quadruplex- over duplex- selectivities, 
comparable or surpassing well established quadruplex binders. Additionally, the complexes 
displayed some selectivity for c-Myc over Htelo DNA. This can be explained by considering the 
conformations of the two quadruplex sequences under the conditions of the experiments.  c-Myc 
folds into an intramolecular parallel structure with three tetrads and well defined side loops. The 
external tetrads of the c-Myc structure (unlike the Htelo structure) are unhindered by loops and 
therefore easily accessed by the metal complexes. Interestingly, 3b displayed similar affinity and 
selectivity to 4 and 5, this may be due to the protonation state of the cyclen. The positively charged 
amines could facilitate tight electrostatic interactions with the loops and grooves. The di-copper(II) 
complex, 2 (scheme 2-2), with a square-pyramidal geometry about the terpyridine core, exhibited 
moderate affinity and selectivity. The di-zinc(II) complex, 1 (scheme 2-2), with no planar surfaces, 
bound relatively weakly to quadruplex DNA. This result highlights the importance of an accessible 
planar surface to allow for π-π stacking interactions. Despite displaying the weakest binding within 
the molecules tested, complex 1 still bound to quadruplex DNA with reasonable strength when 
compared to other mono- and di- zinc complexes reported by our group and others. This can be 
attributed to the interactions of the zinc(II) cyclen with the loops and grooves. The platinum(II)-
terpyridine thiolate complex, 6 (scheme 2-5),  was designed with an additional appendage, opposite 
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to the cyclen. It was hoped that this would improve the selectivity of the complex by preventing the 
complex from intercalating between base pairs in duplex DNA. Unfortunately, complex 6 displayed 
both poorer quadruplex affinity and selectivity than the other platinum(II) complexes. It is possible 
that the additional appendage, in reality, hinders π-π stacking with quadruplex DNA through 
unfavourable steric interactions.  
The biological activity of the complexes was investigated. The cytotoxicity of the complexes were 
tested against two cancer cell lines (U2OS and SHSY5Y, with intrinsically high levels of c-Myc) and 
one normal cell line (GM05757). Complexes 3b, 4 and 5 exhibited selective toxicity towards the two 
cancer cell lines; furthermore these values were comparable to those observed for cisplatin. As 3b, 4 
and 5 displayed high affinity for quadruplex DNA it is possible that, toxicity may be related to the 
interaction of the complexes with quadruplex DNA. It is also possible that these complexes could 
induce cell death by forming covalent adducts with DNA and/or proteins (via displacement of the 
chloride ligand).  Immunoblotting analysis was carried out to determine the effect of complexes on 
the cellular expression of c-Myc (protein).  Complexes 2, 3b, 4 and 5 downregulated c-Myc protein 
expression significantly. Taking into account their high affinity for c-Myc DNA (elucidated by DNA 
binding studies), the inhibition of c-Myc protein expression can be proposed to result from the 
stabilisation of c-Myc quadruplex DNA.  
This thesis has also described the design and preparation of the first metal complex containing 
affinity tags.  The affinity tags were studied for their ability to “pull down” quadruplex DNA from 
solution, in the absence and presence of competitors. The metal salphen affinity tags, T2-6 displayed 
unique binding profiles for the three oligo sequences (Htelo, c-Myc and ds26) under study.  These 
binding profiles correlated well with those obtained for the related “free” complexes.  Affinity tag, T2 
was able to selectively isolate quadruplex DNA (Htelo) in the presence of high concentrations of 
competing species (e.g ds26 DNA, ct-DNA and BSA protein).  G-quadruplex RNA was also successfully 
isolated from solution by T2 (in the absence and presence of competing RNA and DNA 
oligonucleotides). Finally, conditions were established to enable the isolated DNA/RNA to be 
recovered from the resin.   
As an extension to this project, it would be interesting to investigate the ability of T2 to selectively 
identify and isolate unknown quadruplex forming DNA/RNA sequences within cell lysates. Prior to 
conducting these studies the affinity tags have to be optimised in terms of (i) affinity towards 
quadruplex sequences, by extending the aromatic component, (ii) selectivity, by inseting extra side 
arms, and (iii) inertness, to prevent unwanted interactions with the reagents used in the “pull down” 
or “release” steps.  Upon optimisation, the ability of the affinity tag to isolate quadruplex forming 
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DNA/RNA sequences in whole cell DNA/RNA extracts should be investigated. If the affinity tag is able 
successfully isolate quadruplex forming DNA/RNA sequences at this stage, further studies with 
nuclear, cytoplasmic, whole cancer and normal cell extracts will be carried out. The pulled down 
sequences could then be amplified and analysed by RT q-PCR and deep sequencing methods to 
identify those sequences with the potential to form quadruplex structures.  These sequences could 
then be further investigated for their biological relevance and drugability.  
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Chapter 6 
Experimental Details 
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6.1 General Procedures and Materials 
1H NMR, 13C NMR, 19F NMR and 31P NMR spectra were recorded on a Bruker Avance 400 MHz 
Ultrashield NMR spectrometer. Electron spray ionisation mass spectra were recorded on a 
BrukerDaltronics Esquire 3000 spectrometer by Mr. J. Barton (Imperial College London). UV-Vis 
spectra were collected with a Perkin Elmer UV-Vis Spectrophotometer. IR spectra were recorded by 
a Perkin Elmer Spectrum 100 FT-IR Spectrometer. Elemental analyses of the compounds prepared 
were performed by Mr. Alan Dickerson (University of Cambridge). The X-ray crystal structures where 
resolved by Dr. A. J. P. White (Imperial College London) using a OD Xcalibur PX Ultra Diffractometer 
(1.54184 Å).   
 
Reagents, solvents and chemicals were purchased from Sigma-Aldrich, Fluka, Alfa Aesar, Apollo 
Scientific, TCI Europe or BDH Scientific and were used as supplied without further purification, 
however were verified by 1H NMR.  HPLC-purified, desalted oligonucleotides were purchased 
from Eurogentec and were used without further purification. 
 
6.2 Synthesis of the Ligands 
 
Synthesis of 1,4,7-Tris(tert-butyloxycarbonyl)-1,4,7,10-tetraazacyclododecane, L1.  This compound 
was prepared following a reported procedure.161   A solution of di-tert -butyl dicarbonate (3.59 g, 
16.4 mmol) in chloroform (40 mL) was added over a 3 h period to a solution of cyclen (1.00 g, 5.8 
mmol) and triethylamine (2.5 mL, 17.9 mL) in chloroform (60 mL). The reaction mixture was stirred 
overnight at RT after which time the solvent was evaporated under reduced pressure. The solid 
residue was purified by column chromatography using neutral alumina (chloroform/hexanes, 2:1 ) to 
yield the desired product as a white solid (1.15 g, 42 % yield). 1H NMR (400 MHz, CDCl3): δH 3.53-3.75 
(m, 4H, cyclen), 3.14-3.48 (m, 8H, cyclen), 2.73-2.84 (m, 4H, cyclen), 1.47 (s, 9H, Boc-CH3), 1.45 (s, 
18H, Boc-CH3); 
13C NMR (100 MHz, CDCl3): δC 155.67, 79.33, 79.12, 50.87, 49.50, 45.41, 28.63, 28.46; 
ESI-MS Cald. for C23H44N4O6 [M]
+: 472 a.m.u. Found [M+H]+: 473 a.m.u. 
156 
 
 
 
Synthesis of 1-{1-[4,7,10-Tris-(tert-butyloxycarbonyl)]-1,4,7,10-tetraazacyclododecane}-3-bromo-
propane, L2.   This compound was prepared following a reported procedure.162  Under N2 
atmosphere, a solution of 1,3-dibromopropane (1 mL, 9.85 mmol) and Na2CO3
 
(0.25 g, 2.17 mmol) in 
30 mL of dry acetonitrile was stirred at room temperature; L1 (0.50 g, 1.06 mmol) was added slowly 
in 20 mL of dry acetonitrile.  The reaction mixture was then stirred at 80 oC for another 72 h. The 
insoluble inorganic salt was filtered off and the filtrate was concentrated under reduced pressure. 
The resulting residue was dissolved in CHCl3
 
and then purified by silica gel column chromatography 
(ethyl acetate:petroleum ether = 1:4). A colourless amorphous solid was obtained (0.25 g, 40 % 
yield).  1H-NMR (400 MHz, CDCl3) δH 3.7-3.1 (12H, br, cyclen), 3.43 (2H, t, 
3JHH = 8.0, propyl 1-H), 2.8-
2.5 (4H, br, cyclen), 2.72 (t, 3JHH = 8.0, propyl 3-H ), 2.05 (2H, m, propyl 2-H ),  1.49-1.47 (27H, s, Boc-
CH3); M.p: 58–60 
oC; ESI-MS Cald. for BrC26H50N4O6 [M]
+: 594 a.m.u. Found [M+Na]+: 617 a.m.u.   
 
 
Synthesis of Boc protected terpyridine cyclen ligand, L3. A solution of L2 (0.086 g, 0.145 mmol) in 
acetone (10 mL) was added dropwise to a stirred refluxing mixture of 2,6-bis(2-pyridyl) 4(1H) 
pyridone (0.037 g, 0.149 mmol) and potassium carbonate (0.082 g, 0.596 mmol) in acetone (15 mL). 
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The stirred mixture was heated under reflux for 48 h. After this time, the mixture was filtered to 
remove inorganic salts, water was added to the filtrate and the product was extracted into diethyl 
ether (20 mL × 2). The combined ethereal extracts were washed with water, 5% sodium hydroxide 
and water then dried with Na2SO4. The solvent was removed under reduced pressure to yield an off-
white solid (81 mg, 74 %); 1H NMR (400 MHz, CDCl3): δH 8.71 (d, 2H, 
3JHH = 8.0, tpy 2-H), 8.64 (d, 2H, 
3JHH = 8.0, tpy 5-H), 8.03 (s, 2H, tpy’ 3-H and 5-H), 7.88 (dd, 2H, 
3JHH = 8.0, 
3JHH = 8.0), 7.37 (dd, 2H, 
3JHH 
= 8.0, 3JHH =  8.0, py 3-H), 4.28 (t, 2H, 
3JHH = 6.0,  propyl 3-H), 3.60-2.60 (br m, 16H, cyclen), 2.83 (t, 2H, 
3JHH = 8.0, propyl 1-H), 2.06 (m, 2H, propyl 2-H), 1.48 (s, 27H, Boc-CH3); 
13C NMR (100 MHz, CDCl3): δC 
179.0, 166.9, 157.3, 156.1, 149.1, 136.6, 123.9, 121.3, 107.3, 79.5, 79.1, 66.6, 54.6, 54.3, 50.1, 49.1, 
29.3, 23.9; ESI-MS Calcd. for C41H59N7O7 [M]
+: 762 a.m.u. Found [M+H]+: 763 a.m.u.  
 
 
Synthesis of the deprotected terpyridine cyclen ligand:TFA salt, L4.  L3 (0.045 g, 0.057 mmol) was 
dissolved in a solution of dichloromethane:TFA (1:1) (5 mL) and stirred at room temperature for 24h.  
The solvents were then removed under reduced pressure and the resulting solid dried (0.071 g, 96 
%); 1H NMR (400 MHz, DMSO-d6): δH 8.77 (d, 2H, 
3JHH = 8.0, tpy 2-H), 8.64 (d, 2H, 
3JHH = 8.0, tpy 5-H), 
8.10 (dd, 2H, 3JHH = 4.0, 
3JHH = 4.0), 8.04 (s, 2H, tpy’ 3-H and 5-H), 7.59 (dd, 2H, 
3JHH = 4.0, 
3JHH =  4.0, py 
3-H), 4.32 (t, 2H, 3JHH = 8.0,  propyl 3-H), 3.20-2.70 (br m, 18H, cyclen), 2.78 (t, 2H, 
3JHH = 8.0, propyl 1-
H), 2.02 (m, 2H, propyl 2-H); 19F NMR (376 MHz, DMSO-d6): δF -77.8; ESI-MS Calcd. for C40H42F21N7O15 
[M]+: 1973 a.m.u. Found [M-nCF3COOH+H]
+: 462 a.m.u. 
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Synthesis of the neutral terpyridine cyclen ligand, L5.  The crude ligand salt, L4 (0.065 g, 0.052 
mmol), was then dissolved in water and NaOH 2M (aq) was added dropwise until the solution 
became alkaline (pH 12).  The product was then extracted into dichloromethane.  The solvent was 
removed under reduced pressure to yield a pale yellow sticky solid (0.016 g, 67 %); 1H NMR (400 
MHz, DMSO-d6): δH 8.74 (d, 2H, 
3JHH = 8.0, tpy 2-H), 8.66 (d, 2H, 
3JHH = 8.0, tpy 5-H), 8.06 (dd, 2H, 
3JHH 
= 8.0, 3JHH = 8.0, tpy 4-H), 8.02 (s, 2H, tpy’ 3-H and 5-H), 7.55 (dd, 2H, 
3JHH = 8.0, 
3JHH =  8.0, tpy 3-H), 
4.32 (t, 2H, 3JHH = 4.0,  propyl 3-H), 3.12-2.82 (br m, 16H, cyclen), 2.92 (t, 2H, 
3JHH = 4.0, propyl 1-H), 
2.01 (m, 2H, propyl 2-H); COSY 1H-1H NMR (400 MHz, DMSO-d6): see appendix; 
13C NMR (100 MHz, 
DMSO-d6): δC 166.6, 156.3, 154.6, 148.9, 137.0, 124.2, 120.8, 106.4, 65.7, 51.4, 50.5, 47.3, 46.0, 44.9, 
26.0; 19F NMR (376 MHz, DMSO-d6): absence of peak at  δF -77.8; IR (cm
-1): 1672, 1585, 1565, 1464, 
1444, 1420, 1393, 1198, 1127, 1008, 871, 828, 794, 744, 719; ESI-MS Calcd. for C26H35N7O [M]
+: 461 
a.m.u. Found [M+H]+: 462 a.m.u. 
 
 
Synthesis of terpyridine cyclen ligand hydrochloride salt L6. L5 (0.040 g, 0.087 mmol) was dissolved 
in methanol (2 mL) and a solution of HCl in methanol (3 mL) was then added.  The solution was 
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stirred before addition of diethyl ether (5 mL) to precipitate the product as an off-white solid (48 g, 
97 %); 1H NMR (400 MHz, DMSO-d6): δH 8.79 (d, 2H, 
3JHH = 8.0, tpy 2-H), 8.74 (d, 2H, 
3JHH = 8.0, tpy 5-
H), 8.29 (dd, 2H, 3JHH = 8.0, 
3JHH = 8.0, tpy 4-H), 8.04 (s, 2H, tpy’ 3-H and 5-H), 7.76 (dd, 2H, 
3JHH = 8.0, 
3JHH =  8.0, tpy 3-H), 4.32 (t, 2H, 
3JHH = 4.0,  propyl 3-H), 3.20-2.70 (br m, 16H, cyclen), 2.75 (t, 2H, 
3JHH 
= 4.0, propyl 1-H), 2.01 (m, 2H, propyl 2-H); LCMS-MS Calcd. for C26H35N7O [M]
+: 461 a.m.u. Found 
[M-nHCl+H]+: 462 a.m.u.; Anal. Calcd. for C26H42Cl7N7O∙16HCl: C, 29.89; H, 4.92; N, 9.38; Found: C 
29.56, H 4.34, N 8.84.   
 
 
Synthesis of 2-(piperidin-1-yl)ethanethiol, L7.  This compound was prepared following a reported 
procedure.169
 
Piperidine (2.0 g, 23.8 mmol) was added to dry benzene (5 mL) and the mixture was 
flushed with nitrogen. Etylenesulfide (1.42 mL, 47.6 mmol) was added dropwise and the resulting 
solution was stirred at room temperature for 48 h. The solvent was then removed and the product 
re-dissolved in dichloromethane.  This solution was then filtered through a plug of celite to remove 
any polymeric material. The solvent was then removed to yield the product as a yellow oil (2.54 g, 
75%); 1H NMR (400MHz, CDCl3): δH 2.86 (t,2H,
 3JHH= 6.0, ethyl 1-H), 2.53 (t, 2H,
 3JHH= 6.0, ethyl 2-H), 
2.35 (m, 4H, pip 1-H), 1.49 (m, 4H, pip 2-H), 1.38 (m, 2H, pip 3-H). 
 
 
 
Synthesis of N, N'-di-(tert-Butoxycarbonyl)-3,4-diaminobenzoic acid, L8. This compound was 
prepared following a previously reported procedure.220 To a magnetically stirred solution of 
guanidine hydrochloride (30 mol%) and di-tert-butyl dicarbonate (1.31 g, 6 mmol, 6 eq) in EtOH (2 mL), 
3,4-diaminobenzoic acid (152 mg, 1 mmol, 1eq) was added at 35-40 °C for 8 h.  After completion of 
the reaction (followed by TLC (ethyl acetate:hexane)), ethanol was removed under vacuum and the 
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residue was dissolved in ethyl acetate and filtered to remove insoluble particles.  The solvent was 
subsequently removed and petroleum ether added to remove the excess di-tert-butyl dicarbonate.  
The solid was filtered and washed with petroleum ether to yield the product as an off-white solid 
(0.251 g, 71 %).  1H NMR (400 MHz, DMSO): δH 8.75 (s, 1H, NH), 8.70 (s, 1H, NH), 8.09 (s, 1 H, phenyl 
H-2), 7.72 (d, 1H, 3JHH = 8.0, phenyl H-5), 7.64 (d, 1H, 
3JHH = 8.0, phenyl H-6), 1.49 (s, 18H, Boc-CH3); 
13C NMR (100 MHz, DMSO): δC 166.9, 153.2, 152.7, 134.3, 128.8, 125.7, 125.3, 125.1, 122.1, 80, 28.1, 
28.   
 
 
Synthesis of 2-hydroxy-4-(2-(piperidin-1-yl)ethoxy)benzaldehyde, L9.  This compound was prepared 
using modifications to a previously reported procedure.223  A suspension of 2,4-
dihydroxybenzaldehyde (3.00 g, 21.29 mmol), 1-(2-chloroethyl)piperidine hydrochloride (4.00 g, 
21.28 mmol) and NaHCO3 (3.58 g, 42.57 mmol) in dry acetone (150 mL) was refluxed (60-65 
oC) for 
68h.  After that period of time the excess of salt was removed by filtration and the acetone was 
evaporated to dryness.  The crude product was purified by column chromatography over silica gel 
using ethyl acetate:hexane. The compound was obtained as a yellow solid (1.744 g, 49.3 %).  1H NMR 
(400 MHz, CDCl3): δH 9.71 (s, 1H, CHO), 7.41 (d, 1H, 
3JHH = 8.0, phenyl H-6), 6.59 (dd, 1H, 
3JHH = 8.0, 
4JHH = 2.0, phenyl H-5), 6.42 (d, 1H,
 4JHH = 2.0,  phenyl H-3),  4.17 (t, 2H,
 3JHH = 6.0,  ethyl 2-H), 2.79 (t, 
2H, 3JHH = 6.0,
 ethyl 1-H), 2.51 (m, 4H, piperidine H2-6), 1.62 (m, 4H, piperidine H3-5), 1.45 (m, 2H, 
piperidine H-4); 13C NMR (100 MHz, CDCl3): δC 193.3, 165.0, 163.4, 134.1, 114.1, 107.7, 100.2, 65.4, 
56.4, 54.0, 24.8,  23.0; ESI-MS Calcd. for C14H19NO3 [M]
+: 249.1 a.m.u. Found [M+H]+: 250 a.m.u. 
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6.3 Synthesis of the Metal Complexes 
 
Synthesis of the di-zinc terpyridine cyclen complex, 1.  L5 (0.020 g, 0.043 mmol) was dissolved in 
methanol (3 ml) and added to a solution of ZnCl2
 (0.012 g, 0.086 mmol) in methanol (2 mL).  A white 
precipitate was seen to form immediately. The solution was heated to 40 oC and set to stir for 48 h.  
The solution was then allowed to cool and the off-white solid was filtered and washed with 
methanol and diethyl ether and dried under vacuo (0.022 g, 71 %); 1H NMR (400 MHz, DMSO-d6): δH 
8.81 (d, 2H, 3JHH = 8.0, tpy 2-H), 8.79 (d, 2H, 
3JHH = 8.0, tpy 5-H), 8.37 (s, 2H, tpy’ 3-H and 5-H), 8.33 
(dd, 2H, 3JHH = 8.0, 
3JHH = 8.0), 7.88 (dd, 2H, 
3JHH = 8.0, 
3JHH =  8.0, py 3-H), 4.50 (br, 2H, propyl 3-H), 
3.00-2.60 (br m, 18H, cyclen and propyl 1-H),), 2.21 (m, 2H, propyl 2-H); COSY 1H-1H NMR (400 MHz, 
DMSO-d6): see appendix; 
13C NMR (100 MHz, DMSO-d6): δC 170.0, 150.3, 148.8, 147.0, 140.5, 127.0, 
122.0, 109.2, 68.4, 49.4, 49.1, 44.2, 43.2, 42.0, 21.7; ESI-MS Calcd. for C26H35Cl5Zn2.5N7O [M]
+: 797 
a.m.u. Found [M-0.5ZnCl4]
+: 698 a.m.u.; Anal. Calcd. for C26H35Cl5N7OZn2.5∙2H2O: C, 37.25; H, 4.69; N, 
11.69; Found: C 36.92, H 4.27, N 11.19.   
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Synthesis of the di-copper terpyridine cyclen complex, 2.  L5 (0.020 g, 0.043 mmol) was dissolved in 
methanol (3 ml) and added to a solution of CuCl2.2H2O (0.015g, 0.086 mmol) in methanol (2 mL).  A 
blue precipitate was seen to form immediately. The solution was heated to 40 oC and set to stir for 
48 h.  The solution was then allowed to cool and the blue solid was filtered and washed with diethyl 
ether and dried under vacuo (0.021 g, 68 %); IR (cm-1): 1613, 1563, 1475, 1441, 1366, 1225, 1081, 
1058, 1040, 1022, 991, 858, 803, 726, 700; UV/Vis (DMSO) λmax/ nm (ε/ cm
-1M-1): 317 (11080), 331 
(8940); ESI-MS Calcd. for C26H35Cl4Cu2N7O [M]
+: 729 a.m.u. Found [M-Cl]+: 694 a.m.u.; Anal. Calcd. for 
C26H35Cl4Cu2N7O∙3H2O: C, 39.80; H, 5.27; N, 12.50; Found: C 39.44, H 4.96, N 12.24.   
 
 
Synthesis of the platinum terpyridine cyclen complex, 3a.  L5 (0.020 g, 0.043 mmol) was dissolved in 
dimethyl sulphoxide (2 mL) and added to a solution of K2PtCl4 (0.020 mg, 0.047 mmol) in dimethyl 
sulphoxide (2 mL).  The solution was heated to 45 oC and set to stir for 24 h.  The solution was then 
allowed to cool and acetone was added to precipitate out the product as the yellow chloride salt. 
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The product was filtered, washed with acetone and dried.  The product was obtained as an orange, 
amorphous solid (0.018 g, 59%); 1H NMR (400 MHz, DMSO-d6): δH 8.96 (d, 2H, 
3JHH = 8.0, tpy 2-H), 
8.83 (d, 2H, 3JHH = 8.0, tpy 5-H), 8.57 (s, 2H, tpy’ 3-H and 5-H), 8.53 (dd, 2H, 
3JHH = 8.0, 
3JHH = 8.0), 7.95 
(dd, 2H, 3JHH = 8.0, 
3JHH =  8.0, py 3-H), 4.74 (t, 2H, 
3JHH = 6.0,  propyl 3-H), 3.91 (t, 2H, 
3JHH = 6.0, propyl 
1-H), 3.65-2.85 (br m, 16H, cyclen), 2.5 (m, 2H, propyl 2-H); ESI-MS Calcd. for C26H35Cl2N7OPt [M+]
+: 
727 a.m.u., Found [M-Cl]+: 692 a.m.u. 
 
 
 
Synthesis of the platinum terpyridine cyclen complex, 3b. The chloride salt, 3a (0.018 g, 0.025 
mmol) was dissolved in the minimum amount of DMSO and to this an aqueous solution of NaPF6 was 
added. This resulted in an orange precipitate which was filtered, washed with diethyl ether and 
dried.  The product was obtained as a yellow PF6 salt (0.023, 73%); 
1H NMR (400 MHz, DMSO-d6): δH 
9.02 (d, 2H, 3JHH = 8.0, tpy 2-H), 8.72 (d, 2H, 
3JHH = 8.0, tpy 5-H), 8.57 (dd, 2H, 
3JHH = 8.0, 
3JHH = 8.0), 
8.35 (s, 2H, tpy’ 3-H and 5-H), 8.01 (dd, 2H, 3JHH = 8.0, 
3JHH =  8.0, py 3-H), 4.57 (t, 2H, 
3JHH = 8.0,  
propyl 3-H), 3.84 (t, 2H, 3JHH = 8.0, propyl 1-H), 3.58-2.86 (br m, 16H, cyclen), 2.38 (m, 2H, propyl 2-
H); COSY 1H-1H NMR (400 MHz, DMSO-d6): see appendix; 
31P NMR (162 MHz, DMSO-d6): δP  -143.95 
(sep); IR (cm-1): 1570, 1442, 1405, 1334, 1219, 998, 827; UV/Vis (DMSO) λmax/ nm (ε/ cm
-1M-1): 320 
(7700), 334 (8120); ESI-MS Calcd. for C26H38ClF6N7OP4Pt [M]
+: 1275 a.m.u., Found [M]+: 838 a.m.u., 
[M-2H-3PF6]
+: 838 a.m.u.; Anal. Calcd. for C26H38ClF24N7OP4Pt∙2H2O: C 23.82, H 3.23, N 7.48; Found: C 
23.60, H 2.71, N 7.03. 
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Synthesis of the platinum zinc terpyridine cyclen complex, 4.  L5 (0.020 g, 0.043 mmol) was 
dissolved in dimethyl sulphoxide (2 mL) and added to a solution of K2PtCl4 (0.019 mg, 0.047 mmol)  in 
dimethyl sulphoxide (2 mL).  The solution was heated to 45 oC and set to stir for 24 h.  To the 
resultant orange solution 1.1 eq of ZnCl2 (0.0064 g, 0.047 mmol) was added and the solution stirred 
for a further 24 h at 45oC.  An aqueous solution of NaPF6 was added directly to the reaction mixture 
which yielded a yellow precipitate, which was filtered, washed with diethyl ether and dried. The 
product was isolated as a yellow PF6 salt (0.026 g, 51% ); 
1H NMR (400 MHz, DMSO-d6): δH 9.01 (d, 
2H, 3JHH = 8.0, tpy 2-H), 8.70 (d, 2H, 
3JHH = 8.0, tpy 5-H), 8.56 (dd, 2H, 
3JHH = 8.0, 
3JHH = 8.0), 8.33 (s, 2H, 
tpy’ 3-H and 5-H), 8.01 (dd, 2H, 3JHH = 8.0, 
3JHH =  8.0, py 3-H), 4.55 (t, 2H, 
3JHH = 4.0,  propyl 3-H), 3.83 
(t, 2H, 3JHH = 8.0, propyl 1-H), 3.60-2.80 (br m, 16H, cyclen), 2.37 (m, 2H, propyl 2-H); COSY 
1H-1H 
NMR (400 MHz, DMSO-d6): see appendix;
  13C NMR (100 MHz, DMSO-d6): δC 176.8, 168.9, 158.2, 
155.6, 151.0, 142.2, 129.4, 125.5, 110.9, 68.0, 60.6, 54.7 53.0, 52.3, 50.6, 26.5; 31P NMR (162 MHz, 
DMSO-d6): δp -144.40 (sep); IR (cm
-1): 1610, 1475, 1429, 1363, 1220,1034, 826, 779, 739; UV/Vis 
(DMSO) λmax/ nm (ε/ cm
-1M-1): 319 (9380), 334 (9480); Anal. Calcd. For C26H35ClF18N7OP3PtZn∙4.8H2O: 
C, 24.42; H, 3.52; Cl, 2.77; N, 7.67; Found: C 24.97, H 3.05, N 7.17. 
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Synthesis of the platinum copper terpyridine cyclen complex, 5.  L5 (0.020 g, 0.043 mmol) was 
dissolved in dimethyl sulphoxide (2 mL) and added to a solution of K2PtCl4 (0.019 mg, 0.047 mmol)  in 
dimethyl sulphoxide (2 mL).  The solution was heated to 45 oC and set to stir for 24 h.  To the 
resultant orange solution 1.1 eq of CuCl2.2H2O (0.0080 g, 0.047 mmol) was added and the solution 
stirred for a further 24h at 45oC.  During this time the colour of the solution turned from yellow to a 
pale green.  An aqueous solution of NaPF6 was added directly to the reaction mixture which yielded 
a green precipitate, which was filtered, washed with diethyl ether and dried. The product was 
isolated as a pale green PF6 salt (0.031 g, 61 %); IR (cm
-1): 1621, 1428, 1205, 1035, 831, 779, 741; 
UV/Vis (DMSO) λmax/ nm (ε/ cm
-1M-1): 319 (11500), 334 (12240); ESI-MS Calcd. for 
C26H35ClCuF18N7OP3Pt [M]
+: 1189 a.m.u. Found [M-PF6]
+: 1450 a.m.u.; Anal. Calcd. For 
C26H35Cl2CuF18N7NaOP3Pt∙4H2O∙NaCl: C, 23.64; H, 3.28; N, 7.42; Found: C 23.45, H 2.83, N 7.04. 
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Synthesis of the platinum terpyridine cyclen thiol complex, 6.  The platinum terpyridine complex, 
isolated as the chloride, (0.020 g, 0.028 mmol) was dissolved in H2O (4 mL).  L
7 (0.020 g, 0.138 mmol) 
was added dropwise.  The solution was stirred at room temperature for 3 days.  An aqueous solution 
of NaPF6 was added directly to the reaction mixture which yielded a pink precipitate, which was 
filtered, washed with diethyl ether and dried. The product was isolated as a pink/red PF6 salt (0.016 
g, 42% ); 1H NMR (400 MHz, DMSO-d6): δH 8.74 (d, 2H, 
3JHH = 6.0, tpy 2-H), 8.67 (d, 2H, 
3JHH = 6.0, tpy 
5-H), 8.05 (dd, 2H, 3JHH = 8.0, 
3JHH = 8.0), 8.04 (s, 2H, tpy’ 3-H and 5-H), 7.56 (dd, 2H, 
3JHH = 8.0, 
3JHH =  
8.0, py 3-H), 4.48 (t, 2H, 3JHH = 6.0,  propyl 3-H), 3.80 (t, 2H, 
3JHH = 6.0, propyl 1-H), 3.30-2.20 (br m, 
16H, cyclen), 3.25 (t, 2H, 3JHH = 8.0, S-ethyl 1-H), 2.80 (t, 2H, 
3JHH = 8.0, S-ethyl 2-H), 2.38 (m, 2H, 
propyl 2-H),  2.00 (m, 4H, S-pip 1-H), 1.85 (m, 4H, S-pip 2-H), 1.64 (m, 2H, S-pip 3-H); 31P NMR (162 
MHz, DMSO-d6): δp -145.30 (sep); IR (cm
-1): 1596, 1435, 826, 739; ESI-MS Calcd. for 
C33H52F24N8OP4PtS [M]
+: 1383 a.m.u., Found [M-2PF6]
2+: 545 a.m.u.; Anal. Calcd. for 
C33H52F24N8O3P4PtS∙2H2O: C, 27.92; H, 3.98; N, 7.89; Found: C 28.32, H 3.78, N 7.40. 
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Synthesis of N,N’-bis[4-[hydroxysalicylidene]-3,4-diiminobenzoic acid, 7Ligand. The compound was 
synthesised following modification of a previously reported procedure.226 To a solution of 2,4-
dihydroxybenzaldehyde (0.449 g, 3.20 mmol) in methanol (10 mL) was added at once 3,4-
diaminobenzoic acid (0.250 g, 1.59 mmol) in methanol (10 mL). The reaction mixture was stirred for 
2 h after which time the solvent was evaporated under reduced pressure. Methanol (5 mL) was 
added to the crude solid to yield a solution and a solid. The latter was filtered and washed with 
methanol (2 mL) to yield 8 as a yellow solid (0.385 g, 61% yield). 1H NMR (400 MHz, DMSO-d6): δH 
13.22 (s, 1H, phenyl OH), 13.13 (s, 1H, phenyl’’-OH), 10.35 (s, 1H, phenyl -OH), 8.84 (s, 1H, phenyl -
HCN), 8.80 (s, 1H phenyl’’-HCN), 7.89 ( br d, 1H, phenyl’-H6), 7.86 (br d, 1H, phenyl’-H3), 7.45-7.52 
(m, 3H, phenyl-H6, phenyl’’-H2, phenyl’-H2), 6.41-6.43 (dd, 1H, 3JHH = 4.0, 
4JHH= 2.0, phenyl -H5), 
6.39-6.41 (dd, 1H, 3JHH = 4.0, 
4JHH = 2.0, phenyl’’-H3), 6.30-6.31 (d, 1H, 
4JHH = 2.0, phenyl -H3), 6.29-
6.30 (d, 1H, 4JHH = 2.4, phenyl’’-H5); 
13C NMR (100 MHz, DMSO-d6): δC 191.5, 167.9, 167.3, 164.2, 
164.0, 163.9, 163.7, 163.6, 163.3, 1146.4, 142.5, 135.1, 129.4, 128.4, 120.7, 120.2, 112.8, 108.6, 
108.4, 102.9, 102.8; ESI-MS Calcd. for C21H16N2O6 [M]
+: 392 a.m.u. Found [M+H]+: 391 a.m.u; IR (cm-
1): 1634 (C=N), 1546(Ar), 1478 (Ar), 1128 (C-O), 885 (Ar C-H), 776 (Ar C-H). Once the formation of this 
product was spectroscopically confirmed, it was not further purified and was used as crude for the 
synthesis of compound 7. 
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Synthesis of N,N’-bis[4-[hydroxysalicylidene]-3,4-diiminobenzoic acid nickel(II), 7. The compound 
was synthesised following a previously reported procedure.226 To a solution of 6 (0.200 g, 0.50 
mmol) in hot methanol (10 mL, 45 oC) it was added at once Ni(OAc)2·4H2O (0.254 g, 1.00 mmol) in 
methanol (30 mL). A red precipitate appeared immediately. The reaction mixture was heated at 60 
oC for 30 min and then cooled to room temperature. The orange/red precipitate formed was filtered 
and washed with methanol (50 mL), water (50 mL) and diethyl ether (25 mL) to obtain 7 as an 
orange solid (0.260 g, 46% yield).  ESI-MS Calcd. for C21H14N2NiO6 [M]
+: 449 a.m.u. Found [M-H]+: 447 
a.m.u.; IR (cm-1): 1611 (C=N), 1544 (Ar), 1488 (Ar), 1124 (C-O), 770 (Ar C-H). 7 was not further 
characterised nor purified due to its insolubility. It was used as crude for the synthesis of compound 
8. 
 
 
Synthesis of N,N’-bis[4-[[1-(2-ethyl)piperidine]oxy]salicylidene]-3,4-diiminobenzoic acid nickel(II), 
8. The compound was synthesised following a previously reported procedure.227 A suspension of 7 
(0.25 g, 0.56 mmol), 1-(2-chloroethyl)piperidine hydrochloride (0.412 g, 2.24 mmol), K2CO3 (0.541 g, 
3.92 mmol) and dry DMF (20 mL) was stirred for 72 h under N2. After this period of time the excess 
salts were removed by filtration and the DMF evaporated under reduced pressure. The resulting 
solid was recrystallised using a CH2Cl2:toluene mixture and slow addition of pentane to give 8 as an 
orange/red solid (0.376 g, 10% yield). 1H NMR (400 MHz, CDCl3): δH 8.33(s, 1H, phenyl’-H6), 8.19 (s, 
1H, phenyl’’-HCN), 8.11 (s, 1H, phenyl-HCN), 7.85 (dd, 1H, 3JHH = 8.0, 
4JHH = 2.0  phenyl’-H2), 7.69 (d, 
1H, 3JHH = 8.0, phenyl’-H3), 7.24 (d, 1H,
 3JHH = 8.0, phenyl’’-H2), 7.19 (d, 1H,
 3JHH = 8.0, phenyl -H6), 6.61 
(m, 2H, phenyl -H3 and phenyl’’-H5), 6.38 (d, 2H, phenyl-H5 and phenyl’’-H3), 4.50 (t, 2H, 3JHH = 6.0, 
ethyl-H2), 4.14 (t, 2H, 3JHH = 6.0, ethyl’-H2), 2.79 (m, 4H, ethyl-H1 and ethyl’-H1), 1.48 (m, 4H, 
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piperidine H4), 1.61 (m, 8H, piperidine H3-5); IR (cm-1): 2924 (CH), 1711 (-COOH), 1612 (C=N), 1573 
(Ar), 1509 (Ar), 1121 (C-O), 829 (Ar C-H), 788 (Ar C-H), 758 (Ar C-H); ESI-MS Calcd. for C35H40N4NiO6 
[M]+: 671 a.m.u. Found [M-H]+: 669 a.m.u.; Anal. Calcd. for C35H40N4NiO6: C, 62.61; H, 6.00; N, 8.34. 
Found: C, 63.02; H, 6.50; N, 8.53. 
 
 
6.4 Synthesis of Affinity Tags 
The Tentagel® S SH and Tentagel® S NH2 resins were purchased from Rapp Polymer GmbH. 
 
Synthesis T1. Tentagel S SH resin (capacity: 0.2-0.3 mmol/g, 160 mg, 0.032 – 0.048 mmol) was 
swollen in water (2 mL) for 30 mins. Complex 3a (36 mg, 0.05 mmol) in water (2 mL) was added and 
the reaction mixture stirred at room temperature for 72 h. After this time the resin was observed to 
have changed from a yellow to a deep pink colour.  The resin was filtered through a fritted syringe 
and the resin washed thoroughly with water (the water washings were analysed via UV-vis 
spectroscopy until it was determined that all residual complex had been washed off). The water 
filtrates were combined and the concentration of 3a present was determined via UV-vis 
spectroscopy.  
The concentration of unbound complex was determined as 9.2 µM (A = 0.207 at λ = 282 nm), 
whereas the concentration of total complex initially available was 26.2 µM (A = 0.660 at λ = 282 nm). 
Therefore the amount of complex on the resin was estimated to be 17.0 µM. This corresponds to 
80% loading, taking into account that 1.25 equivalents of 3a for every SH site was used in the 
reaction (80% of the terminal SH groups contain 3a). The loading of the Tentagel S SH resin is 0.2 - 
0.3 mmol/g (indicated by the manufacturer), since ca. 80% of the sites reacted, 1 mg of resin 
equates to ca. 0.16 – 0.24 µM of 3a. 
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Synthesis of T2a. Tentagel S NH2 resin (capacity: 0.27 mmol/g, 148 mg, 0.04 mmol) was swollen in 
DMF (5 mL) for 30 min. The suspension was filtered and 20% piperidine in DMF (4 mL) was added (3 
x 5 mins). The resin was washed with DMF (3 x 5 mL), DCM (3 x 5 mL) and (3 x 5 mL). Ligand L8 (17.6 
mg, 0.05 mmol) was dissolved in DMF (2 mL) and HOBt (6.8 mg, 0.05 mmol), EDCI (7.8, 0.05 mmol) 
and NEt3 (8 µL, 0.1 mmol) were added. The resulting solution was then added to a suspension of 
resin in DMF (2 mL). The reaction mixture was stirred at room temperature for 24 h. Upon 
completion, the resin was washed thoroughly with DMF to remove any remaining starting material. 
The UV-vis spectrum of the combined washings was measured to determine concentration of 
unbound L8. To calculate the amount of L8 loading, a control reaction was also set up whereby the 
coupling reagents and L8 were reacted in the absence of resin. The control reaction was carried out 
to establish the concentration of total available L8.  
The concentration of unbound compound, L8 was determined as 0.85 µM (A = 0.34 at λ = 283 nm), 
whereas the concentration of total compound, L8 available was 2.5 µM (A = 1.00 at λ = 283 nm). 
Therefore the amount of compound, L8 on the beads was estimated to be 1.65 µM. This corresponds 
to 80 % loading, taking into account that 1.25 equivalents of L8 for every NH2 site was used in the 
reaction. The maximum loading of the Tentagel S NH2 resin is 0.27 mmol/g (indicated by the 
manufacturer), since ca. 80 % of the sites reacted, 1 mg of resin equates to ca. 0.22 µM of L8. 
 
 Synthesis of T2b. T2a (148 mg, 0.032 mmol) was swollen in DMF (5 mL) for 30 mins. The suspension 
was filtered and Ac2O:DiPEA:DMF (1:2:7) (4 mL) was added and the suspension was agitated for 1h. 
The solution was then filtered and the resin was washed with DMF (3 x 5 mL), DCM (3 x 5 mL), MeOH 
(3 x 5 MeOH mL) and Et2O (3 x 5 mL). 
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Synthesis of T2c. T2b (148 mg, 0.032 mmol) was suspended in TFA:H2O (95:5) (5 mL) overnight. The 
solution was then filtered and the resin was washed with H2O (20 mL) then with decreasing 
H2O:MeOH (4:1, 3:2, 1:1, 2:3, 1:4) gradient (20 mL) and finally 100% MeOH (20 mL).   
 
 
Synthesis of T2.  A solution of L9 (24.0 mg, 0.096 mmol) in methanol (2 mL) was added to a 
suspension of T2c (148 mg, 0.032 mmol) in methanol (2 mL). The reaction was stirred for 30 min at 45 
oC. Nickel(II) acetate (Ni(OAc)2·4H2O) (10.2 mg, 0.048 mmol) in MeOH (2 mL) was added and the 
reaction stirred overnight at 45 oC.  Upon addition of Ni(OAc)2·4H2O there was an instantaneous 
change in colour of the resin from pale yellow to deep red. A control reaction was also set up 
whereby the reagents were reacted in the absence of resin. The amount of nickel complex loading 
was calculated using UV-vis spectroscopy traces as described for L8 loading (on T2a). The difference in 
intensity of the UV bands corresponding to total available reagents (L9 and nickel(II) acetate)  and 
unbound reagents gave the amount of complex loading.  
The concentration of unbound L9, was determined as 2.5 µM (A = 0.70 at λ = 279 nm), whereas the 
concentration of total L9, available was 5 µM (A = 1.35 at λ = 279 nm). Therefore the amount of 
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nickel complex on the resin was estimated to be 2.5 µM. This corresponds to 75 % loading (taking 
into account 1.5 equivalents of L9 were used for every amine on T2c).  The maximum loading of T2c is 
0.22 mmol/g (calculated from step 2), since ca. 75 % of the sites reacted, 1 mg of resin equates to ca. 
0.17 µM of nickel complex (63 % overall loading). 
 
 
Synthesis of T3.  A solution of 2,4-dihydroxybenzaldehyde (13.5 mg, 0.096 mmol) in methanol (2 mL) 
was added to a suspension of T2c (148 mg, 0.032 mmol) in methanol (2 mL). The reaction was stirred 
for 30 min at 45 oC. Nickel(II) acetate (Ni(OAc)2·4H2O) (10.2 mg, 0.048 mmol) in MeOH (2 mL) was 
added and the reaction stirred overnight at 45 oC.  Upon addition of Ni(OAc)2·4H2O there was an 
instantaneous change in colour of the resin from pale yellow to deep red. A control reaction was also 
set up whereby the reagents were reacted in the absence of resin.  
The concentration of unbound aldehyde, was determined as 1.7 µM (A = 0.47 at λ = 280 nm), 
whereas the concentration of total aldehyde, available was 4 µM (A = 1.08 at λ = 280 nm). Therefore 
the amount of nickel complex on the resin was estimated to be 2.3 µM. This corresponds to 86 % 
loading (taking into account 1.5 equivalents of aldehyde were used for every amine on T2c).  The 
maximum loading of T2c is 0.22 mmol/g (calculated from step 2), since ca. 86 % of the sites reacted, 1 
mg of resin equates to ca. 0.19 µM of nickel complex (70 % overall loading). 
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Synthesis of T4.  A solution of L9 (24.0 mg, 0.096 mmol) in methanol (2 mL) was added to a 
suspension of T2c (148 mg, 0.032 mmol) in methanol (2 mL). The reaction was stirred for 30 min at 45 
oC. VOSO4⋅H2O (8.7 mg, 0.048 mmol) in MeOH (2 mL) was added and the reaction stirred overnight 
at 45 oC.  Upon addition of VOSO4⋅H2O2 there was an instantaneous change in colour of the resin 
from pale yellow to green.  
A control reaction was also set up in each case whereby the reagents were reacted in the absence of 
resin. The concentration of unbound L9, was determined as 1.6 µM (A = 0.44 at λ = 279 nm), whereas 
the concentration of total L9, available was 4.2 µM (A = 1.11 at λ = 279 nm). Therefore the amount of 
nickel complex on the resin was estimated to be 2.6 µM. This corresponds to 91 % loading (taking 
into account 1.5 equivalents of L9 were used for every amine on T2c).  The maximum loading of T2c is 
0.22 mmol/g (calculated from step 2), since ca. 91 % of the sites reacted, 1 mg of resin equates to ca. 
0.20 µM of vanadium complex (74 % overall loading). 
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Synthesis of T5.  A solution of L9 (24.0 mg, 0.096 mmol) in methanol (2 mL) was added to a 
suspension of T2c (148 mg, 0.032 mmol) in methanol (2 mL). The reaction was stirred for 30 min at 45 
oC. Cu(OAc)2·H2O  (9.6 mg, 0.048 mmol) in MeOH (2 mL) was added and the reaction stirred 
overnight at 45 oC.  Upon addition of Cu(OAc)2·H2O there was an instantaneous change in colour of 
the resin from pale yellow to brown.  
A control reaction was also set up in each case whereby the reagents were reacted in the absence of 
resin. The concentration of unbound L9, was determined as 2.5 µM (A = 0.70 at λ = 279 nm), whereas 
the concentration of total L9, available was 3.5 µM (A = 0.96 at λ = 279 nm). Therefore the amount of 
nickel complex on the resin was estimated to be 1.8µM. This corresponds to 82 % loading (taking 
into account 1.5 equivalents of L9 were used for every amine on T2c).  The maximum loading of T2c is 
0.22 mmol/g (calculated from step 2), since ca. 82 % of the sites reacted, 1 mg of resin equates to ca. 
18 µM of copper complex (67 % overall loading). 
 
175 
 
 
Synthesis of T6.  A solution of L9 (24.0 mg, 0.096 mmol) in methanol (2 mL) was added to a 
suspension of T2c (148 mg, 0.032 mmol) in methanol (2 mL). The reaction was stirred for 30 min at 45 
oC. Zn(OAc)2·2H2O (10.6 mg, 0.048 mmol) in MeOH (2 mL) was added and the reaction stirred 
overnight at 45 oC.  Upon addition of Zn(OAc)2·2H2O there was an instantaneous change in colour of 
the resin from pale yellow to dark yellow.  
A control reaction was also set up in each case whereby the reagents were reacted in the absence of 
resin. The concentration of unbound L9, was determined as 2.3 µM (A = 0.64 at λ = 279 nm), whereas 
the concentration of total L9, available was 3.2 µM (A = 0.88 at λ = 279 nm). Therefore the amount of 
nickel complex on the resin was estimated to be 1.8 µM. This corresponds to 82 % loading (taking 
into account 1.5 equivalents of L9 were used for every amine on T2c).  The maximum loading of T2c is 
0.22 mmol/g (calculated from step 2), since ca. 82 % of the sites reacted, 1 mg of resin equates to ca. 
18 µM of zinc complex (67 % overall loading). 
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6.5 Biophysical studies  
 6.5.1 Variable Temperature 1H NMR Spectroscopic Studies  
The 1H NMR spectroscopic studies were carried out in DMSO-d6. Spectra were conducted on a 
BrukerAvance 400 MHz Ultrashield NMR spectrometer. The 1H NMR spectra were recorded at 25-95 
oC in steps of 10 oC. The concentration used for the VT studies was 0.007 M.  
 
6.5.2 DFT Calculations 
The molecular structure of 1, 2 and 4 were optimized by DFT calculations using the Gaussian 03 
program at the B3lyp level of theory. The LANL2DZ basis set was used for the platinum atom; other 
atoms were described by a 6-31G** basis set. 
 
6.5.3 Computational Docking Studies  
Docking studies were carried out using Autodock (Version 4.2) docking software.173  The structure of 
human telomeric intramolecular G4 (PDB:1KF1) was used as a model to study the interaction 
between the metal complex and quadruplex DNA. The structures of the metal complexes were 
obtained by DFT calculations (see 6.5.2). Autodock Tools was used to generate the pdbqt files 
required for both the DNA and metal complexes. All the polar hydrogens were added and non-polar 
hydrogens emerged in these files. The DNA structure was kept rigid during the docking while the 
metal complex was allowed to have rotatable bonds. DNA was enclosed in the grid box defined by 
Auto Grid (dimensions 40" × 40" × 40" Å) used for dispersion/repulsion, hydrogen bonding, 
electrostatics, and desolvation, respectively. Auto Grid performed a pre-calculated atomic affinity 
grid maps for each atom type in the ligand plus an electrostatics map and a separate desolvation 
map present in the substrate molecule. Then, during the AutoDock calculation, the energetics of a 
particular complex configuration was evaluated using the values from the grids. Complex docking 
was carried out with the AutoDock 4.2 Lamarckian Genetic Algorithm (LGA) with an initial population 
of 150 randomly placed individuals, a maximum number of 25 × 106 energy evaluations and a 
probability of performing local search on individual of 0.15. One hundred and fifty independent 
docking runs were performed and the results clustered with a RMSD of 5.0 Å. Other parameters 
were set as default. After clustering all the docking solutions, the most populated cluster was the 
most favourable by energy of binding. 
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6.5.4 Fluorescent Intercalator Displacement (FID) Assay  
Oligonucleotide Preparation for FID Assay: All the RP-Cartridge purified oligonucleotides used were 
purchased from Eurogentec S.A. (U.K.). The 22AG strand (5’-AGGGTTAGGGTTAGGGTTAGGG-3’) and 
20AG strand (5’-GGGAGGGTGGGGAGGGTGGG-3’) were used for the human telomeric (Htelo) and c-
Myc studies, respectively. For the duplex DNA studies, a 26 base pair self-complementary strand (5’-
CAATCGGATCGAATTCGATCCGATTG-3’) was used. The oligonucleotides were dissolved in Milli Q 
water to yield 20 μM (strand concentration) stock solutions. The stock solutions were then diluted 
using 10 mM potassium cacodylate (pH 7.4)/ 50 mM potassium chloride (60 mM K+) buffer to the 
appropriate concentrations. Prior to use in the FID assay, the DNA strands were annealed by heating 
to 95°C for 5 min and then by cooling to room temperature overnight. 
Sample Preparation: The test compounds and thiazole orange (TO) were dissolved in DMSO to give 1 
mM stock solutions. The corresponding solutions were then diluted using 10 mM potassium 
cacodylate (pH 7.4)/50 mM potassium chloride (60 mM K+) buffer to the appropriate concentrations.  
FID Assay Procedure: To a mixture of DNA sequence (0.25 μM, strand concentration) and TO (0.50 
μM) in 10 mM potassium cacodylate (pH 7.4)/ 50 mM potassium chloride (60 mM K+) buffer an 
increasing amount of the complex under study was added (0.033 - 10 μM, corresponding to 0.125 - 
40 equiv). The mixture was allowed to equilibrate for 3 minutes after which time the emission 
spectrum was recorded, with an excitation wavelength of 501 nm, between 510 and 750 nm. The 
fluorescence was recorded on a Varian Cary Eclipse Spectrometer. The fluorescence area was 
calculated using the “trapezium rule” method. The area was converted into percentage TO 
displacement by the following formula: % TO displacement = 100 − [(fluorescence area of 
sample/fluorescence area of standard) × 100]. The standard fluorescence spectrum was obtained in 
the absence of any molecule. % TO displacement was then plotted against each of the compound 
concentrations to give the respective FID curves.  The data points were fitted to a first order 
exponential curve.  
 
6.5.5 UV-Vis Titration Studies  
Oligonucleotide Preparation for UV-vis Titration: The quadruplex forming oligonucleotides were 
purchased from Eurogentec S.A. (U.K.) and were the same as those used in the FID assay (Section 
6.6.4). For the duplex DNA studies, calf-thymus DNA (ct-DNA) was used (purchased from Sigma 
Aldrich). The oligonucleotides were dissolved in Milli Q water to yield 1-4 mM (nucleotide 
concentration) stock solutions. The stock solutions were then diluted using 50 mM Tris-HCl (pH 
7.4)/100 mM KCl buffer to the appropriate concentrations. Prior to use in the UV-vis titrations, the 
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Htelo and c-Myc DNA strands were annealed by heating to 95°C for 5 min and then by cooling to 
room temperature overnight. 
Sample Preparation: The test compounds were dissolved in DMSO to give 1 mM stock solutions. The 
corresponding solutions were then diluted using 50 mM Tris-HCl (pH 7.4)/100 mM KCl buffer to the 
appropriate concentrations.  
UV-vis Titration Procedure: The UV-Vis spectra were recorded on a Perkin Elmer Lambda 25 
spectrometer. In order to determine the binding constants of the selected complexes with Htelo, c-
Myc and ct-DNA, the complexes (20-50 μM) were titrated with concentrated solutions of DNA (ca. 
Htelo: 1 mM, c-Myc: 1 mM, and ct-DNA: 4 mM, nucleotide concentration) in 50 mM Tris-HCl (pH 
7.4)/100 mM KCl buffer. A 1cm path-length quartz cuvette was used to carry out the measurements. 
The binding constants were obtained by fitting the data to a reciprocal plot of D/Δεap versus D using 
the following equation:D / Δεap = D / Δε+ 1 / (Δε × K) where the concentration of DNA is expressed in 
terms of base pairs (determined by measuring the absorption at 260 nm and the appropriate 
extinction coefficients), the apparent molar extinction coefficient εa = Aobserved/ [Complex], Δεap = [εa 
– εf] and Δε = [εb – εf]. εb is the extinction coefficient of the DNA bound complex and εf is the 
extinction coefficient of the free complex.   
 
6.5.6 Fluoresence Resonance Energy Transfer (FRET) Assay 
Oligonucleotide Preparation for FRET Assay: All the RP-HPLC purified oligonucleotides used were 
purchased from Eurogentec S.A. (U.K.). The strands were all doubly labelled with fluorescent dyes 
FAM and TAMRA at the 5’ and 3’ ends respectively. The 22AG strand (5’-
AGGGTTAGGGTTAGGGTTAGGG-3’) and 20AG strand (5’-GGGAGGGTGGGGAGGGTGGG-3’) were used 
for the Htelo and c-Myc studies, respectively. For the duplex DNA studies, a 26 base pair self-
complimentary strand (5’-CAATCGGATCGAATTCGATCCGATTG-3’) was used. The lyophilised strands 
were firstly diluted in deionised water to yield 20 mM (strand concentration) stock solutions. Htelo 
and ds26 DNA structures were then diluted to 0.4 mM (strand concentration) in a Caco.K buffer 
comprising lithium cacodylate (10 mM, pH 7.2) and KCl/LiCl (10 mM/90 mM). c-Myc DNA was diluted 
to 0.4 mM in a Caco.K buffer comprising lithium cacodylate (10 mM, pH 7.2) and KCl/LiCl (1 mM/99 
mM). Prior to use in the FID assay, the DNA strands were annealed by heating to 95°C for 5 min and 
then by cooling to room temperature overnight. 
Sample Preparation: The test compounds were dissolved in DMSO to give 1 mM stock solutions. The 
corresponding solutions were then diluted lithium cacodylate (10 mM, pH 7.2) and KCl/LiCl (10 
mM/90 mM) or lithium cacodylate (10 mM, pH 7.2) and KCl/LiCl (1 mM/99 mM) to the appropriate 
concentrations.  
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FRET Melting and Competition Procedures: Experiments were performed in a 96-well format by using 
an Mx3005P real-time PCR machine (Agilent) equipped with a FAM filter (lex=492 nm; lem=516 nm). 
All the experiments were carried out with a total reaction volume of 100 µL. Each well of a 96-well 
plate contained 0.2 mM oligo and 0.1 – 0.4 mM compound to test. Measurements were performed 
with excitation at 450-495 nm and detection at 515-545 nm. Readings were taken from 20 to 95 °C 
at intervals of 0.7 °C, maintaining a constant temperature for 30 s before each reading. The emission 
of FAM was normalised (0 to 1), the data points were fitted to a sigmoidal curve and T1/2 was defined 
as the temperature for which the normalised emission is 0.5. ∆T1/2 values were the means of three 
experiments. 
Competitive FRET melting experiments were carried out with Htelo and c-Myc DNA in competition 
with ds26 DNA or ct-DNA, expressed in motif concentration and base pair concentration 
respectively, and in the presence of test compound (2 eq.).  Measurements were recorded in the 
same manner described above. 
 
6.5.7 Circular Dichroism (CD) Studies   
Oligonucleotide Preparation for CD Studies: All oligonucleotides used were purchased from 
Eurogentec S.A. (U.K.). The Htelo and c-Myc DNA sequences used were the same as those used in 
the FID assay (Section 6.6.4). The oligonucleotides were dissolved in Milli Q water to yield a 100 μM 
stock solution. This was then diluted using 50 mM Tris-HCl (pH 7.4) or 50 mM Tris-HCl (pH 7.4)/150 
mM KCl buffer to 20 μM (strand concentration). Prior to use in the CD assay, the DNA solution was 
annealed by heating to 95°C for 5 min and then by cooling to room temperature (only for DNA 
solutions in Tris-HCl/KCl buffer to be used in experiment (1)).  
Sample Preparation: The test compounds were dissolved in DMSO to yield a 1 mM stock solution. 
This was then diluted using Tris-HCl or Tris-HCl/KCl buffer to the appropriate concentrations.  
CD procedure: The CD spectra were recorded in a strainfree 10 mm × 2 mm rectangular cell path 
length cuvette. The data was obtained on an Applied Photophysics Ltd Chirascan spectrometer. The 
CD spectra were measured in the wavelength region of 700-180 nm with the following parameters: 
bandwidth, 1 nm; spectral range, 230-360 nm; step-size, 0.5 nm; time-pep-point, 1.5 s. The CD 
spectra were collected and analysed using the Chirascan and Chirascan Viewer softwares 
respectively. The following CD experiments were conducted: (1) CD spectra for the Htelo sequence 
(10 μM, strand concentration) with varying oligonucleotide/test compound ratios (0.5- 3) in Tris-HCl/ 
KCl buffer (2) CD spectra for the Htelo sequence (10 μM, strand concentration) with and without the 
presence of the test compounds (25 μM, 2.5 eq.) in Tris-HCl buffer (3) CD spectra for the c-Myc 
sequence (5 μM, strand concentration) with and without the presence of the test compounds (12.5 
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μM, 2.5 eq.) in Tris-HCl buffer (4) variable temperature CD studies were recorded for the c-Myc 
sequence (5 μM, strand concentration) with and without the presence of  test compound (10 μM, 
2eq.) in Tris-HCl buffer. The temperature was increased from 20 oC to 95 oC at 1oC min-1, at 5oC 
increments at a range of 230-360 nm.    The data points were fitted to a sigmoidal curve. 
6.6 Cellular Studies 
6.6.1 Cell Culture  
The U2OS human osteosarcoma, SH-SY5Y human derived neuroblastoma and GM05757 normal 
human fibroblast cell lines were obtained from Dr David Mann (Division of Cell and Molecular 
Biology, Imperial College London). The U2OS and GM05757 cells were maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM- low glucose) media which was supplemented with 10% foetal 
bovine serum and 1% penicillin/streptomycin. The SH-SY5Y cells were maintained in RPMI-1640 
media which was supplemented with 10% foetal bovine serum and 1% penicillin/streptomycin. All 
cells were grown at 310 K in a humidified atmosphere containing 5% CO2.  
 
6.6.2 Cytotoxicity Studies: MTS Assay  
Cells (5 × 104 for U20S, 5 × 104 for SH-SY5Y and 1 × 104 for GM05757) were seeded in each well of a 
96-well plate. After 24 h the cells were exposed to various concentrations of the test compound (0.2-
500 μM) for a further 24 h (total volume 100 μL). The test compounds were prepared as 10 mM 
solutions in DMSO and diluted further using DMSO. The final concentration of DMSO in each well 
was 4%. After the incubation period, 20 μL of the MTS solution (made up of 2 mg/mL MTS reagent + 
100 μL of PMS 0.96 mg/mL) was added to each well. The mixture was incubated for a further 1 – 12 
h at 37 °C. After this time, a spectrophotometer was used to record the absorption at 490 nm and 
the IC50 values were determined using the Conventional Method. This method involves determining 
the Abs IC50 value for each test. This was calculated from the following equation: Abs IC50 = (Abs IC0 + 
Abs IC100)/ 2; where IC0 is the mean absorption at 490 nm of the media only and IC100 is the mean 
absorption at 490 nm of the cells only. Then the X-axis intercept of the dose-response curve at Abs 
IC50 (determined by the above equation) was considered as IC50 value for each test compound. The 
dose-response curve is a plot of absorption at 490 nm (y-axis) and the concentration of test 
compound exposed to the cells (x-axis). Prior to plotting the curve the background absorption (due 
to the reaction of the test compound and MTS reagents) was subtracted from the absorption values 
obtained from the cells that had been incubated with the compounds. 
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6.6.3 Immunoblot analysis 
For protein analysis by immunoblotting, U2OS cells (5 x 105 cells) were incubated with metal 
complexes (1 to 6) at 10 µM for 24 h at 37 oC. Cells were washed with PBS, scraped into lysis buffer 
(64 mM Tris-HCl (pH 6.8)/9.6% glycerol/2% SDS, 5% β-mercaptoethanol, Bromophenol Blue) and 
incubated at 95 oC for 10 min.  Whole cell lysates were resolved by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (12%; SDS-PAGE; 200 V for 1 h) followed by electro transfer to 
nitrocellulose membrane (400 mA for 1 h). Membranes were blocked in 5% (w/v) non-fat milk in 
PBST (PBS, 0.1% Tween 20) and incubated with the following primary antibodies: anti-cMyc from 
Santa Cruz and anti-α-tubulin (TAT-1, Cancer Research UK). After incubation with horseradish 
peroxidase-conjugated secondary antibodies, immune complexes were detected with the ECL 
detection reagent (Millipore) and analysed by using the Fujifilm Image Reader LAS-3000. 
 
 
6.7 Affinity Tag Assays 
All RP-HPLC purified oligonucleotides used in this study were purchased from Eurogentec.  The 
sequences were FAM labelled on the 5’ position.  The labelled sequences used in the affinity tag 
assays were; Htelo DNA ([6FAM]AGGGTTAGGGTTAGGGTTAGG G), c-Myc DNA 
([6FAM]GGGGAGGGTGGGGAGGGTGGG), ds26 DNA ([6FAM]CAATCGGATCGAATTCGATCCGATTG),  
TRF2 RNA ([6FAM]CGGGAGGGCGGGGAGGGC) and hairpin RNA ([6FAM]CAATCGGATCG 
AATTCGATCCGATTG).  The unlabelled sequences used were: Htelo DNA 
(AGGGTTAGGGTTAGGGTTAGG G), ds26 DNA (CAATCGGATCGAATTCGATCCGATTG), TRF2 RNA 
(CGGGAGGGCGGGGAGGGC) and hairpin RNA (CAATCGGATCG AATTCGATCCGATTG). The calf-thymus 
DNA (ct-DNA), transfer RNA (tRNA) and bovine serum albumin (BSA) were purchased from Sigma 
Aldrich. 
 
6.7.1 Nucleic Acid Isolation Assays with Affinity Tags 
Oligonucleotide Preparation for Isolation Assay: Oligonucleotide stock solutions of 200 μM were 
prepared using MiliQ water. Further dilutions to 20 μM were carried out in annealing buffer 
containing 10 mM Tris.HCl (pH 7.4) and 60 mM potassium chloride. Samples were annealed by 
heating at 95 oC for 5 min followed by slow cooling to room temperature.                                            
Isolation Assay Procedure: In a typical experiment, oligonucleotide solutions (0.5 μM, 1 mL) were 
incubated with a defined quantity of affinity tag (T) (ca. 0 - 20 mg) for 1 hour, with shaking at room 
temperature.  After incubation the solutions were filtered through fritted syringes.  The beads were 
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washed once with buffer (1 mL) and this was combined with the supernatant.  The fluorescence of 
the supernatant was recorded between 500 nm and 600 nm with excitation at 490 nm, to gauge the 
amount of unbound DNA. Graphs were plotted of affinity tag (T) mass against percentage decrease 
in FAM emission corresponding to each labelled oligonucleotide (with respect to FAM emission with 
no beads).  
For isolation assays involving RNA oligonucleotides Mili Q water and buffer solutions were prepared 
using RNase free water. Otherwise the same protocol was followed. 
 
6.7.2 Nucleic Acid Competition Assays with Affinity Tags 
Oligonucleotide Preparation for Isolation Assay: Oligonucleotides were prepared as in Section 6.8.2. 
Competition Assay Procedure:  A solution of FAM DNA (1 µM, 500 µL) was mixed with a solution of 
unlabelled DNA (0 - 100 µM, 500 µL). The mixture was incubated with a defined quantity of affinity 
tag (T) (ca. 0 - 20 mg) for 1 hour, with shaking at room temperature. After incubation the solutions 
were filtered through fritted syringes.  The beads were washed once with buffer (1 mL) and this was 
combined with the supernatant.  The fluorescence of the supernatant was recorded between 500 
nm and 600 nm with excitation at 490 nm, to gauge the amount of unbound DNA. Graphs were 
plotted of affinity tag (T) mass against percentage decrease in FAM emission corresponding to each 
labelled oligonucleotide (with respect to FAM emission with no beads).  
Competition assays with ct-DNA, tRNA and BSA (0 – 1000 µM, 500 µL) as competiting agents were 
also carried out. For competition assays involving RNA oligonucleotides Mili Q water and buffer 
solutions were prepared using RNase free water. Otherwise the same protocol was followed. 
 
6.7.3 Nucleic Acid Recovery Assays from Affinity Tags 
In a typical recovery experiment, the affinity tags collected after pull-down were washed once with 1 
mL of Tris.HCl/KCl buffer. For experiments involving DNA, 1 mL of a 1 M aqueous solution of 
guanidine HCl was added per eppendorf of resin and incubated for 30 min at 37 oC.  For experiments 
involving RNA, 1 mL of an 8 M aqueous urea solution was added to each eppendorf of resin and 
incubated for 30 min at 37 oC. The solution was separated from the affinity tags by filtration. The 
fluorescence of the supernatant was recorded between 500 nm and 600 nm with excitation at 490 
nm, to gauge the amount of recovered DNA/RNA. 
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A.1 1H-1H COSY NMR 
 
 
Figure A-1: 
1
H-
1
H COSY NMR of L
5
 in d
6
-DMSO. 
    
 
Figure A-2: 
1
H-
1
H COSY NMR of 1 in d
6
-DMSO.  
δ/ ppm 
δ/ ppm 
δ/ ppm 
δ/ ppm 
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Figure A-3: 
1
H-
1
H COSY NMR of 4 in d
6
-DMSO. 
 
 
Figure A-4: 
1
H-
1
H COSY NMR of 6 in d
6
-DMSO. 
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A.2 X-ray Crystallography Data  
 
Data for 1 · 0.5ZnCL4 · 0.5(CH3)2CO · 2H2O 
Formula  
 
Formula weight 
Temperature 
Diffractometer, wavelength 
Crystal system, space group 
Unit cell dimensions  
 
 
 
Volume, Z 
Density (calculated) 
Absorption coefficient 
F(000) 
Crystal colour / morphology 
Crystal size  
 range for data collection 
Index ranges 
Reflns collected / unique 
Reflns observed [F>4 (F)] 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [F>4 (F)]  
R indices (all data) 
Largest diff. peak, hole 
Mean and maximum shift/error  
C26 H35 Cl3 N7 O Zn2, 0.5(Cl4 Zn), 
0.5(C3 H6 O), 2(H2 O) 
867.36 
173 K 
OD Xcalibur 3, 1.54184 Å 
Triclinic, P-1 
a = 14.9174(4) Å    α = 69.026(3)° 
b = 15.4884(5) Å    β = 81.075(2)° 
c = 18.5245(5) Å    γ = 63.677(3)° 
3582.0(2) Å3, 4 
1.608 Mg/m3 
5.773 mm-1 
1776 
Colourless needles 
0.29 x 0.04 x 0.03 mm3 
2.55 to 72.44° 
-17<=h<=18, -18<=k<=17, -22<=l<=22 
29201 / 13810 [R(int) = 0.0342] 
11772 
Analytical 
0.850 and 0.451 
Full-matrix least-squares on F2 
13810 / 142 / 876 
1.052 
R1 = 0.0378, wR2 = 0.1039 
R1 = 0.0475, wR2 = 0.1087 
1.112, -0.986 eÅ-3 
0.000 and 0.001 
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Bond lengths [Å] and angles [°] 
Zn(1A)-N(1A)       2.094(2) 
Zn(1A)-N(8A) 2.183(2) 
Zn(1A)-N(14A) 2.193(2) 
Zn(1A)-Cl(1A) 2.2614(8) 
Zn(1A)-Cl(2A) 2.2903(7) 
Zn(2A)-N(32A) 2.131(2) 
Zn(2A)-N(26A) 2.138(2) 
Zn(2A)-N(29A) 2.164(3) 
Zn(2A)-N(23A) 2.219(2) 
Zn(2A)-Cl(3A) 2.2311(8) 
N(1A)-C(2A) 1.337(3) 
N(1A)-C(6A) 1.342(3) 
C(2A)-C(3A) 1.394(4) 
C(2A)-C(7A) 1.486(4) 
C(3A)-C(4A) 1.390(4) 
C(4A)-O(19A) 1.344(3) 
C(4A)-C(5A) 1.407(4) 
C(5A)-C(6A) 1.385(4) 
C(6A)-C(13A) 1.490(3) 
C(7A)-N(8A) 1.350(3) 
C(7A)-C(12A) 1.387(4) 
N(8A)-C(9A) 1.336(4) 
C(9A)-C(10A) 1.381(5) 
C(10A)-C(11A) 1.385(5) 
C(11A)-C(12A) 1.383(4) 
C(13A)-N(14A) 1.357(3) 
C(13A)-C(18A) 1.380(4) 
N(14A)-C(15A) 1.336(4) 
C(15A)-C(16A) 1.376(4) 
C(16A)-C(17A) 1.386(4) 
C(17A)-C(18A) 1.390(4) 
O(19A)-C(20A) 1.449(3) 
C(20A)-C(21A) 1.513(4) 
C(21A)-C(22A) 1.532(4) 
C(22A)-N(23A) 1.484(3) 
N(23A)-C(34A) 1.484(4) 
N(23A)-C(24A) 1.487(3) 
C(24A)-C(25A) 1.519(4) 
C(25A)-N(26A) 1.468(4) 
N(26A)-C(27A) 1.482(4) 
C(27A)-C(28A) 1.515(5) 
C(28A)-N(29A) 1.479(4) 
N(29A)-C(30A) 1.470(4) 
C(30A)-C(31A) 1.510(5) 
C(31A)-N(32A) 1.471(4) 
N(32A)-C(33A) 1.480(4) 
C(33A)-C(34A) 1.516(4) 
Zn(1B)-N(1B) 2.077(2) 
Zn(1B)-N(8B) 2.175(3) 
Zn(1B)-N(14B) 2.205(2) 
C(9A)-N(8A)-Zn(1A) 125.27(19) 
C(7A)-N(8A)-Zn(1A) 115.74(18) 
N(8A)-C(9A)-C(10A) 122.9(3) 
C(9A)-C(10A)-C(11A) 118.3(3) 
C(12A)-C(11A)-C(10A) 119.7(3) 
C(11A)-C(12A)-C(7A) 118.5(3) 
N(14A)-C(13A)-C(18A) 122.1(2) 
N(14A)-C(13A)-C(6A) 114.0(2) 
C(18A)-C(13A)-C(6A) 124.0(2) 
C(15A)-N(14A)-C(13A) 118.4(2) 
C(15A)-N(14A)-Zn(1A) 125.28(19) 
C(13A)-N(14A)-Zn(1A) 115.92(17) 
N(14A)-C(15A)-C(16A) 122.9(3) 
C(15A)-C(16A)-C(17A) 118.8(3) 
C(16A)-C(17A)-C(18A) 119.0(3) 
C(13A)-C(18A)-C(17A) 118.8(3) 
C(4A)-O(19A)-C(20A) 117.4(2) 
O(19A)-C(20A)-C(21A) 106.8(2) 
C(20A)-C(21A)-C(22A) 110.3(2) 
N(23A)-C(22A)-C(21A) 115.9(2) 
C(34A)-N(23A)-C(22A) 112.6(2) 
C(34A)-N(23A)-C(24A) 110.5(2) 
C(22A)-N(23A)-C(24A) 111.3(2) 
C(34A)-N(23A)-Zn(2A) 104.25(16) 
C(22A)-N(23A)-Zn(2A) 110.63(16) 
C(24A)-N(23A)-Zn(2A) 107.22(16) 
N(23A)-C(24A)-C(25A) 110.2(2) 
N(26A)-C(25A)-C(24A) 109.3(2) 
C(25A)-N(26A)-C(27A) 114.5(2) 
C(25A)-N(26A)-Zn(2A) 106.04(16) 
C(27A)-N(26A)-Zn(2A) 109.69(19) 
N(26A)-C(27A)-C(28A) 109.0(2) 
N(29A)-C(28A)-C(27A) 108.7(3) 
C(30A)-N(29A)-C(28A) 114.6(3) 
C(30A)-N(29A)-Zn(2A) 107.16(19) 
C(28A)-N(29A)-Zn(2A) 106.64(18) 
N(29A)-C(30A)-C(31A) 110.2(3) 
N(32A)-C(31A)-C(30A) 109.4(3) 
C(31A)-N(32A)-C(33A) 114.8(3) 
C(31A)-N(32A)-Zn(2A) 106.12(18) 
C(33A)-N(32A)-Zn(2A) 110.85(17) 
N(32A)-C(33A)-C(34A) 110.2(2) 
N(23A)-C(34A)-C(33A) 111.3(2) 
N(1B)-Zn(1B)-N(8B) 75.24(9) 
N(1B)-Zn(1B)-N(14B) 75.10(8) 
N(8B)-Zn(1B)-N(14B) 150.33(9) 
N(1B)-Zn(1B)-Cl(1B) 116.47(7) 
N(8B)-Zn(1B)-Cl(1B) 96.22(7) 
N(14B)-Zn(1B)-Cl(1B) 97.65(6) 
N(1B)-Zn(1B)-Cl(2B) 130.07(7) 
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Zn(1B)-Cl(1B) 2.2678(8) 
Zn(1B)-Cl(2B) 2.2680(7) 
Zn(2B)-N(26B) 2.137(3) 
Zn(2B)-N(29B) 2.138(3) 
Zn(2B)-N(32B) 2.144(3) 
Zn(2B)-N(23B) 2.186(2) 
Zn(2B)-Cl(3B) 2.2358(9) 
N(1B)-C(2B) 1.338(4) 
N(1B)-C(6B) 1.347(3) 
C(2B)-C(3B) 1.388(4) 
C(2B)-C(7B) 1.493(4) 
C(3B)-C(4B) 1.396(4) 
C(4B)-O(19B) 1.348(3) 
C(4B)-C(5B) 1.391(4) 
C(5B)-C(6B) 1.384(4) 
C(6B)-C(13B) 1.487(4) 
C(7B)-N(8B) 1.344(4) 
C(7B)-C(12B) 1.375(4) 
N(8B)-C(9B) 1.336(4) 
C(9B)-C(10B) 1.373(5) 
C(10B)-C(11B) 1.367(5) 
C(11B)-C(12B) 1.392(5) 
C(13B)-N(14B) 1.348(3) 
C(13B)-C(18B) 1.392(4) 
N(14B)-C(15B) 1.332(4) 
C(15B)-C(16B) 1.380(4) 
C(16B)-C(17B) 1.388(4) 
C(17B)-C(18B) 1.389(4) 
O(19B)-C(20B) 1.454(4) 
C(20B)-C(21B) 1.516(4) 
C(21B)-C(22B) 1.526(4) 
C(22B)-N(23B) 1.487(4) 
N(23B)-C(34B) 1.478(4) 
N(23B)-C(24B) 1.482(4) 
C(24B)-C(25B) 1.526(4) 
C(25B)-N(26B) 1.474(4) 
N(26B)-C(27B) 1.476(5) 
C(27B)-C(28B) 1.510(6) 
C(28B)-N(29B) 1.465(5) 
N(29B)-C(30B) 1.472(5) 
C(30B)-C(31B) 1.506(6) 
C(31B)-N(32B) 1.466(5) 
N(32B)-C(33B) 1.484(4) 
C(33B)-C(34B) 1.511(4) 
 
N(1A)-Zn(1A)-N(8A) 74.91(8) 
N(1A)-Zn(1A)-N(14A) 74.25(8) 
N(8A)-Zn(1A)-N(14A) 146.69(9) 
N(1A)-Zn(1A)-Cl(1A) 114.19(6) 
N(8A)-Zn(1A)-Cl(1A) 106.41(7) 
N(14A)-Zn(1A)-Cl(1A) 97.47(6) 
N(8B)-Zn(1B)-Cl(2B) 99.28(7) 
N(14B)-Zn(1B)-Cl(2B) 99.02(6) 
Cl(1B)-Zn(1B)-Cl(2B) 113.46(3) 
N(26B)-Zn(2B)-N(29B) 82.17(11) 
N(26B)-Zn(2B)-N(32B) 134.89(11) 
N(29B)-Zn(2B)-N(32B) 81.91(12) 
N(26B)-Zn(2B)-N(23B) 81.80(10) 
N(29B)-Zn(2B)-N(23B) 137.91(10) 
N(32B)-Zn(2B)-N(23B) 82.45(10) 
N(26B)-Zn(2B)-Cl(3B) 112.52(9) 
N(29B)-Zn(2B)-Cl(3B) 111.29(9) 
N(32B)-Zn(2B)-Cl(3B) 112.59(8) 
N(23B)-Zn(2B)-Cl(3B) 110.80(7) 
C(2B)-N(1B)-C(6B) 119.9(2) 
C(2B)-N(1B)-Zn(1B) 119.81(17) 
C(6B)-N(1B)-Zn(1B) 120.10(18) 
N(1B)-C(2B)-C(3B) 122.4(2) 
N(1B)-C(2B)-C(7B) 114.4(2) 
C(3B)-C(2B)-C(7B) 123.3(2) 
C(2B)-C(3B)-C(4B) 117.6(3) 
O(19B)-C(4B)-C(5B) 115.6(2) 
O(19B)-C(4B)-C(3B) 124.4(2) 
C(5B)-C(4B)-C(3B) 120.0(2) 
C(6B)-C(5B)-C(4B) 118.7(2) 
N(1B)-C(6B)-C(5B) 121.3(2) 
N(1B)-C(6B)-C(13B) 114.3(2) 
C(5B)-C(6B)-C(13B) 124.4(2) 
N(8B)-C(7B)-C(12B) 122.0(3) 
N(8B)-C(7B)-C(2B) 114.2(2) 
C(12B)-C(7B)-C(2B) 123.7(3) 
C(9B)-N(8B)-C(7B) 118.3(3) 
C(9B)-N(8B)-Zn(1B) 125.3(2) 
C(7B)-N(8B)-Zn(1B) 116.21(18) 
N(8B)-C(9B)-C(10B) 122.8(3) 
C(11B)-C(10B)-C(9B) 119.1(3) 
C(10B)-C(11B)-C(12B) 118.9(3) 
C(7B)-C(12B)-C(11B) 118.9(3) 
N(14B)-C(13B)-C(18B) 121.6(3) 
N(14B)-C(13B)-C(6B) 115.0(2) 
C(18B)-C(13B)-C(6B) 123.4(2) 
C(15B)-N(14B)-C(13B) 119.1(2) 
C(15B)-N(14B)-Zn(1B) 125.53(19) 
C(13B)-N(14B)-Zn(1B) 115.26(18) 
N(14B)-C(15B)-C(16B) 122.9(3) 
C(15B)-C(16B)-C(17B) 118.3(3) 
C(16B)-C(17B)-C(18B) 119.4(3) 
C(17B)-C(18B)-C(13B) 118.6(3) 
C(4B)-O(19B)-C(20B) 118.5(2) 
O(19B)-C(20B)-C(21B) 106.4(2) 
C(20B)-C(21B)-C(22B) 109.9(2) 
N(23B)-C(22B)-C(21B) 116.4(2) 
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N(1A)-Zn(1A)-Cl(2A) 136.40(6) 
N(8A)-Zn(1A)-Cl(2A) 94.80(6) 
N(14A)-Zn(1A)-Cl(2A) 98.85(6) 
Cl(1A)-Zn(1A)-Cl(2A) 109.38(3) 
N(32A)-Zn(2A)-N(26A) 132.50(10) 
N(32A)-Zn(2A)-N(29A) 82.37(10) 
N(26A)-Zn(2A)-N(29A) 81.10(10) 
N(32A)-Zn(2A)-N(23A) 81.66(9) 
N(26A)-Zn(2A)-N(23A) 81.26(9) 
N(29A)-Zn(2A)-N(23A) 137.46(10) 
N(32A)-Zn(2A)-Cl(3A) 112.14(7) 
N(26A)-Zn(2A)-Cl(3A) 115.30(7) 
N(29A)-Zn(2A)-Cl(3A) 108.09(8) 
N(23A)-Zn(2A)-Cl(3A) 114.45(6) 
C(2A)-N(1A)-C(6A) 120.2(2) 
C(2A)-N(1A)-Zn(1A) 119.28(18) 
C(6A)-N(1A)-Zn(1A) 119.69(17) 
N(1A)-C(2A)-C(3A) 122.1(2) 
N(1A)-C(2A)-C(7A) 113.9(2) 
C(3A)-C(2A)-C(7A) 124.1(2) 
C(4A)-C(3A)-C(2A) 117.8(2) 
O(19A)-C(4A)-C(3A) 124.8(2) 
O(19A)-C(4A)-C(5A) 115.1(2) 
C(3A)-C(4A)-C(5A) 120.1(2) 
C(6A)-C(5A)-C(4A) 117.9(2) 
N(1A)-C(6A)-C(5A) 121.8(2) 
N(1A)-C(6A)-C(13A) 114.1(2) 
C(5A)-C(6A)-C(13A) 124.1(2) 
N(8A)-C(7A)-C(12A) 122.0(3) 
N(8A)-C(7A)-C(2A) 114.7(2) 
C(12A)-C(7A)-C(2A) 123.1(2) 
C(9A)-N(8A)-C(7A) 118.6(2) 
C(34B)-N(23B)-C(24B) 111.5(2) 
C(34B)-N(23B)-C(22B) 112.7(2) 
C(24B)-N(23B)-C(22B) 111.7(2) 
C(34B)-N(23B)-Zn(2B) 102.46(18) 
C(24B)-N(23B)-Zn(2B) 107.47(17) 
C(22B)-N(23B)-Zn(2B) 110.60(17) 
N(23B)-C(24B)-C(25B) 110.8(2) 
N(26B)-C(25B)-C(24B) 108.6(3) 
C(25B)-N(26B)-C(27B) 114.7(3) 
C(25B)-N(26B)-Zn(2B) 107.08(18) 
C(27B)-N(26B)-Zn(2B) 108.5(2) 
N(26B)-C(27B)-C(28B) 110.4(3) 
N(29B)-C(28B)-C(27B) 109.4(3) 
C(28B)-N(29B)-C(30B) 115.5(3) 
C(28B)-N(29B)-Zn(2B) 106.1(2) 
C(30B)-N(29B)-Zn(2B) 108.5(2) 
N(29B)-C(30B)-C(31B) 109.8(3) 
N(32B)-C(31B)-C(30B) 109.6(3) 
C(31B)-N(32B)-C(33B) 113.6(3) 
C(31B)-N(32B)-Zn(2B) 106.4(2) 
C(33B)-N(32B)-Zn(2B) 108.76(19) 
N(32B)-C(33B)-C(34B) 110.2(2) 
N(23B)-C(34B)-C(33B) 110.5(2) 
 
 
 
Data for 2 · 6.5H2O 
Formula  
Formula weight  
Temperature 
Diffractometer, wavelength 
Crystal system, space group 
Unit cell dimensions  
 
 
 
C26 H35 Cu2 Cl3 N7 O, Cl, 6.5(H2 O) 
847.59 
173 K 
OD Xcalibur PX Ultra, 1.54184 Å 
Monoclinic, C2/c 
a = 38.832(4) Å    α = 90° 
b = 14.0405(8) Å   β = 101.090(9)° 
c = 13.7761(10) Å  γ = 90° 
7370.8(10) Å3, 8 
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Volume, Z 
Density (calculated) 
Absorption coefficient 
F(000) 
Crystal colour / morphology 
Crystal size  
 range for data collection 
Index ranges 
Reflns collected / unique 
Reflns observed [F>4 (F)] 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [F>4 (F)]  
R indices (all data) 
Largest diff. peak, hole  
Mean and maximum shift/error  
1.528 Mg/m3 
4.532 mm-1 
3512 
Blue platy needles 
0.32 x 0.06 x 0.01 mm3 
.32 to 72.67° 
-47<=h<=47, -17<=k<=15, -17<=l<=16 
24406 / 7202 [R(int) = 0.0735] 
4286 
Analytical 
0.937 and 0.422 
Full-matrix least-squares on F2 
7202 / 503 / 431 
1.130 
R1 = 0.0779, wR2 = 0.2300 
R1 = 0.1086, wR2 = 0.2702 
0.864, -0.809 eÅ-3 
0.000 and 0.001 
 
Bond lengths [Å] and angles [°] 
Cu(1)-N(1)         1.944(5) 
Cu(1)-N(14)   2.030(6) 
Cu(1)-N(8) 2.051(4) 
Cu(1)-Cl(2) 2.2341(18) 
Cu(1)-Cl(1) 2.5361(17) 
Cu(2)-N(26) 1.995(9) 
Cu(2)-N(32) 2.036(8) 
Cu(2)-N(29) 2.038(9) 
Cu(2)-N(23) 2.039(8) 
Cu(2)-Cl(3) 2.405(5) 
Cu(2')-N(26') 1.990(12) 
Cu(2')-N(29') 2.025(12) 
Cu(2')-N(23') 2.028(10) 
Cu(2')-N(32') 2.034(11) 
Cu(2')-Cl(3') 2.390(6) 
N(1)-C(6) 1.324(7) 
N(1)-C(2) 1.344(6) 
C(2)-C(3) 1.368(7) 
C(2)-C(7) 1.485(7) 
N(26')-Cu(2')-Cl(3') 109.4(5) 
N(29')-Cu(2')-Cl(3') 105.3(4) 
N(23')-Cu(2')-Cl(3') 105.7(3) 
N(32')-Cu(2')-Cl(3') 103.4(4) 
 
C(6)-N(1)-C(2) 121.1(5) 
C(6)-N(1)-Cu(1) 119.8(3) 
C(2)-N(1)-Cu(1) 119.1(4) 
N(1)-C(2)-C(3) 120.7(5) 
N(1)-C(2)-C(7) 112.6(4) 
C(3)-C(2)-C(7) 126.8(4) 
C(2)-C(3)-C(4) 118.1(4) 
O(19)-C(4)-C(3) 115.6(5) 
O(19)-C(4)-C(5) 123.6(6) 
C(3)-C(4)-C(5) 120.8(6) 
C(6)-C(5)-C(4) 116.9(5) 
N(1)-C(6)-C(5) 122.4(5) 
N(1)-C(6)-C(13) 111.4(6) 
C(5)-C(6)-C(13) 126.2(6) 
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C(3)-C(4) 1.391(8) 
C(4)-O(19) 1.342(8) 
C(4)-C(5) 1.397(9) 
C(5)-C(6) 1.367(10) 
C(6)-C(13) 1.496(8) 
C(7)-N(8) 1.348(7) 
C(7)-C(12) 1.370(7) 
N(8)-C(9) 1.313(8) 
C(9)-C(10) 1.406(10) 
C(10)-C(11) 1.370(10) 
C(11)-C(12) 1.391(9) 
C(13)-N(14) 1.333(11) 
C(13)-C(18) 1.395(10) 
N(14)-C(15) 1.348(8) 
C(15)-C(16) 1.401(16) 
C(16)-C(17) 1.283(17) 
C(17)-C(18) 1.452(15) 
O(19)-C(20) 1.386(12) 
O(19)-C(20') 1.502(15) 
C(20)-C(21) 1.535(15) 
C(21)-C(22) 1.518(12) 
C(22)-N(23) 1.483(15) 
N(23)-C(24) 1.479(11) 
N(23)-C(34) 1.496(10) 
C(24)-C(25) 1.449(13) 
C(25)-N(26) 1.478(10) 
N(26)-C(27) 1.470(12) 
C(27)-C(28) 1.445(12) 
C(28)-N(29) 1.469(12) 
N(29)-C(30) 1.446(12) 
C(30)-C(31) 1.479(14) 
C(31)-N(32) 1.474(10) 
N(32)-C(33) 1.468(12) 
C(33)-C(34) 1.484(13) 
C(20')-C(21') 1.501(15) 
C(21')-C(22') 1.527(15) 
C(22')-N(23') 1.488(16) 
N(23')-C(24') 1.468(13) 
N(23')-C(34') 1.494(12) 
C(24')-C(25') 1.467(15) 
C(25')-N(26') 1.505(13) 
N(26')-C(27') 1.475(14) 
C(27')-C(28') 1.435(16) 
C(28')-N(29') 1.478(14) 
N(29')-C(30') 1.472(14) 
C(30')-C(31') 1.448(16) 
C(31')-N(32') 1.464(13) 
N(32')-C(33') 1.471(13) 
C(33')-C(34') 1.449(15) 
 
 
N(8)-C(7)-C(12) 121.2(5) 
N(8)-C(7)-C(2) 114.6(4) 
C(12)-C(7)-C(2) 124.2(5) 
C(9)-N(8)-C(7) 120.3(5) 
C(9)-N(8)-Cu(1) 125.6(4) 
C(7)-N(8)-Cu(1) 114.0(3) 
N(8)-C(9)-C(10) 121.2(6) 
C(11)-C(10)-C(9) 119.0(6) 
C(10)-C(11)-C(12) 118.8(5) 
C(7)-C(12)-C(11) 119.4(6) 
N(14)-C(13)-C(18) 122.0(7) 
N(14)-C(13)-C(6) 114.7(6) 
C(18)-C(13)-C(6) 123.3(9) 
C(13)-N(14)-C(15) 122.2(7) 
C(13)-N(14)-Cu(1) 114.3(4) 
C(15)-N(14)-Cu(1) 123.1(7) 
N(14)-C(15)-C(16) 117.4(11) 
C(17)-C(16)-C(15) 122.3(9) 
C(16)-C(17)-C(18) 121.4(8) 
C(13)-C(18)-C(17) 114.5(10) 
C(4)-O(19)-C(20) 125.4(9) 
C(4)-O(19)-C(20') 109.5(8) 
O(19)-C(20)-C(21) 108.2(11) 
C(22)-C(21)-C(20) 113.4(9) 
N(23)-C(22)-C(21) 118.5(9) 
C(24)-N(23)-C(22) 112.5(7) 
C(24)-N(23)-C(34) 111.9(9) 
C(22)-N(23)-C(34) 110.2(8) 
C(24)-N(23)-Cu(2) 100.3(7) 
C(22)-N(23)-Cu(2) 115.7(6) 
C(34)-N(23)-Cu(2) 105.7(6) 
C(25)-C(24)-N(23) 112.0(8) 
C(24)-C(25)-N(26) 111.6(8) 
C(27)-N(26)-C(25) 115.0(9) 
C(27)-N(26)-Cu(2) 105.0(6) 
C(25)-N(26)-Cu(2) 108.0(6) 
C(28)-C(27)-N(26) 113.1(10) 
C(27)-C(28)-N(29) 110.6(9) 
C(30)-N(29)-C(28) 119.1(10) 
C(30)-N(29)-Cu(2) 103.1(7) 
C(28)-N(29)-Cu(2) 108.2(6) 
N(29)-C(30)-C(31) 110.9(9) 
N(32)-C(31)-C(30) 110.9(7) 
C(33)-N(32)-C(31) 116.7(9) 
C(33)-N(32)-Cu(2) 100.7(6) 
C(31)-N(32)-Cu(2) 106.9(6) 
N(32)-C(33)-C(34) 109.5(10) 
C(33)-C(34)-N(23) 110.4(9) 
C(21')-C(20')-O(19) 105.5(12) 
C(20')-C(21')-C(22') 112.4(13) 
N(23')-C(22')-C(21') 116.2(11) 
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N(1)-Cu(1)-N(14) 79.3(2) 
N(1)-Cu(1)-N(8) 79.71(17) 
N(14)-Cu(1)-N(8) 158.3(2) 
N(1)-Cu(1)-Cl(2) 155.73(13) 
N(14)-Cu(1)-Cl(2) 98.4(2) 
N(8)-Cu(1)-Cl(2) 98.34(14) 
N(1)-Cu(1)-Cl(1) 102.66(12) 
N(14)-Cu(1)-Cl(1) 96.10(15) 
N(8)-Cu(1)-Cl(1) 94.06(12) 
Cl(2)-Cu(1)-Cl(1) 101.61(7) 
N(26)-Cu(2)-N(32) 150.0(4) 
N(26)-Cu(2)-N(29) 86.0(4) 
N(32)-Cu(2)-N(29) 86.1(4) 
N(26)-Cu(2)-N(23) 86.5(3) 
N(32)-Cu(2)-N(23) 86.9(3) 
N(29)-Cu(2)-N(23) 152.0(4) 
N(26)-Cu(2)-Cl(3) 107.0(3) 
N(32)-Cu(2)-Cl(3) 103.0(3) 
N(29)-Cu(2)-Cl(3) 102.7(3) 
N(23)-Cu(2)-Cl(3) 105.3(3) 
N(26')-Cu(2')-N(29') 85.6(6) 
N(26')-Cu(2')-N(23') 86.5(5) 
N(29')-Cu(2')-N(23') 149.0(5) 
N(26')-Cu(2')-N(32') 147.2(6) 
N(29')-Cu(2')-N(32') 84.3(5) 
N(23')-Cu(2')-N(32') 86.3(5) 
C(24')-N(23')-C(22') 113.3(10) 
C(24')-N(23')-C(34') 113.2(10) 
C(22')-N(23')-C(34') 108.5(9) 
C(24')-N(23')-Cu(2') 101.6(10) 
C(22')-N(23')-Cu(2') 113.6(8) 
C(34')-N(23')-Cu(2') 106.4(8) 
C(25')-C(24')-N(23') 111.2(11) 
C(24')-C(25')-N(26') 108.9(11) 
C(27')-N(26')-C(25') 112.5(12) 
C(27')-N(26')-Cu(2') 105.7(11) 
C(25')-N(26')-Cu(2') 108.5(9) 
C(28')-C(27')-N(26') 112.3(12) 
C(27')-C(28')-N(29') 112.8(12) 
C(30')-N(29')-C(28') 113.5(12) 
C(30')-N(29')-Cu(2') 107.9(10) 
C(28')-N(29')-Cu(2') 108.4(9) 
C(31')-C(30')-N(29') 112.0(12) 
C(30')-C(31')-N(32') 113.3(12) 
C(31')-N(32')-C(33') 115.9(12) 
C(31')-N(32')-Cu(2') 110.0(9) 
C(33')-N(32')-Cu(2') 102.9(9) 
C(34')-C(33')-N(32')  110.2(11) 
C(33')-C(34')-N(23') 111.4(11) 
 
 
A.3 Fluorescence Displacement Assay (FID): TO Displacement Curves  
 
Figure A-5: Graphical representation of TO displacement from Htelo quadruplex DNA, c-Myc quadruplex 
DNA and duplex 26-mer DNA upon increasing concentration of L
5
 from 1.25 to 10 μM. 
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Figure A-6: Graphical representation of TO displacement from Htelo quadruplex DNA, c-Myc quadruplex 
DNA and duplex 26-mer DNA upon increasing concentration of 1 from 1.25 to 10 μM. 
 
Figure A-7: Graphical representation of TO displacement from Htelo quadruplex DNA, c-Myc quadruplex 
DNA and duplex 26-mer DNA upon increasing concentration of 2 from 0.0325 to 5 μM. 
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Figure A-8: Graphical representation of TO displacement from Htelo quadruplex DNA, c-Myc quadruplex 
DNA and duplex 26-mer DNA upon increasing concentration of 3b from 0.0325 to 5 μM. 
 
Figure A-9: Graphical representation of TO displacement from Htelo quadruplex DNA, c-Myc quadruplex 
DNA and duplex 26-mer DNA upon increasing concentration of 4 from 0.0325 to 5 μM. 
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Figure A-10: Graphical representation of TO displacement from Htelo quadruplex DNA, c-myc quadruplex 
DNA and duplex 26-mer DNA upon increasing concentration of 5 from 0.0325 to 5 μM. 
 
Figure A-11: Graphical representation of TO displacement from Htelo quadruplex DNA, c-Myc quadruplex 
DNA and duplex 26-mer DNA upon increasing concentration of 6 from 0.5 to 10 μM. 
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A.4 Fluorescence Resonance Energy Transfer (FRET) Assays 
A.4.1 Preliminary Quenching Studies 
 
Figure A-12: FAM DNA emission spectra in the presence of increasing concentrations of 4.  Study carried out 
for complexes; results with 4 were representative of the series.  
A.4.2 FRET Melting Assays 
 
Figure A-13: Stabilisation of Htelo DNA (5’-FAM- AGGGTTAGGGTTAGGGTTAGGG -TAMRA-3’) in the presence 
of various concentrations of 1. The thermal denaturation profile of Htelo in K
+
 conditions is recorded alone 
(black) or in the presence of various concentrations of 1. Normalised melting curves are plotted.  
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Figure A-14: Stabilisation of Htelo DNA (5’-FAM- AGGGTTAGGGTTAGGGTTAGGG -TAMRA-3’) in the presence 
of various concentrations of 2. The thermal denaturation profile of Htelo in K
+
 conditions is recorded alone 
(black) or in the presence of various concentrations of 2. Normalised melting curves are plotted.  
 
 
 
 
Figure A-15: Stabilisation of Htelo DNA (5’-FAM- AGGGTTAGGGTTAGGGTTAGGG -TAMRA-3’) in the presence 
of various concentrations of 3b. The thermal denaturation profile of Htelo in K
+
 conditions is recorded alone 
(black) or in the presence of various concentrations of 3b. Normalised melting curves are plotted.  
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Figure A-16:Stabilisation of Htelo DNA (5’-FAM- AGGGTTAGGGTTAGGGTTAGGG -TAMRA-3’) in the presence 
of various concentrations of 4. The thermal denaturation profile of Htelo in K
+
 conditions is recorded alone 
(black) or in the presence of various concentrations of 4. Normalised melting curves are plotted.  
 
 
 
Figure A-17: Stabilisation of Htelo DNA (5’-FAM- AGGGTTAGGGTTAGGGTTAGGG -TAMRA-3’) in the presence 
of various concentrations of 5. The thermal denaturation profile of Htelo in K
+
 conditions is recorded alone 
(black) or in the presence of various concentrations of 5. Normalised melting curves are plotted.  
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Figure A-18: Stabilisation of Htelo DNA (5’-FAM-AGGGTTAGGGTTAGGGTTAGGG-TAMRA-3’) in the presence 
of various concentrations of 6. The thermal denaturation profile of Htelo in K
+
 conditions is recorded alone 
(black) or in the presence of various concentrations of 6. Normalised melting curves are plotted.  
 
 
 
Figure A-19: Stabilisation of c-Myc DNA (5’-FAM-GGGAGGGTGGGGAGGGTGGG-TAMRA-3’) in the presence of 
various concentrations of 1. The thermal denaturation profile of c-Myc in K
+
 conditions is recorded alone 
(black) or in the presence of various concentrations of 1. Normalised melting curves are plotted.  
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Figure A-20: Stabilisation of c-Myc DNA (5’-FAM-GGGAGGGTGGGGAGGGTGGG-TAMRA-3’) in the presence of 
various concentrations of 2. The thermal denaturation profile of c-Myc in K
+
 conditions is recorded alone 
(black) or in the presence of various concentrations of 2. Normalised melting curves are plotted. 
 
 
Figure A-21: Stabilisation of c-Myc DNA (5’-FAM-GGGAGGGTGGGGAGGGTGGG-TAMRA-3’) in the presence of 
various concentrations of 3b. The thermal denaturation profile of c-Myc in K
+
 conditions is recorded alone 
(black) or in the presence of various concentrations of 3b. Normalised melting curves are plotted. 
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Figure A-22: Stabilisation of c-Myc DNA (5’-FAM-GGGAGGGTGGGGAGGGTGGG-TAMRA-3’) in the presence of 
various concentrations of 4. The thermal denaturation profile of c-Myc in K
+
 conditions is recorded alone 
(black) or in the presence of various concentrations of 4. Normalised melting curves are plotted. 
 
Figure A-23: Stabilisation of c-Myc DNA (5’-FAM-GGGAGGGTGGGGAGGGTGGG-TAMRA-3’) in the presence of 
various concentrations of 5. The thermal denaturation profile of c-Myc in K
+
 conditions is recorded alone 
(black) or in the presence of various concentrations of 5. Normalised melting curves are plotted. 
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Figure A-24: Stabilisation of c-Myc DNA (5’-FAM-GGGAGGGTGGGGAGGGTGGG-TAMRA-3’) in the presence of 
various concentrations of 6. The thermal denaturation profile of c-Myc in K
+
 conditions is recorded alone 
(black) or in the presence of various concentrations of 6. Normalised melting curves are plotted. 
 
A.4.2 FRET Competition Assays 
 
Figure A-25: Competition curves of normalised Htelo DNA (black) in the presence of 2 equiv. 3b without any 
competitor (red) and in the presence of increasing amounts of competitor (ct DNA). Normalised melting 
curves are plotted.  
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Figure A-26: Competition curves of normalised Htelo DNA (black) in the presence of 2 equiv. 4 without any 
competitor (red) and in the presence of increasing amounts of competitor (ct DNA). Normalised melting 
curves are plotted. 
 
Figure A-27: Competition curves of normalised Htelo DNA (black) in the presence of 2 equiv. 5 without any 
competitor (red) and in the presence of increasing amounts of competitor (ct DNA). Normalised melting 
curves are plotted. 
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Figure A-28: Competition curves of normalised Htelo DNA (black) in the presence of 2 equiv. 3b without any 
competitor (red) and in the presence of increasing amounts of competitor (ds26 DNA). Normalised melting 
curves are plotted. 
 
 
Figure A-29: Competition curves of normalised Htelo DNA (black) in the presence of 2 equiv. 4 without any 
competitor (red) and in the presence of increasing amounts of competitor (ds26 DNA). Normalised melting 
curves are plotted. 
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Figure A-30: Competition curves of normalised Htelo DNA (black) in the presence of 2 equiv. 5 without any 
competitor (red) and in the presence of increasing amounts of competitor (ct DNA). Normalised melting 
curves are plotted. 
 
 
Figure A-31: Competition curves of normalised c-Myc DNA (black) in the presence of 2 equiv. 3b without any 
competitor (red) and in the presence of increasing amounts of competitor (ct DNA). Normalised melting 
curves are plotted. 
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Figure A-32: Competition curves of normalised c-Myc DNA (black) in the presence of 2 equiv. 4 without any 
competitor (red) and in the presence of increasing amounts of competitor (ct DNA). Normalised melting 
curves are plotted. 
 
 
Figure A-33: Competition curves of normalised c-Myc DNA (black) in the presence of 2 equiv. 5 without any 
competitor (red) and in the presence of increasing amounts of competitor (ct DNA). Normalised melting 
curves are plotted. 
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Figure A-34: Competition curves of normalised c-Myc DNA (black) in the presence of 2 equiv. 3b without any 
competitor (red) and in the presence of increasing amounts of competitor (ds26 DNA). Normalised melting 
curves are plotted. 
 
 
Figure A-35: Competition curves of normalised c-Myc DNA (black) in the presence of 2 equiv. 4 without any 
competitor (red) and in the presence of increasing amounts of competitor (ds26 DNA). Normalised melting 
curves are plotted. 
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Figure A-36: Competition curves of normalised c-Myc DNA (black) in the presence of 2 equiv. 5 without any 
competitor (red) and in the presence of increasing amounts of competitor (ds26 DNA). Normalised melting 
curves are plotted. 
 
 
Figure A-37: Competition curves of normalised Htelo DNA (black) in the presence of 2 equiv. 3b without any 
competitor (red) and in the presence of increasing amounts of competitor (c-Myc DNA). Normalised melting 
curves are plotted. 
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Figure A-38: Competition curves of normalised Htelo DNA (black) in the presence of 2 equiv. 4 without any 
competitor (red) and in the presence of increasing amounts of competitor (c-Myc DNA). Normalised melting 
curves are plotted. 
 
 
Figure A-39: Competition curves of normalised Htelo DNA (black) in the presence of 2 equiv. 5 without any 
competitor (red) and in the presence of increasing amounts of competitor (c-Myc DNA). Normalised melting 
curves are plotted. 
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Figure A-40: Competition curves of normalised c-Myc DNA (black) in the presence of 2 equiv. 3b without any 
competitor (red) and in the presence of increasing amounts of competitor (Htelo DNA). Normalised melting 
curves are plotted. 
 
 
Figure A-41: Competition curves of normalised c-Myc DNA (black) in the presence of 2 equiv. 3b without any 
competitor (red) and in the presence of increasing amounts of competitor (Htelo DNA). Normalised melting 
curves are plotted. 
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Figure A-42: Competition curves of normalised c-Myc DNA (black) in the presence of 2 equiv. 3b without any 
competitor (red) and in the presence of increasing amounts of competitor (Htelo DNA). Normalised melting 
curves are plotted. 
 
A.5 UV-Vis: UV-Vis Titrations and Reciprocal Plots of D/Δεap vs. D 
                                                                            
Figure A-43: UV-Vis titration and reciprocal plot of D/Δεap versus D for 1 (20μM) upon addition of Htelo 
DNA. 
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Figure A-44: UV-Vis titration and reciprocal plot of D/Δεap versus D for 1 (20μM) upon addition of c-Myc 
DNA. 
 
Figure A-45: UV-Vis titration and reciprocal plot of D/Δεap versus D for 1 (50μM) upon addition of ct DNA. 
  
Figure A-46: UV-Vis titration and reciprocal plot of D/Δεap versus D for 2 (50μM) upon addition of Htelo 
DNA. 
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Figure A-47: UV-Vis titration and reciprocal plot of D/Δεap versus D for 2 (50μM) upon addition of c-Myc 
DNA. 
  
Figure A-48: UV-Vis titration and reciprocal plot of D/Δεap versus D for 2 (50μM) upon addition of ct DNA. 
  
Figure A-49: UV-Vis titration and reciprocal plot of D/Δεap versus D for 3b (20μM) upon addition of Htelo 
DNA. 
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Figure A-50: UV-Vis titration and reciprocal plot of D/Δεap versus D for 3b (50μM) upon addition of c-Myc 
DNA. 
  
Figure A-51: UV-Vis titration and reciprocal plot of D/Δεap versus D for 3b (20μM) upon addition of ct DNA. 
 
Figure A-52: UV-Vis titration and reciprocal plot of D/Δεap versus D for 4 (50μM) upon addition of Htelo 
DNA. 
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Figure A-53: UV-Vis titration and reciprocal plot of D/Δεap versus D for 4 (50μM) upon addition of c-Myc 
DNA. 
 
Figure A-54: UV-Vis titration and reciprocal plot of D/Δεap versus D for 4 (20μM) upon addition of ct DNA. 
  
Figure A-55: UV-Vis titration and reciprocal plot of D/Δεap versus D for 5 (20μM) upon addition of Htelo 
DNA. 
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Figure A-56: UV-Vis titration and reciprocal plot of D/Δεap versus D for 5 (50μM) upon addition of c-Myc 
DNA. 
 
Figure A-57: UV-Vis titration and reciprocal plot of D/Δεap versus D for 5 (50μM) upon addition of ct DNA. 
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A.6 Circular Dichroism (CD) Studies  
A.6.1 Htelo DNA CD Titrations (in the presence of K+ ions). 
 
Figure A-58: The CD spectra of Htelo DNA (10 μM) in the presence of potassium ions, upon addition of 
increasing amounts of 1. 
 
Figure A-59: The CD spectra of Htelo DNA (10 μM) in the presence of potassium ions, upon addition of 
increasing amounts of 2. 
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Figure A-60: The CD spectra of Htelo DNA (10 μM) in the presence of potassium ions, upon addition of 
increasing amounts of 3b. 
 
 
 
Figure A-61: The CD spectra of Htelo DNA (10 μM) in the presence of potassium ions, upon addition of 
increasing amounts of 4. 
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Figure A-62: The CD spectra of Htelo DNA (10 μM) in the presence of potassium ions, upon addition of 
increasing amounts of 5. 
 
 
Figure A-63: The CD spectra of Htelo DNA (10 μM) in the presence of potassium ions, upon addition of 
increasing amounts of 6. 
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A.6.2 c-Myc DNA VTCD melting curves (in the absence of K+ ions)  
 
Figure A-64: CD melting curves for c-Myc DNA (5 μM) with (red) and without (black) the presence of 1 (2eq., 
10 μM). 
 
Figure A-65: CD melting curves for c-Myc DNA (5 μM) with (red) and without (black) the presence of 2 (2eq., 
10 μM). 
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Figure A-66: CD melting curves for c-Myc DNA (5 μM) with (red) and without (black) the presence of 3b 
(2eq., 10 μM). 
 
 
Figure A-67: CD melting curves for c-Myc DNA (5 μM) with (red) and without (black) the presence of 4 (2eq., 
10 μM). 
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Figure A-68: CD melting curves for c-Myc DNA (5 μM) with (red) and without (black) the presence of 5 (2eq., 
10 μM). 
 
 
Figure A-69: CD melting curves for c-Myc DNA (5 μM) with (red) and without (black) the presence of 6 (2eq., 
10 μM). 
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A.7 MTS Assay: Cytotoxicity 
 
Figure A-70: MTS assay profile for 1 with the U2OS cell line. 
 
Figure A-71: MTS assay profile for 2 with the U2OS cell line. 
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Figure A-72: MTS assay profile for 3b with the U2OS cell line. 
 
 
Figure A-73: MTS assay profile for 4 with the U2OS cell line. 
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Figure A-74: MTS assay profile for 5 with the U2OS cell line. 
 
 
Figure A-75: MTS assay profile for 6 with the U2OS cell line. 
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Figure A-76: MTS assay profile for 1 with the SHSY5Y cell line. 
 
 
Figure A-77: MTS assay profile for 2 with the SHSY5Y cell line. 
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Figure A-78: MTS assay profile for 3b with the SHSY5Y cell line. 
 
 
Figure A-79: MTS assay profile for 4 with the SHSY5Y cell line. 
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Figure A-80: MTS assay profile for 5 with the SHSY5Y cell line. 
 
 
Figure A-81: MTS assay profile for 6 with the SHSY5Y cell line. 
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Figure A-82: MTS assay profile for 1 with the GM05757 cell line. 
 
 
Figure A-83: MTS assay profile for 2 with the GM05757 cell line. 
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Figure A-84: MTS assay profile for 3b with the GM05757 cell line. 
 
 
Figure A-85: MTS assay profile for 4 with the GM05757 cell line. 
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Figure A-86: MTS assay profile for 5 with the GM05757 cell line. 
 
 
Figure A-87: MTS assay profile for 6 with the GM05757 cell line. 
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